AMERICAN SUPERCONDUCTOR CORP /DE/
10-K, 1998-06-26
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: PREMIERE TECHNOLOGIES INC, 8-A12G, 1998-06-26
Next: AIM INTERNATIONAL FUNDS INC, NSAR-A, 1998-06-26



<PAGE>   1
 
================================================================================
 
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                            ------------------------
 
                                   FORM 10-K
                       FOR ANNUAL AND TRANSITION REPORTS
                    PURSUANT TO SECTIONS 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934
 
[X]   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
      ACT OF 1934
                    FOR THE FISCAL YEAR ENDED MARCH 31, 1998
                                       OR
 
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934
 
        FOR THE TRANSITION PERIOD FROM                TO
 
                         COMMISSION FILE NUMBER 0-19672
 
                      AMERICAN SUPERCONDUCTOR CORPORATION
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 
<TABLE>
<S>                              <C>
           DELAWARE                            04-2959321
(STATE OR OTHER JURISDICTION OF  (I.R.S. EMPLOYER IDENTIFICATION NUMBER)
INCORPORATION OR ORGANIZATION)
 
     TWO TECHNOLOGY DRIVE,
  WESTBOROUGH, MASSACHUSETTS                      01581
(ADDRESS OF PRINCIPAL EXECUTIVE                (ZIP CODE)
           OFFICES)
</TABLE>
 
       REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE  (508) 836-4200
 
       SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:  NONE
 
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:  COMMON STOCK, $.01
                                   PAR VALUE
 
     Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.  Yes  [X]     No  [ ]
 
     Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K.  [ ]
 
     On April 30, 1998, the aggregate market value of voting Common Stock held
by nonaffiliates of the registrant was $199,641,072 based on the closing price
of the Common Stock on the Nasdaq National Market on April 30, 1998.
 
     The number of shares of Common Stock outstanding as of April 30, 1998 was
15,272,874.
 
                      DOCUMENTS INCORPORATED BY REFERENCE
 
<TABLE>
<CAPTION>
DOCUMENT                                                        FORM 10-K PART
- --------                                                        --------------
<S>                                                             <C>
Definitive Proxy Statement with respect to the Annual              Part III
  Meeting of Stockholders for the fiscal year ended March
  31, 1998, filed with the Securities and Exchange
  Commission.
</TABLE>
 
================================================================================
<PAGE>   2
 
                               TABLE OF CONTENTS
 
<TABLE>
<CAPTION>
ITEM                                                                   PAGE
- ----                                                                   ----
<C>    <S>                                                             <C>
                                  PART I
 1.    Business....................................................      2
 2.    Properties..................................................     14
 3.    Legal Proceedings...........................................     14
 4.    Submission of Matters to a Vote of Security Holders.........     14
                                  PART II
 5.    Market for Registrant's Common Stock and Related Stockholder
       Matters.....................................................     16
 6.    Selected Financial Data.....................................     16
 7.    Management's Discussion and Analysis of Financial Conditions
       and Results of Operations...................................     16
 8.    Financial Statements and Supplementary Data.................     16
 9.    Changes and Disagreements with Accountants on Accounting and
       Financial Disclosure........................................     17
                                 PART III
10.    Directors and Executive Officers of the Registrant..........     17
11.    Executive Compensation......................................     17
12.    Security Ownership of Certain Beneficial Owners and
       Management..................................................     17
13.    Certain Relationships and Related Transactions..............     17
                                  PART IV
14.    Exhibits, Financial Statement Schedules, and Reports on Form
       8-K.........................................................     17
</TABLE>
 
     This Annual Report on Form 10-K contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
For this purpose, any statements contained herein that do not relate to
historical matters, including without limitation, the statements under "Item 1.
Business" and "Item 7. Management's Discussion and Analysis of Financial
Condition and Results of Operations" and located elsewhere herein regarding
industry prospects and the Company's prospective results of operations or
financial position, may be deemed to be forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates," "plans," "expects,"
and similar expressions are intended to identify forward-looking statements.
Such forward-looking statements represent management's current expectations and
are inherently uncertain. The important factors discussed below under the
caption "Management's Discussion and Analysis of Financial Conditions and
Results of Operations -- Future Operating Results," among others, could cause
actual results to differ materially from those indicated by forward-looking
statements made herein and presented elsewhere by management from time to time.
 
                                        1
<PAGE>   3
 
ITEM 1.  BUSINESS
 
     American Superconductor Corporation (the "Company") is an industry leader
in developing, manufacturing and marketing products utilizing superconducting
materials for electric power applications. Electrical products that incorporate
superconducting wires can be more efficient, compact and cost effective than
those utilizing conventional copper wires. Products incorporating
superconducting materials are currently utilized in the medical, electronics,
power equipment and transportation industries.
 
     Superconducting wires provide significant advantages over conventional
copper wires because superconducting wires conduct electricity with little or no
resistance and associated energy loss, and can transmit much larger amounts of
electricity than conventional wires of the same size. The Company's development
and commercialization efforts have been focused on electrical products and
equipment utilizing superconductors for use in the electric power industry.
According to industry sources, it is estimated that in the year 2010, worldwide
products based on superconductors that are sold to the electric power industry
will generate approximately $12 billion of revenues.
 
SUPERCONDUCTIVITY
 
     A superconductor is a perfect conductor of electricity; it carries direct
current with 100% efficiency because no energy is dissipated by resistive
heating. Once induced in a superconducting loop, direct current can flow
undiminished forever. Superconductors can also conduct alternating current, but
with some slight dissipation of energy.
 
     Superconductors lose all resistance to the flow of direct electrical
current and nearly all resistance to the flow of alternating electrical current
when cooled below a critical temperature, which is different for each
superconducting material. Superconducting materials known today, including both
high temperature superconductor ("HTS") and low temperature superconductor
("LTS") materials, need to be cooled to cryogenic temperatures in order to
exhibit the property of superconductivity.
 
                           [Superconductivity Graph]
 
        This graph illustrates the complete loss of resistance to the
        flow of electricity through wires of an LTS material
        (niobium-titanium alloy) and an HTS material (bismuth-based,
        copper oxide ceramic) at the critical temperature, T(c), which
        is different for each superconducting material. The specific HTS
        material in this chart has no electrical resistance below 108K
        (-265 degreesF), as opposed to the specific LTS material in this
        chart, which has no electrical resistance below 10 K (-441
        degreesF).
 
                                        2
<PAGE>   4
 
     A combination of three conditions must actually be met for a material to
exhibit superconducting behavior:
 
          - The material must be cooled below a characteristic temperature,
            known as its superconducting transition or critical temperature
            (T(c));
 
          - The current passing through a given cross-section of the material
            must be below a characteristic level known as the critical current
            density (J(c)); and
 
          - The magnetic field to which the material is exposed must be below a
            characteristic value known as the critical magnetic field (H(c)).
 
     These conditions are interdependent, and define the environmental operating
conditions for the superconductor.
 
                            [Superconducting Graph]
 
        Not only must a superconducting material be cooled below its
        critical temperature, T(c), to lose all resistance to the flow
        of electricity, but also the amount of current flowing through a
        given cross sectional area of superconducting wire must not
        exceed a critical amount, the critical current density, J(c),
        and the magnetic field to which the superconductor is exposed
        must not be above a critical level, Hc. The key focus of the
        Company's HTS development program is to increase the critical
        current density of its wires through research advancements and
        through optimization of its wire manufacturing methodologies.
 
     The initial discovery of superconductive materials was made in 1911. Before
1986, the critical temperatures for all known superconductors did not exceed 23
Kelvin (23K or -418 degrees Fahrenheit; 0K is absolute zero, or -459 degrees
Fahrenheit). Before the discovery and development of HTS materials, the use of
superconductivity had not been practical for widespread commercial applications,
except for magnetic resonance imaging ("MRI") and superconducting magnetic
energy storage ("SMES") applications, principally because commercially available
superconductors (i.e., LTS materials) are made superconductive only when these
materials are cooled to near 0K. Although it is technologically possible to cool
LTS materials to a temperature at which they become superconductive, broad
commercialization of LTS materials has been inhibited by the high cost
associated with the cooling process. For example, liquid helium, which can be
used to cool materials to about 4K (-452 degrees Fahrenheit), and which has been
commonly used to cool LTS materials, is expensive and relatively costly to
maintain.
 
     In 1986, a breakthrough in superconductivity occurred when two scientists,
Dr. K. Alex Muller, who is currently under contract as a consultant to the
Company, and Dr. J. Georg Bednorz, at an IBM laboratory in Zurich, Switzerland,
identified a ceramic oxide compound which was shown to be superconductive at 36K
(-395 degrees Fahrenheit). This discovery earned them the Nobel Prize for
Physics in 1987, which is one of the four Nobel Prizes that have been awarded
for work on superconductivity. A series of related ceramic oxide
 
                                        3
<PAGE>   5
 
compounds which have higher critical temperatures were subsequently discovered,
including those being used by the Company.
 
APPLICATIONS AND MARKETS FOR SUPERCONDUCTORS
 
     Wire is an integral component of most products that transmit, transfer or
utilize electricity. Superconducting wires provide significant advantages over
conventional wires because superconducting wires conduct electricity with little
or no energy loss, which enables them to transmit much larger amounts of
electricity than conventional wires of the same size. These underlying
characteristics lead to the potential for more efficient, smaller and lighter
electrical products and equipment, such as motors, generators, power
transmission cables, and transformers. Deregulation of the electric power
industry, which is an increasing trend in the United States and certain other
countries, may enhance the potential market for superconducting wires by
providing opportunities in markets that were not previously open to the Company.
 
     Because the superconducting wire in a coil of this material exhibits no
resistance to the passage of electrical current, large amounts of electricity
can be stored in coils of superconducting wire, and because the wire coil has no
electrical resistance, the stored electricity can be removed from the coil very
rapidly. These features provide the basis for the Company's line of SMES systems
utilizing LTS electromagnets ("LT-SMES"). The Company's LT-SMES power quality
products are currently being sold or leased to industrial users of power to
prevent factory downtime and loss of "work in process" caused by momentary dips
in voltage that occur in power distribution networks.
 
     LTS products are used in a number of applications, including MRI diagnostic
equipment, which currently represents the single largest commercial use of LTS
materials, commercial magnetic separation equipment, commercial SMES power
quality products, commercial laboratory electromagnets and electromagnets used
in particle accelerators. The Company's development efforts with respect to LTS
products are focused on commercial SMES power quality products. LTS products
have been under development since the early 1960s and LTS technology is
relatively mature as compared with HTS technology. However, commercial
acceptance of LTS products in power applications other than SMES systems has
been significantly limited by the cooling requirements of LTS materials. LTS
materials generally require costly cooling by liquid helium at nearly the
absolute zero temperature or cooling by cryocoolers at below 10 K (-441 degrees
Fahrenheit).
 
     In contrast, HTS wires maintain their superconductivity at higher
temperatures than LTS wires. They can be cooled with liquid nitrogen or
closed-cycle refrigerators at temperatures above 20 K (-423 degrees Fahrenheit),
which are much less expensive and easier to utilize than liquid helium.
Closed-cycle refrigerators operate in much the same way as household
refrigerators, but because of their lower operating temperature they are
somewhat more complicated to build and maintain. Specially designed closed-cycle
refrigerators have been used by the Company to cool a variety of commercial and
developmental HTS electromagnets. It is presently anticipated that HTS power
cables would be cooled by maintaining liquid nitrogen within hollow cores of an
HTS cable, and/or by flowing liquid nitrogen around the power cables, much the
same as oil is now maintained within the cores of some conventional underground
power cables and used to cool power cables maintained within steel pipes under
the streets of cities.
 
     The Company anticipates that HTS motors and generators would be cooled by
cryocoolers, without the presence of a liquid cryogen, such as liquid nitrogen.
However, it is anticipated that HTS transformers would be cooled by submerging
the HTS coils in liquid nitrogen, with the nitrogen maintained at temperature by
a closed cycle refrigerator. In this application, the liquid nitrogen acts both
as a coolant and as an electrical insulating medium, or dielectric. Therefore,
HTS products may replace or compete with LTS products in certain applications in
which LTS products are currently used and the Company believes that the less
demanding cooling requirements of HTS materials will permit their use in a broad
range of applications not currently available to LTS products.
 
     The Company is currently focusing on two markets for superconductivity
products: the industrial power quality market, for which the Company currently
manufactures and markets commercial industrial power quality systems and
services; and the market for other electric power products, for which the
Company is currently developing a number of HTS products.
 
                                        4
<PAGE>   6
 
  Industrial Power Quality Systems and Services
 
     The Company has focused initially on SMES systems as its product platform
to address the need for solutions for industrial power quality problems, which
industry sources estimate cost U.S. industry alone more than $10 billion per
year in factory downtime. Protection against power quality problems such as
momentary (typically less than two seconds) voltage sags can provide significant
economic value to large industrial users of power. SMES systems are designed to
protect industrial customers from the adverse effects of voltage sags by
releasing large quantities of power within a fraction of a cycle to normalize
the degraded incoming power supply. It is estimated that more than 80% of all
power quality events, including brownouts and blackouts, are less than two
seconds in duration. With large energy storage capacities and fast recharging
capabilities, SMES systems can provide a solution to momentary aberrations in
power quality.
 
     In April 1997, the Company acquired Superconductivity, Inc. ("SI"), a
manufacturer of SMES power quality systems based on LTS electromagnets. The
Company believes that this acquisition provides it with a strong presence in the
industrial power quality market, and will allow it to accelerate its plan to
penetrate this sector of the market. The Company is currently expanding sales
and marketing and manufacturing capacity for its existing SMES-based power
quality products. The Company also plans to expand its current SMES product line
and to introduce high temperature SMES ("HT-SMES") products within three to five
years. The Company is also incorporating its HTS current leads product into its
LT-SMES products in order to reduce systems manufacturing costs and to improve
the efficiency of operation of the LT-SMES products.
 
     The Company introduced two commercial SMES-based products in calendar year
1997. Both are designed to provide instantaneous boosts in voltage, either
within individual pieces of electrical equipment, such as motor drives, or to
power lines supplying industrial users of power, in both cases to prevent
factory downtime caused by momentary dips in voltage that occur in distribution
power networks. The Company also has units at customer sites that are designed
to prevent factory downtime and lost work in process caused by momentary
(typically less than one to two seconds) outages (a dip in voltage to zero),
which also occur on power distribution networks. The Company has sold or leased
nine SMES units, which are currently located at customer sites in the United
States and in South Africa.
 
     The Company is developing multiple channels to market for its power quality
products, including, but not limited to, distributors, OEMs and direct sales.
The Company has a distribution agreement with Eskom, the largest utility in
Africa, to distribute the Company's power quality products exclusively in South
Africa.
 
     The Company currently offers a service component of its industrial power
quality business that assesses the power quality needs of industrial sites, and
provides extended warranties. The Company plans to expand this portion of its
industrial power quality business area.
 
  HTS Electric Power Products
 
     HTS electric power products under development include power transmission
cables, motors, transformers, generators and SMES systems. The Company's
development efforts for this market segment are focused on HTS wires and
products made from these wires, such as electromagnetic motor coils integrated
with appropriate cryogenic cooling systems. The Company's revenues in this
business area currently come primarily from research and development contracts,
including governmental contracts, prototype sales and funds from corporate
partners Pirelli Cavi E Sistemi S.p.A. ("Pirelli"), Electricite de France
("EDF") and ABB Power Transmission and Distribution Company ("ABB"). See
"Business -- Strategic Relationships, Research Arrangements and Government
Contracts."
 
     The Company has produced and sold prototype HTS wires and electromagnetic
coils for use in several development and demonstration programs. Nevertheless,
significantly better strength, flexibility, and electrical performance need to
be achieved, over longer wire lengths, and at lower costs, for the
commercialization of HTS wire and wire products to be successful. Despite the
advances being made, to date neither the Company nor, to the Company's
knowledge, any other company has produced HTS wires in commercial quantities
adequate for the electrical equipment market, and hurdles to commercialization
continue to exist.
 
     The Company's strategy is to develop its HTS products through a combination
of internally funded and customer-, and government-sponsored programs, as well
as through other research programs, and to market these products through
strategic partners or directly through its sales and marketing organization. In
addition
 
                                        5
<PAGE>   7
 
to its strategic alliances with Pirelli, EDF and ABB, the Company has
established research arrangements with several US National Laboratories and with
Industrial Research Limited, and is currently a party to development contracts
with several U.S. government agencies to build prototype HTS electromagnetic
coils. As the Company develops HTS electric power applications and industrial
power quality systems and services, it expects to continue to pursue strategic
acquisitions to enhance its market position, add value to its product line and
strengthen its technology base. In April 1997, the Company acquired SI in order
to establish a presence in the industrial power quality market; in July 1997,
the Company acquired Applied Engineering Technologies, Ltd. ("AET") in order to
strengthen its core capabilities in cryogenic engineering. The Company has sold
several prototype HTS products to private-sector companies, including HTS wires
to ABB Secheron SA and Pirelli, HTS motor coils to Rockwell Automation, an
HT-SMES system to E.-U.-S. GmbH of Germany, and an HTS accelerator magnet system
to Alphatech International. It has also sold HTS coils to U.S. government
laboratories, including HTS generator coils to Wright-Patterson Air Force Base,
and a high field (7 Tesla) research magnet to the Naval Research Laboratory. The
Company is selling HTS current leads commercially to a variety of customers
including MRI manufacturers and particle accelerator laboratories.
 
     If the Company is successful in developing its HTS technology for
commercial applications, the Company intends to bring the following product
lines to market in the next several years.
 
     Wires for Power Transmission Cables.  In cooperation with Pirelli, the
Company is developing HTS wires for underground HTS cables designed to provide
more efficient and economical ways for utilities to transmit power. Underground
power cables using HTS wires have the potential to carry two to five times more
power than cables of the same size made from copper wires. The use of HTS wires
would therefore result in more efficient transmission, more effective use of
existing rights of way, reduced environmental stress and cost-effective
replacement of worn-out infrastructure. This is very attractive both to urban
planners who need to retrofit aging infrastructures with increased power
capacity and to suburban engineers who find it increasingly difficult to secure
clearance for overhead transmission lines. At least two underground copper
cables are required to replace one equally rated overhead transmission line,
whereas a single HTS cable could replace one equally rated overhead line.
Moreover the liquid nitrogen used to cool underground HTS cables is less
expensive and presents less environmental risks than the oil used to cool copper
cables. The Company expects that the first significant demonstration of utility
networks utilizing HTS-based power transmission cables will occur in 2000 and
that the first sales of its HTS wire for such applications will occur in 2001.
 
     Coils for Motors and Generators.  The Company is designing, developing and
fabricating HTS rotor coils and cryocoolers for use in high-horsepower electric
motors with the potential for use in industrial and utility applications. HTS
motors utilizing these rotor coils are expected to be half the weight and size
of conventional motors and would provide greater operating efficiency. Since
industrial electric motors consume most of the electricity used in a typical
manufacturing operation, increased efficiency should yield significant savings
in power costs. The Company and Reliance Electric Company, a Rockwell Automation
business, are developing 1,000 and 5,000 horsepower (hp) motors under a U.S.
Department of Energy Superconductivity Partnership Initiative. The Company
expects the 1,000 hp motor to be in initial laboratory tests in early 1999 and
to be installed in an industrial site during the second half of 1999. The
Company expects that the first sales of its HTS rotor coils and cryocoolers for
these motors for commercial applications will occur in 2001.
 
     Cables for Transformers.  In cooperation with ABB, one of the largest
transformer suppliers in the world, and EDF, the Company is developing
alternating current HTS transformer wire that can be used for fabrication of HTS
transformers. Utilities and industrial power customers use transformers to
increase and decrease voltage levels. HTS transformers are expected to offer a
number of improved features relative to conventional transformers as well as
entirely new functionality with important utility systems benefits. HTS
transformers are expected to be half the size and weight of conventional
transformers, which would increase existing substation capacity, reduce land
area needed for new substations, and greatly relieve transportation challenges
currently faced by electric utilities for conventional transformers. In
addition, HTS transformers would replace the dielectric oil which surrounds the
copper coils in today's power transformers with low-cost, environmentally-safe
liquid nitrogen, which would eliminate the spill risks associated with
dielectric oil. This is expected to lower associated insurance costs and allow
transformers to be installed closer to large load centers even within large
cities. The Company expects that the first sales of its HTS transformer wires or
cables for commercial applications will occur in 2002.

                                        6
<PAGE>   8
 
     In addition to the products described above, the Company plans to develop
fault current limiters, which would instantaneously protect a power grid from
electric surges caused by lightning, short circuits and other common
fluctuations. If this product development is successful, the Company may
manufacture and sell fault current limiter systems. The Company expects that the
first sales of this product for commercial applications will occur in 2002.
 
     Ultimately, if successful in developing HTS technology for commercial power
transmission and distribution products and equipment, the Company intends to
introduce and market these HTS products primarily through strategic partners and
original equipment manufacturers ("OEMs"). However, there can be no assurance
that the Company will be successful in overcoming the technological hurdles to
the development of these products or that it will be able to successfully market
and sell any products developed.
 
HTS DEVELOPMENT
 
     Since its inception, the Company's main efforts have been directed towards
the development of HTS wire and its applications, primarily in the electric
power sector, including electric utilities and industrial users of electric
power. In late 1987 the Company developed its first length of current-carrying
HTS wire. In 1989 the Company added electromagnetic coils, electromagnets and
multistrand conductors to its development program, and in December 1989 the
Company sold its first prototype coil to a commercial customer. Since commencing
operations in 1987, the Company has been able to significantly increase both the
length and the current-carrying capacity of its HTS wires as well as the
magnetic field strength generated by its HTS electromagnetic coils.
 
     The Company has chosen to focus on HTS wires and HTS wire products (rather
than HTS electronics applications) because it believes that HTS wires and wire
products offer the largest potential commercial market in the HTS field. The
Company is not devoting any efforts to the discovery of new HTS materials. The
Company primarily focuses on processing the most promising of the HTS materials
available into wires and from these wires, manufacturing components and
subsystems, such as multistrand conductors, electromagnetic coils and
electromagnets. In some cases, higher level integration is performed in
collaboration with or by the Company's customers and/or strategic partners. In
other cases, the Company itself integrates these subsystems into a full
cryogenic and electrical system, using its cryogenic and power electronics
expertise.
 
     The Company has obtained patent licenses for a number of HTS materials. The
Company expects to be required to obtain additional licenses with respect to
these or other known HTS materials. In addition, as new HTS materials are
discovered, the Company expects that patent or other proprietary rights will be
asserted with respect to such materials, and that the Company may be required to
obtain licenses for the use of such materials. While the Company is optimistic
that it will be able to obtain such licenses, there can be no assurance of this,
and even if such licenses can be obtained the costs of obtaining such licenses
may be substantial. See "Business -- Patents, Trade Secrets and
Licenses -- Patents and the Choice of HTS Materials" and "-- Patents and the
Processing of HTS Materials." Furthermore, the Company's ability to apply its
wire processing and component and subsystem manufacturing processes to newly
discovered HTS materials will depend on the nature of the materials, although
the Company believes that its manufacturing processes are sufficiently generic
that they can be adapted to newly discovered HTS materials.
 
STATUS OF HTS WIRE DEVELOPMENT
 
     During the last several years considerable progress in the development of
HTS wire has occurred, both at the Company and at other institutions and
companies worldwide. There remain, however, significant technical hurdles that
will need to be overcome before HTS wires can be produced in commercial amounts
for the full range of potential applications. For commercial applications, the
critical current density of long wire lengths will need to be increased further
from present levels to higher levels already demonstrated on short-length
research samples. In addition, the wire will need to be able to be wound in a
variety of shapes to create multistrand conductors, electromagnetic coils and
electromagnets without loss of the wire's critical current density during
winding. The wire also will need to be able to withstand forces arising from the
interplay of its own current with a surrounding magnetic field. For alternating
current magnet and coil applications, special conductor architectures will need
to be developed. In January 1998, the Company announced a significant program in
collaboration with ABB and EDF to develop such architectures.
 
                                        7
<PAGE>   9
 
     The HTS wires used in the electromagnetic coils, electromagnets and
multistrand conductors will need to have critical current densities in the
superconducting filament of the wires (excluding any metal sheathing,
strengthening members, etc.) in the range of 30,000 to 100,000 Amperes per
square centimeter (A/cm(2)) in the magnetic field required for the application.
Most applications will require magnetic fields in the range of 0.1 to 5 Tesla (a
typical LTS magnet in an MRI system operates at about 0.5 to 1.5 Tesla; a
kitchen magnet typically has a magnetic field of less than 0.05 Tesla).
 
     Research samples of HTS wires have already exhibited sufficient current
density in very high magnetic fields to enable applications to be developed. The
Company has reported that short lengths of multifilamentary HTS wires (typically
one centimeter) produced on a laboratory scale have filament critical current
densities of 100,000 A/cm(2) in a magnetic field of up to 3 Tesla at 20 K (-423
degrees Fahrenheit). The challenge is to produce cost effective wires with these
electrical properties by high-volume manufacturing processes in long lengths
(typically greater than 10,000 feet) and with the flexibility, strength and
durability required to fabricate and utilize multistrand conductors,
electromagnetic coils and electromagnets in end-use applications.
 
     The Company has made considerable progress in achieving these combined
goals; it routinely manufactures wire in greater than five-hundred-foot lengths
with over 10,000 A/cm(2) at 77K over the full cross-sectional area of the
composite wire, with the actual current density in the superconducting filaments
reaching three times this level. This represents an advance by a factor of two
in performance of the Company's wires in the last two years. An earlier
generation of the Company's wires was incorporated into a number of
demonstration products. In 1996, Pirelli built and demonstrated a 50 meter cable
conductor that carried 3,300 Amperes of direct current, and Rockwell Automation
built and demonstrated a 286 horsepower HTS motor utilizing rotor coils
fabricated by the Company. The Company's wire was also incorporated into an HTS
transformer prototype built by ABB, which was installed in the headquarters
building of the electric utility of Geneva, Switzerland and operated from March
1997 to December 1997. However, considerable progress is still required to meet
the commercial needs of electric power and high-field magnet customers. The
Company believes that several years of further development will be necessary
before HTS wires and wire products are available for significant commercial
end-use applications, although HTS wires of sufficient performance are now
available for the Company's commercial current leads.
 
     In addition to the technical hurdles described above, there are energy
losses when alternating current is employed in a superconductor (as opposed to
the zero loss that occurs when the superconductor carries direct current), and
it has been established in LTS wires that these losses can be reduced in a
multifilamentary configuration. While the Company has produced prototype
multifilamentary composite wires, the superconducting and mechanical properties
of such wires will need to be improved before they can be used for commercial
alternating current magnet applications. The Company has been engaged in a
research and development program, with partial funding of this program coming
from both EDF and ABB, to develop wires specifically for these applications.
However, there can be no assurance that the Company will succeed in developing
this technology for commercial use. The Company has applied for patents on its
developments in this area. However, the Company may be required to obtain patent
licenses from third parties in order to utilize certain aspects of this
technology. While the Company is optimistic that it will be able to obtain such
licenses, there can be no assurance of this, and if such licenses can be
obtained, the license fees may be substantial. See "Business -- Patents, Trade
Secrets and Licenses."
 
THE COMPANY'S HTS COIL, MAGNET, CONDUCTOR, CRYOINTEGRATION AND POWER ELECTRONICS
DEVELOPMENT
 
     Simultaneously with its development of HTS wires, the Company is engaged in
the development of electromagnetic coils, electromagnets and alternating current
cables using these wires, and the integration of these products with related
cooling systems (known as "cryointegration"). Electromagnetic coils are wire-
wound structures such as those used in the rotors or stators of electric motors;
electromagnets are coils used to produce a magnetic field, such as that required
for MRI. Alternating current cables are bundles of HTS wires woven together to
form a long conducting body, such as that needed for alternating current
applications such as power transformers.
 
     The Company's HTS prototype coils, electromagnets and conductors are made
from multifilamentary wires. This form of wire, which is more flexible and
durable than single filament wires that contain the same amount of
superconductor, can permit winding with no further high temperature heat
treatment being
 
                                        8
<PAGE>   10
 
required (referred to as the "react and wind" method). The Company believes that
this approach permits more versatile application of its wires to a variety of
prototypes, although the alternative method, the "wind and react" technique, may
be appropriate in certain circumstances. The "wind and react" technique, which
can also use multifilamentary wires, means that an additional heat treatment is
required after winding a coil, electromagnet or cable. Both techniques are being
utilized by the Company.
 
     The Company has demonstrated increasingly advanced prototypes of
electromagnetic coils and multistrand conductors, including an electromagnet
that produces a magnetic field of 7 Tesla at 27K (-411 degrees Fahrenheit) when
cooled by a mechanical cryocooler, which magnetic field exceeds significantly
the maximum field (2 Tesla) obtainable from iron. The principal hurdle to
increased commercial use of this technology is to lower the cost of the system.
The Company believes that this can be achieved through the development of more
efficient manufacturing systems for its coils, cryogenics and systems
integration, and through the further reduction in the cost of HTS wire. Longer
term, the Company believes that the introduction of HTS "coated conductor" wire
will lead to more significant cost reductions. See "-- HTS Wire Production
Processes."
 
     The Company has also developed and is selling current leads that
incorporate the Company's multifilamentary wires, and which, as compared to
normal metal current leads, reduce the heat leak into, and the heat generated
in, cryogenic systems operating at temperatures below 77K (-321 degrees
Fahrenheit).
 
     The Company is also developing improvements to its SMES-based industrial
power quality products and enhancing and expanding its SMES product line. It is
working to decrease the cost of these products by introducing HTS current leads
to simplify the cryogenic system, by improving the cryostat and by upgrading the
magnet design. It is also seeking to expand the functionality of these products
by developing new power electronics to provide higher voltage capability and
dc-to-ac conversion, and to reduce the costs of the power electronics components
of the SMES products. There can be no assurance that the Company will succeed in
reducing the costs of SMES systems sufficiently to create a significantly larger
market.
 
HTS WIRE PRODUCTION PROCESSES
 
     The Company produces HTS wires by a variety of techniques. The principal
technique involves deformation processing, which is in some respects closely
analogous to the technique used in the existing metal wire industry. In this
approach a metal tube, typically silver, is packed with a precursor powder and
sealed to form a "billet." The billet is then deformed into a wire shape by a
variety of classical deformation processing techniques: extrusion, wire-drawing,
multifilamentary bundling and rolling. Finally, the wire is heat-treated to
transform the precursor powder inside the wire into a high-temperature
superconductor. The resulting multifilamentary composite structure, consisting
of many fine superconducting filaments imbedded in a metal matrix, is considered
by the Company to be a preferred method of achieving flexibility and durability
in its wires and wire products. This composite structure is the subject of a
patent owned by MIT, based on an invention by Dr. Gregory Yurek, Chairman of the
Board, President and Chief Executive Officer and a founder of the Company and at
the time a professor at MIT, and Dr. John Vander Sande, a professor at MIT, a
director and a founder of the Company, which patent is licensed to the Company
on an exclusive basis until 2010 in return for license fees and shares of the
Company's Common Stock. See "Business -- Patents, Trade Secrets and Licenses."
 
     The Company has pursued two basic approaches to the deformation processing
of silver-sheathed, powder-in-tube, multifilamentary composite wires. They
differ principally in the type of powder that is packed into the silver billet.
One, referred to as the oxide-powder-in-tube or "OPIT" process, involves the use
of oxide powders. The Company is presently focused primarily on the OPIT process
and has established a manufacturing line using this method. The manufacturing
line has produced sufficient lengths of wire with sufficient performance to
enable the Company to use the wire in commercial current lead products as well
as in prototype electromagnetic coils and multistrand conductors and to permit
other companies to demonstrate prototype HTS transformers, power cables and
motors using the Company's HTS wires or coils.
 
     In the alternative technique for making multifilamentary wires, referred to
as the metallic precursor or "MP" process, metallic (rather than oxide) powders
are packed into the silver billet. While the Company is not manufacturing HTS
wire by this methodology at the present time, it continues to use the technology
in certain of its wire development programs.

                                        9
<PAGE>   11
 
     Precise control of initial composition, heat-treatment temperatures and
their interplay with the deformation are required to obtain the best
superconducting performance of the wire material. The Company has protected many
aspects of its processes with patents. However, the Company expects to be
required to obtain patent licenses from third parties in order to utilize
certain aspects of these processes. While the Company is optimistic that it will
be able to obtain such licenses, there can be no assurance of this, and even if
such licenses can be obtained, the license fees may be substantial. See
"Business -- Patents, Trade Secrets and Licenses."
 
     Within the past few years, very high levels of current carrying performance
have been reported in small laboratory samples of HTS coated conductors, which
comprise a thick film of HTS material deposited on a flexible substrate,
typically with an intermediate buffer layer. One variation of this process is
called IBAD, or ion beam assisted deposition. In this process, thick films of
HTS material are deposited on an aligned buffer layer (the IBAD layer) which is
placed on a flexible substrate. This process improves the alignment of the HTS
thick films and consequently their electrical performance. Initially developed
by Fujikura Ltd., the Company believes that this process has been significantly
improved by Los Alamos National Laboratory.
 
     Another variant of coated conductor, called deformation texturing of
substrates, has been developed by Toshiba Corporation and significantly improved
by Oak Ridge National Laboratory (whose trademark for their version of this
process is "RABiTS"). The Company has studied both processes and believes that
these processes have the potential to be future processes for manufacturing HTS
wire with high current carrying capacity and lower cost than composite
deformation-processed wire. The Company is pursuing the development of these
processes with an active internal program in collaboration with Electric Power
Research Institute, Inc. ("EPRI"), Los Alamos National Laboratory, MIT and other
organizations. However, only short coated conductor wire samples have been
fabricated at high-performance levels, and there can be no assurance that the
Company will succeed in developing this technology for commercial use. The
Company has applied for patent protection on many aspects of its preferred
coated conductor process. However, the Company may be required to obtain patent
licenses from third parties in order to utilize the process. While the Company
is optimistic that it will be able to obtain such licenses, there can be no
assurance of this, and even if such licenses can be obtained, the license fees
may be substantial. See "Business -- Patents, Trade Secrets and Licenses."
 
COMPETITION
 
     The Company does not know of any companies currently selling LT-SMES
products that compete with the SMES products offered by the Company. However, at
least one company, IGC, is developing SMES systems for power quality
applications, and the Company believes there is a government-sponsored program
in Japan to develop SMES systems for power quality applications. The Company's
SMES products also compete against dynamic voltage restorers produced by
companies such as Westinghouse, flywheels under development by various companies
around the world, and battery-based, uninterruptible power supply systems, which
are widely manufactured and used around the world.
 
     There are a number of companies in the United States, Europe and Japan
engaged in attempts to bring to market high performance, technologically
advanced, cost effective HTS products. However, to the Company's knowledge, no
significant commercial amounts of HTS wire or other HTS products have been
produced or sold to date. For HTS applications, the Company's principal
competitors presently include several Japanese companies, such as Sumitomo
Electric Industries, Ltd. ("SEI"), Hitachi, Ltd., and Furukawa Electric Co.,
Ltd.; several European companies, such as Siemens A.G. in Germany and B.I.C.C.
and Oxford Instruments in England; and several companies in the U.S., such as
IGC and 3M. Each of these companies is directing significant efforts to develop
flexible, long-length HTS wires. SEI, Hitachi, Oxford and IGC are also
developing HTS magnets and systems.
 
     Many of the Company's competitors have substantially greater financial
resources, research and development, manufacturing and marketing capabilities
than the Company. In addition, as the power quality and HTS markets develop,
other large industrial companies may enter these fields and compete with the
Company.
 
                                       10
<PAGE>   12
 
STRATEGIC RELATIONSHIPS, RESEARCH ARRANGEMENTS AND GOVERNMENT CONTRACTS
 
     The Company is party to a number of strategic relationships, research
arrangements and government contracts. Its most significant strategic corporate
agreements are with Pirelli, EDF and ABB.
 
     The Pirelli alliance, originally established in February 1990, is designed
to combine Pirelli's cable technology, manufacturing and marketing expertise
with the Company's proprietary wire-manufacturing technologies for the purpose
of developing and producing HTS wires for cables used to transmit both electric
power and control signals. Under the Pirelli alliance, the Company has recorded
as revenue $13.3 million from 1990 to March 31, 1998 and Pirelli has agreed to
pay the Company an aggregate of $2.7 million over the next two years as
"development fees;" however, this agreement may be terminated upon 90 days
notice in certain circumstances. As of April 30, 1998, Pirelli owned less than
1% of the Company's Common Stock.
 
     The EDF relationship, established in April 1997, involves the exchange of
information relating to developments in HTS technology and related fields and
trends in the electricity industry, and the review of technical, industrial and
commercial topics by the parties through an advisory board comprised of
representatives from both the Company and EDF. The EDF relationship also
includes a development program, in conjunction with ABB, on HTS wire for
transformers. Under the EDF alliance, the Company received $10.0 million in 1997
from EDF as an equity contribution in exchange for 1.0 million shares of the
Company's Common Stock, which, together with the 100,000 shares EDF purchased in
the April 1998 public offering, represented, as of April 30, 1998, approximately
7.2% of the Company's outstanding Common Stock. EDF has agreed to pay the
Company an aggregate of $5.0 million (of which $1.8 million has been recorded as
revenue as of March 31, 1998) over the next four years as "development fees;"
however, this agreement may be terminated upon 90 days notice by either party.
 
     The ABB relationship is designed to combine ABB's transformer technology,
manufacturing and marketing expertise with the Company's proprietary
wire-forming technologies for the purpose of developing and producing HTS wires
and cables for transformers. ABB has agreed to pay the Company an aggregate of
$5.0 million (of which $2.3 million has been recorded as revenue as of March 31,
1998) over the next four years as "development fees;" however, this agreement
may be terminated upon 90 days notice by either party.
 
     The Company has also established a number of collaborative research
relationships with various organizations such as Industrial Research, Ltd., four
U.S. Department of Energy laboratories, University of Wisconsin Applied
Superconductivity Center, MIT and EPRI. Finally, the Company is party to a
number of government contracts, with entities such as Wright-Patterson Air Force
Base, the Naval Research Laboratory and the U.S. Department of Energy through
its Superconductivity Partnership Initiative, relating to the development and
supply of prototype products.
 
     The Company believes strategic relationships, research arrangements and
government contracts provide it with several important benefits. First, they
assist the Company in meeting and exceeding the technical benchmarks. Second,
they provide the Company with development and marketing rights to important
technologies. Third, various parties to these arrangements provide the Company
with critical funding as the Company's research and development efforts progress
toward commercialization. Since April 1, 1993, the Company has received more
than $33 million of funding under research and development contracts. Finally,
and perhaps most importantly, several of these relationships, particularly those
with Pirelli and ABB, provide a potential direct market for the Company's HTS
wires.
 
PATENTS, TRADE SECRETS AND LICENSES
 
  The HTS Patent Background
 
     Since the discovery of high temperature superconductors in 1986, the HTS
industry has been characterized by rapid technical advances, which in turn have
resulted in a large number of patents relating to superconductivity being
applied for and granted worldwide. The claims in different granted patents often
overlap, and similar patents in different countries may have different claims or
be owned by different entities. As a result, the patent situation in the field
of HTS technology and products is unusually complex.
 
     Most major potential HTS manufacturers, including the Company and its
competitors, own or may obtain patents which may interfere with each other. A
number of United States and foreign patents and patent applications, held by
third parties, relate to the Company's current products or to products under
development,
 
                                       11
<PAGE>   13
 
or to the technology now or later to be utilized by the Company in the
development or production of certain present and future products. Additional
patents relating to the Company's technology, processes or applications may be
issued to third parties in the future. The Company will need to acquire licenses
to, or to successfully contest the scope or validity of, patents owned by third
parties.
 
     The Company believes that companies holding patent portfolios which may
complement portfolios held by others in the industry are more likely to be
willing to enter into cross-licensing arrangements with such other patent owners
than with companies that do not have such patent positions. The Company believes
that certain patents it has licensed from others covering basic materials
processing methods, and composites of HTS ceramics and noble metals, will
improve the strength of its patent portfolio and therefore its position in these
future licensing negotiations. See "Business -- Patents, Trade Secrets and
Licenses -- Patents and Wire Architecture."
 
     However, many patents and patent applications are held by companies with
which the Company may not compete, and such companies may not be interested in
cross-licensing. Moreover, it is possible that the Company could be required to
obtain licenses under a number of different patents and from a number of
different patent holders in connection with various aspects of its present and
planned business operations. Although the Company is optimistic that it will be
able to obtain any necessary licenses on commercially reasonable terms, there
can be no assurance that all necessary licenses will be available on
commercially reasonable terms, or at all.
 
     The cost of any such licenses is not known, but the Company is likely to be
required to obtain multiple licenses and, to the extent that licenses can be
obtained the cost is expected, in aggregate, to be substantial. The failure to
obtain all necessary licenses upon reasonable terms could significantly reduce
the scope of the Company's business, limit its profit margins, and otherwise
have a material adverse effect on the Company's operations.
 
     The likelihood of successfully contesting the scope or validity of any such
patents is also uncertain; and, in any event, the Company could incur
substantial costs in challenging the patents of other companies. Moreover, the
Company could incur substantial litigation costs in defending the scope and
validity of its own patents.
 
     To understand the Company's approach to patents in light of these
circumstances, it is useful to analyze HTS patents in relation to the issues the
Company needs to consider in the process of designing and manufacturing HTS
products; the choice of material used to make an HTS product; the choice of the
processing method to be applied to that material; and the choice of components
or subsystems to be fabricated and the fabrication methods used.
 
  Patents and the Choice of HTS Materials
 
     Presently, the materials from which HTS products are made are copper
oxides, or "cuprates." The Company does not anticipate that anyone will receive
a broad basic patent on cuprates, but there can be no assurance in this regard.
There are a number of HTS materials within the cuprate family. A number of
patents have been issued with regard to certain specific HTS materials within
the cuprate family and the Company believes that a number of other patent
applications for various HTS materials within the cuprate family, some with
broad claims, are pending.
 
     At any given time, the Company will have a preference for utilizing one or
a few specific HTS materials in the production of its products for commercial
application, and any HTS material used by the Company is likely to be covered by
one or more patents issued to other parties. Because of the number and scope of
patents pending or issued in various parts of the world, the Company may be
required to obtain multiple licenses to use any particular material.
 
     The Company jointly owns or has obtained licenses with respect to patents
covering certain HTS materials through its collaborations with MIT and
Superlink. However, the Company expects that additional materials licenses may
be required. There is no assurance that the Company will be able to obtain on
commercially reasonable terms all the licenses that may be needed for the
Company to use preferred HTS materials, and even if the Company is able to
obtain such licenses, the license fees may be substantial.
 
                                       12
<PAGE>   14
 
  Patents and the Processing of HTS Materials
 
     The Company is concentrating on two main methods for processing the
materials it currently intends to use: the OPIT method, and the "coated
conductor" technology. See "Business -- HTS Wire Production Processes." The
Company's strategy is to obtain a proprietary position in each of these
processes through a combination of patents, licensing and proprietary know-how.
If alternative processes become more promising in the future, the Company will
also seek to develop a proprietary position in these alternative processes.
 
     The Company has filed a number of patent applications which are applicable
to one or more of the MP method, the OPIT method, and coated conductor
technology. Some of these applications have been issued as patents in the U.S.
and abroad while others are pending. The Company also has acquired options to
exclusively license additional intellectual property in the coated conductor
area through its collaborations with EPRI and MIT.
 
     Effective March 31, 1998, the Company signed an agreement with Lucent
Technologies, Inc. ("Lucent"), granting the Company a royalty-bearing,
non-exclusive worldwide license for superconductor wire under Lucent's portfolio
of high temperature superconductor patents and patent applications. The license
runs from March 31, 1998 until the expiration of the last-to-expire patent in
the portfolio.
 
     Additional U.S. and foreign patents have been issued to third parties with
claims directed to HTS processing methods which, if valid, may cover one or more
of the MP, the OPIT or the coated conductor technologies used by the Company.
Several U.S. and foreign patents have been issued with claims which, if valid,
may cover various aspects of the coated conductor process. In addition, the
Company has learned that a number of additional U.S. and foreign patent
applications have been filed which contain similar claims. To the extent any of
these issued patents are valid and cover any processing methods used by the
Company, or if any of the pending applications result in a valid patent with
claims covering the Company's methods, the Company would be required to obtain
licenses under any applicable patents. There is no assurance that the Company
will be able to obtain such licenses, and even if such licenses can be obtained,
the license fees may be substantial.
 
  Patents and Wire Architecture
 
     The Company has an exclusive license from MIT under an issued U.S. patent
that covers composites (including multifilamentary wires) of HTS ceramics and
noble metals such as silver.
 
     A number of other companies have also filed, and in some instances, have
been issued patents on various aspects of wire architecture. To the extent any
of these issued patents are valid and cover the wire architectures used by the
Company, or to the extent any of the pending applications result in a valid
patent with claims covering the Company's methods, the Company would be required
to obtain licenses under any applicable patents. There is no assurance that the
Company will be able to obtain such licenses, and even if such licenses can be
obtained, the license fees may be substantial.
 
  HTS Component and Subsystem Fabrication, HTS Application, and Power Quality
and SMES Patents
 
     The Company has been issued several patents and filed several additional
patent applications regarding the design and fabrication of electromagnetic
coils and electromagnets, the integration of these products with an appropriate
coolant or cryocooler and the application of these products to certain specific
end uses, as well as several patent applications on cryocooled power
electronics. The Company holds several issued patents and pending applications
on power quality systems as a result of the acquisition of SI.
 
     Since the HTS and cryocooled power systems fields are relatively new,
significant applications can and are being patented by others. A number of other
companies have also filed, and in some instances have been issued, patents on
various applications of HTS wire, cryocooled power electronics and component and
subsystem fabrication methods. To the extent any existing or future third party
patents are pertinent to these aspects of the Company's operations, the Company
would be required to obtain licenses under the applicable patents. There is no
assurance that the Company will be able to obtain such licenses, and even if
such licenses can be obtained, the license fees may be substantial.
 
                                       13
<PAGE>   15
 
  Trade Secrets
 
     Some of the technology used in, and that may be important to, the Company's
operations and products is not covered by any patent or patent application owned
by or licensed to the Company. However, the Company takes steps to maintain the
confidentiality of this technology by requiring all employees and all
consultants to sign confidentiality agreements and limiting access to
confidential information. However, no assurance can be given that these measures
will prevent the unauthorized disclosure or use of such information. Further,
there is no assurance that others, including the Company's competitors, will not
independently develop the same or comparable technology.
 
EMPLOYEES
 
     As of March 31, 1998, the Company employed a total of 213 persons, 24 of
whom have Ph.D's in material science, physics or related fields. No Company
employees are represented by a labor union. The Company believes that its
employee relations are good.
 
RESEARCH AND DEVELOPMENT
 
     The Company's research and development expenses in fiscal 1998 were
approximately $8,641,000 compared to $8,477,000 in fiscal 1997. Adjusted
research and development expenses, which consist of company-funded research and
development expenses plus research and development expenses related to
externally-funded development contracts included in costs of revenue and
research and development expenses offset by cost-sharing funding under
government contracts, were $17,048,000 in fiscal 1998 compared to $14,678,000 in
fiscal 1997.
 
ITEM 2.  PROPERTIES.
 
     The Company's operations are located in approximately 102,000 square feet
of space in Westborough, Massachusetts, approximately 60,000 square feet of
space in Middleton, Wisconsin and approximately 3,700 square feet of space in
Woburn, Massachusetts. The Company occupies the Westborough facility under a
lease which expires on May 31, 2003 and has an option to extend the lease for an
additional five-year term. The Company occupies the Middleton facilities under
two leases which expire on December 31, 2003. The Company occupies the Woburn
facility under a lease which expires on January 30, 1999.
 
ITEM 3.  LEGAL PROCEEDINGS.
 
     Neither the Company nor any subsidiary is involved in any material legal
proceedings other than routine litigation incidental to its business.
 
ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY-HOLDERS.
 
     No matters were submitted to a vote of the Company's security-holders
during the fourth quarter of the fiscal year ended March 31, 1998.
 
  Executive Officers of the Company
 
     The following table sets forth the names, ages and offices of all executive
officers of the Company:
 
<TABLE>
<CAPTION>
NAME                                          AGE                       OFFICE
- ----                                          ---                       ------
<S>                                           <C>    <C>
Gregory J. Yurek............................  51     President, Chief Executive Officer and
                                                     Chairman of the Board of Directors
Stanley D. Piekos...........................  50     Vice President, Corporate Development, Chief
                                                     Financial Officer, Treasurer and Secretary
Alexis P. Malozemoff........................  54     Senior Vice President and Chief Technical
                                                     Officer
Roland E. Lefebvre..........................  47     Executive Vice President and Chief Operating
                                                     Officer
Ross S. Gibson..............................  39     Vice President, Human Resources
John B. Howe................................  41     Vice President, Electric Industry Affairs
</TABLE>
 
                                       14
<PAGE>   16
 
     Dr. Yurek co-founded the Company and has been a director since July 1987,
President since March 1989, Chief Executive Officer since December 1989 and
Chairman of the Board since October 1991. Dr. Yurek also served as Vice
President and Chief Technical Officer from August 1988 until March 1989 and as
Chief Operating Officer from March 1989 until December 1989. Prior to joining
the Company, Dr. Yurek was a Professor of Materials Science and Engineering at
MIT for 13 years.
 
     Mr. Piekos joined the Company in February 1998 as Chief Financial Officer,
Vice President, Corporate Development, Treasurer and Secretary. From June 1994
until February 1998, Mr. Piekos served as Vice President and Chief Financial
Officer of Brooks Automation, Inc., a supplier of robotics and controls to the
semiconductor production equipment industry. For the nine years prior to June
1994, Mr. Piekos was employed by Helix Technology Corporation, a manufacturer of
cryogenic equipment, most recently as Vice President and Chief Financial
Officer.
 
     Dr. Malozemoff joined the Company as Vice President, Research and
Development in January 1991 and was elected Chief Technical Officer in January
1993 and Senior Vice President in May 1998. Prior to joining the Company, Dr.
Malozemoff spent 19 years at IBM in a variety of research and management
positions, most recently as IBM Research Coordinator for High Temperature
Superconductivity.
 
     Mr. Lefebvre joined the Company in May 1996 as Vice President, Sales and
Marketing and was elected Executive Vice President and Chief Operating Officer
in May 1998. Prior to joining the Company, Mr. Lefebvre spent 23 years at
General Electric Company in a variety of positions, most recently as General
Manager, National Account Sales.
 
     Mr. Gibson joined the Company as Vice President, Human Resources in July
1997. From April 1992 until June 1997, Mr. Gibson served in a variety of
positions at Cambridge Neuroscience, Inc., most recently as Vice President,
Human Resources and Administration and Chief Administrative Officer.
 
     Mr. Howe joined the Company in November 1997 as Director, Electric Industry
Affairs and was elected Vice President, Electric Industry Affairs in May 1998.
From November 1995 until September 1997, Mr. Howe was Chairman of the
Massachusetts Department of Public Utilities. For the five and one-half years
prior to November 1995, Mr. Howe served in various positions, most recently as
Vice President, Regulatory and Government Affairs, for U.S. Generating Company.
 
                                       15
<PAGE>   17
 
                                    PART II
 
ITEM 5.  MARKET FOR REGISTRANT'S COMMON STOCK AND RELATED STOCKHOLDER MATTERS.
 
     The Company's Common Stock has been quoted on the Nasdaq National Market
under the symbol "AMSC" since 1991. The following table sets forth the high and
low closing price per share of the Company's Common Stock as reported on the
Nasdaq National Market for the two most recent fiscal years:
 
<TABLE>
<CAPTION>
                                                              COMMON STOCK
                                                                  PRICE
                                                              -------------
                                                              HIGH     LOW
                                                              -----    ----
<S>                                                           <C>      <C>
FISCAL YEAR ENDED MARCH 31, 1997:
  First quarter.............................................  14 3/4   12 3/8
  Second quarter............................................  15 3/4   11 5/8
  Third quarter.............................................  15 1/8   10 3/8
  Fourth quarter............................................  11 3/4   7 7/8
FISCAL YEAR ENDED MARCH 31, 1998:
  First quarter.............................................  12 1/4   8 1/4
  Second quarter............................................  13 3/8   8 5/8
  Third quarter.............................................  14 1/8   8 3/8
  Fourth quarter............................................    15     8 1/2
</TABLE>
 
     The number of shareholders of record on June 8, 1998 was 430.
 
ITEM 6.  SELECTED FINANCIAL DATA.
 
     The selected consolidated financial data presented below reflect the
combined results of operations and financial position of the Company and SI
restated for all periods presented pursuant to the pooling of interests method
of accounting. The financial data for the fiscal year ended March 31, 1998 have
been derived from the Company's consolidated financial statements that have been
audited by Coopers & Lybrand L.L.P, independent accountants. The financial data
for each of the four fiscal years in the period ended March 31, 1997 have been
derived from the combination of the Company's consolidated financial statements
that have been audited by Coopers & Lybrand L.L.P., independent accountants, and
the SI financial statements that have been audited by other independent
accountants. In addition, the combination of the separate audited financial
statements of the Company and SI for the three fiscal years in the period ended
March 31, 1997 has been audited by Coopers & Lybrand L.L.P. This financial data
should be read in conjunction with the Consolidated Financial Statements and the
Notes thereto and the other financial information appearing elsewhere in this
Annual Report on Form 10-K.
 
<TABLE>
<CAPTION>
                                                            YEAR ENDED MARCH 31,
                                              ------------------------------------------------
                                               1998       1997       1996      1995      1994
                                              -------    -------    ------    ------    ------
                                                   (IN THOUSANDS, EXCEPT PER SHARE DATA)
<S>                                           <C>        <C>        <C>       <C>       <C>
Revenues....................................   15,129     10,551    10,764     8,593     4,942
Net loss....................................  (12,378)   (13,377)   (9,698)   (7,036)   (7,717)
Net loss per share..........................    (1.06)     (1.27)    (0.94)    (0.69)    (0.86)
Total assets................................   19,551     26,581    35,856    44,887    50,037
Working capital.............................    5,059        318     5,101     2,341     7,666
Cash, cash equivalents and long-term
  marketable securities.....................    8,009     16,031    26,519    33,653    41,774
Stockholders' equity........................   12,859     16,501    29,780    38,416    45,349
</TABLE>
 
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS.
 
     The information required by this Item is attached as Appendix A hereto and
is incorporated herein by reference.
 
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
 
     Not applicable.
 
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
 
     All financial statements required to be filed hereunder are filed as
Appendix B hereto, are listed under Item 14(a), and are incorporated herein by
reference.
 
                                       16
<PAGE>   18
 
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
        FINANCIAL DISCLOSURE.
 
     Not Applicable.
 
                                    PART III
 
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
 
     The response to this item is contained in part under the caption "Executive
Officers of the Company" in Part I of this Annual Report on Form 10-K, and in
part in the Company's Proxy Statement for the Annual Meeting of Stockholders for
the fiscal year ended March 31, 1998 (the "1998 Proxy Statement") in the
sections "Election of Directors -- Nominees," and "Other Matters -- Section 16
Beneficial Ownership Reporting Compliance," which sections are incorporated
herein by reference.
 
ITEM 11. EXECUTIVE COMPENSATION.
 
     The response to this item is contained in the 1998 Proxy Statement in the
sections "Election of Directors -- Directors' Compensation," "-- Executive
Compensation," and "-- Employment Agreements with Senior Executives," which
sections are incorporated herein by reference.
 
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
 
     The response to this item is contained in the 1998 Proxy Statement in the
section "Beneficial Ownership of Common Stock," which section is incorporated
herein by reference.
 
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
 
     The response to this item is contained in the 1998 Proxy Statement in the
section "Election of Directors -- Certain Business Relationships," which section
is incorporated herein by reference.
 
                                    PART IV
 
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.
 
     (a) The following documents are filed as Appendix B hereto and are included
as part of this Annual Report on Form 10-K.
 
        Financial Statements:
 
        Report of Independent Accountants
        Consolidated Balance Sheets
        Consolidated Statements of Operations
        Consolidated Statements of Cash Flows
        Consolidated Statements of Changes in Stockholders' Equity
        Notes to Consolidated Financial Statements
 
     The Company is not filing any financial statement schedules as part of this
Annual Report on Form 10-K because they are not applicable or the required
information is included in the financial statements or notes thereto.
 
     (b) Reports on Form 8-K.
 
     The Company filed a report on Form 8-K on March 24, 1998 to file restated
Financial Data Schedules for all periods affected by the restatement of the
Company's financial statements following the adoption of Financial Accounting
Standard ("FAS") No. 128 relating to earnings per share and the acquisition of
Superconductivity, Inc., accounted for as a pooling of interests. No other
reports on Form 8-K were filed during the last quarter of the Company's fiscal
year ended March 31, 1998.
 
     (c) The list of Exhibits filed as a part of this Annual Report on Form 10-K
is set forth on the Exhibit Index immediately preceding such Exhibits.
 
                                       17
<PAGE>   19
 
                                                                      APPENDIX A
 
          MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
                           AND RESULTS OF OPERATIONS
 
     American Superconductor Corporation (the "Company") was founded in 1987 to
develop for commercialization high temperature superconducting ("HTS") wires and
wire products. On April 8, 1997, the Company acquired Superconductivity, Inc.
("SI"), which is now being operated as the Power Quality Solutions business unit
of the Company, in a transaction accounted for under the pooling of interests
method of accounting. Accordingly, the Company's consolidated financial
statements reflect the combined financial position, operating results and cash
flows of the Company and SI as if they had been combined for all periods
presented. For purposes of the discussion of the results of operations of the
Company for the fiscal years ended March 31, 1997 and 1996, the term "Former
ASC" is used to refer to the Company prior to the SI acquisition. On July 31,
1997, the Company acquired Applied Engineering Technologies, Ltd. ("AET") in a
transaction accounted for under the pooling of interests method of accounting.
Due to the immaterial effect on the Company's consolidated financial statements,
prior periods have not been adjusted to reflect the effect of this transaction
on the financial position, operating results and cash flows of the Company.
 
                             RESULTS OF OPERATIONS
 
FISCAL YEARS ENDED MARCH 31, 1998 AND MARCH 31, 1997
 
  Revenues
 
     Total revenues increased 43% to $15,129,000 in fiscal 1998 from $10,551,000
in fiscal 1997. This increase was due primarily to higher contract revenue
associated with the Company's joint development program with Electricite de
France ("EDF") and ABB Power Transmission and Distribution Company ("ABB") to
develop high temperature superconductor ("HTS") wire for power transformers. The
agreements with ABB and EDF were signed in fiscal 1998, and contributed
$3,075,000 in contract revenue in fiscal 1998, compared to $700,000 in contract
revenue and $300,000 in product sale revenue from ABB in fiscal 1997.
 
     In addition, contract revenue was also positively affected by a $700,000
contract with the Electric Power Research Institute (EPRI) and by an increase in
work performed on seven Phase II Small Business Innovation Research (SBIR)
grants, five of which were awarded during fiscal 1998, from the Department of
Energy, Department of Defense, and National Science Foundation. At SI, fiscal
1998 product sales increased $1,518,000 compared to fiscal 1997, which was
largely offset by a decrease in contract revenue of $1,426,000. Revenue was also
positively affected by the recognition of $565,000 in product sales by AET,
which was acquired on July 31, 1997, four months into the Company's fiscal year.
Fiscal 1997 contract revenue included $825,000 relating to a research and
development agreement with Inco Alloys International, which was discontinued on
December 31, 1996.
 
     In addition to reported revenues, the Company also received funding of
$1,771,000 in fiscal 1998 under government cost-sharing agreements as compared
to $1,706,000 in fiscal 1997. The Company anticipates that a portion of its
funding in the future will continue to come from cost-sharing agreements as the
Company continues to develop joint programs with government agencies. Funding
from government cost-sharing agreements is recorded as an offset to research and
development and selling, general and administrative expenses, as required by
government contract accounting guidelines, rather than as revenue.
 
  Operating expenses
 
     The Company's total operating expenses in fiscal 1998 were $27,884,000
compared to $23,345,000 in fiscal 1997. Costs of revenue, which include costs of
research and development contracts and costs of product sales and prototype
development contracts, increased to $14,333,000 in fiscal 1998 compared to
$10,577,000 in fiscal 1997. This increase reflects expenditures to support the
increase in contract and prototype development revenues, including the hiring of
additional personnel and purchases of materials and equipment. Included in
 
                                       A-1
<PAGE>   20
 
cost of revenue is a write-down provision of $445,000 in fiscal 1997. This
provision was required to adjust the carrying values of certain items of
inventory to their fair values.
 
     Adjusted research and development ("R&D") expenses, which include amounts
classified as costs of revenue and amounts offset by cost sharing funding,
increased to $17,048,000 in fiscal 1998 from $14,678,000 in fiscal 1997. This
increase was due to the continued scale-up of the Company's internal research
and development activities including the hiring of additional personnel, the
purchases of materials and equipment and the payment of patent licensing fees. A
portion of the R&D expenditures related to externally funded development
contracts has been classified as costs of revenue (rather than as R&D expenses).
These R&D expenditures that were included as costs of revenue during fiscal 1998
and fiscal 1997 were $7,494,000 and $5,322,000, respectively. Additionally, R&D
expenses that were offset by cost sharing funding were $913,000 and $879,000 in
fiscal 1998 and 1997, respectively. Net R&D expenses (exclusive of amounts
classified as costs of revenue and amounts offset by cost sharing funding)
increased to $8,641,000 in fiscal 1998 from $8,477,000 the prior year.
 
     Selling, general and administrative ("SG&A") expenses were $4,910,000 in
fiscal 1998 as compared to $4,291,000 in fiscal 1997. These increases were
primarily due to additional recruiting, legal, consulting, and marketing
expenses incurred to support the overall increase in the Company's revenues and
research and development activities, as well as increases in executive bonuses
and other compensation. The SG&A amounts offset by cost share funding were
$858,000 and $828,000 in fiscal years 1998 and 1997, respectively. In addition
to these expenses, a portion of the SG&A expenditures related to externally
funded development contracts has been classified as costs of revenue (rather
than as SG&A expenses). SG&A expenditures included as costs of revenue during
fiscal 1998 and fiscal 1997 were $3,394,000 and $2,186,000, respectively.
 
  Non-operating expenses
 
     Interest income decreased to $782,000 in fiscal 1998, as compared to
$1,177,000 in fiscal 1997. This decrease primarily reflects lower cash, cash
equivalents and long-term marketable securities balances available for
investment as a result of cash being used to fund the Company's operations, pay
liabilities and transaction costs related to the two mergers, and to purchase
capital equipment. Interest expense decreased from $356,000 in fiscal 1997 to
$239,000 in fiscal 1998 primarily due to the payoff of notes payable and the
reduction in long term debt. Other expense, net is comprised primarily of
miscellaneous taxes net of gains on the disposition of excess capital equipment.
 
     Merger related fees of $710,000 in fiscal 1997 related to the costs
incurred through March 31, 1997 in connection with the Company's acquisition of
SI, and consisted primarily of financial advisory and legal fees. In fiscal
1998, the Company incurred an additional $155,000 in transaction fees resulting
from professional fees relating to both the SI ($76,000) and the AET ($79,000)
acquisitions. In fiscal 1997 SI incurred professional fees relating to a
terminated merger negotiation amounting to $670,000.
 
     The Company expects to continue to incur operating losses for the next few
years, as it continues to devote significant financial resources to its research
and development activities and commercialization efforts.
 
     The Company expects to be a party to agreements which, from time to time,
may result in costs incurred exceeding expected revenues under such contracts.
The Company may enter into such agreements for a variety of reasons including,
but not limited to, entering new product application areas, furthering the
development of key technologies, and advancing the demonstration of commercial
prototypes in critical market applications.
 
FISCAL YEARS ENDED MARCH 31, 1997 AND MARCH 31, 1996
 
  Revenues
 
     Total revenues decreased to $10,551,000 in fiscal 1997 from $10,764,000 in
fiscal 1996. The Former ASC's revenues from research and development contracts,
prototype development contracts and the sale of prototypes increased to
$7,175,000 in fiscal 1997 from $7,131,000 in fiscal 1996. This increase was due
primarily to work performed on a research and development contract with Asea
Brown Boveri (ABB) and
                                       A-2
<PAGE>   21
 
increases in funding on various U. S. Government grants and prototype
development contracts. This increase was largely offset by a drop in prototype
sales associated with a major cable prototype on which the Former ASC concluded
shipping HTS wire in the year ended March 31, 1996, and by the discontinuation
(effective December 31, 1996) of the joint research and development program on
metallic precursor wire technology with Inco Alloys International, Inc., which
had been providing $1.1 million in annual funding.
 
     At SI, revenues in fiscal 1997 were $3,376,000 compared to $3,633,000 in
fiscal 1996. This decrease in revenues is due to the completion of a long-term
cost-plus-fixed-fee government contract in September 1996, which was in progress
during all of fiscal 1996. SI began an additional long-term government contract
in October 1996; however, revenue under this firm fixed-price contract was not
recognized until fiscal 1998. The decrease in SI's contract revenue (from a
total of $2,762,000 in 1996 to $1,570,000 in 1997) was partially offset by SI's
first sale of a commercial unit, which generated $993,000 in revenue in fiscal
1997.
 
     In addition to reported revenues, the Former ASC also received funding of
$1,706,000 in fiscal 1997 under government cost-sharing agreements as compared
to $985,000 in fiscal 1996. This increased cost-sharing funding was primarily
due to the award of a $20.5 million Phase II Superconductivity Partnership
Initiative (SPI) contract on commercial-scale HTS motors by the Department of
Energy to the Company and Reliance Electric Company (a Rockwell Automation
business).
 
  Operating expenses
 
     The Company's total operating expenses in fiscal 1997 were $23,345,000
compared to $21,796,000 in fiscal 1996. At the Former ASC, operating expenses
increased to $18,035,000 in fiscal 1997 from $15,992,000 in fiscal 1996. Costs
of revenue increased to $7,508,000 in fiscal 1997 compared to $7,331,000 in
fiscal 1996 at the Former ASC. This increase reflects expenditures to support
the increase in contract and prototype development revenues, including the
hiring of additional personnel and purchases of materials and equipment,
partially offset by lower costs of revenue associated with the decreased sales
of prototypes.
 
     At SI, operating expenses decreased to $5,310,000 in fiscal 1997 from
$5,804,000 in fiscal 1996. SI's cost of revenue decreased to $3,070,000 in
fiscal 1997 from $4,222,000 in fiscal 1996. Included in cost of revenue are
write-down provisions of $445,000 and $1,175,000 in fiscal 1997 and fiscal 1996,
respectively. These provisions were required to adjust the carrying values of
certain items of inventory and equipment to their market values.
 
     R&D expenses increased to $8,477,000 in fiscal 1997 from $5,704,000 the
prior year. The Former ASC's R&D expenses were $7,709,000 in fiscal 1997
compared to $5,341,000 in fiscal 1996. This increase was due to the continued
scale-up of the Former ASC's internal research and development activities
including the hiring of additional personnel and purchases of materials and
equipment. In addition to these expenses, a portion of the Former ASC's R&D
expenditures related to externally funded development contracts has been
classified as costs of revenue (rather than as R&D expenses). These R&D
expenditures that were included as costs of revenue during fiscal 1997 and
fiscal 1996 were $5,322,000 and $5,256,000, respectively. Additionally, R&D
expenses that were offset by cost share funding were $879,000 and $584,000 in
fiscal years 1997 and 1996, respectively. At SI, R&D expenses increased from
$363,000 in fiscal 1996 to $769,000 in fiscal 1997 because a higher proportion
of R&D expenses were classified as cost of revenue as a result of the higher
funding by the government cost-plus-fixed-fee contract in fiscal 1996 because of
the completion of the contract during fiscal 1997.
 
     SG&A expenses were $4,291,000 in fiscal 1997 as compared to $4,538,000 in
fiscal 1996. At the Former ASC, SG&A expenses decreased to $2,818,000 in fiscal
1997 from $3,319,000 in fiscal 1996. This was primarily the result of certain
SG&A expenditures that were offset by the increased funding received under cost
sharing agreements. The SG&A amounts offset by cost share funding at the Former
ASC were $828,000 and $378,000 in fiscal years 1997 and 1996, respectively. SI's
SG&A expenses increased from $1,219,000 in fiscal 1996 to $1,472,000 in fiscal
1997. This increase was principally due to an increase in selling expenses,
primarily relating to the hiring of additional sales and marketing personnel to
support the South African market and SI's expanding line of commercial products.
In addition to these expenses, a portion of the Former ASC's SG&A expenditures
related to externally funded development contracts has been classified as costs
of

                                       A-3
<PAGE>   22
 
revenue (rather than as SG&A expenses). SG&A expenditures included as costs of
revenue during fiscal 1997 and fiscal 1996 were $2,186,000 and $2,075,000,
respectively.
 
  Non-operating expenses
 
     Interest income decreased to $1,177,000 in fiscal 1997, as compared to
$1,585,000 in fiscal 1996. This decrease primarily reflects lower cash, cash
equivalents and long-term marketable securities balances available for
investment as a result of cash being used to fund the Company's operations and
to purchase capital equipment. Interest expense increased from $215,000 in
fiscal 1996 to $356,000 in fiscal 1997 primarily due to SI's $1,200,000
convertible debenture financing. Other expense, net is comprised primarily of
miscellaneous taxes net of gains on the disposition of excess capital equipment.
 
     Merger related fees of $710,000 in fiscal 1997 related to the costs
incurred through March 31, 1997 in connection with the Company's acquisition of
SI, and consisted primarily of financial advisory and legal fees. In fiscal 1997
SI incurred professional fees relating to a terminated merger negotiation
amounting to $670,000.
 
                        LIQUIDITY AND CAPITAL RESOURCES
 
     At March 31, 1998, the Company had cash, cash equivalents and long-term
marketable securities totaling $8,009,000 compared to cash, cash equivalents and
long-term marketable securities totaling $16,031,000 at March 31, 1997. In
fiscal 1998, $14,930,000 was used to fund the Company's operations.
Approximately $4,400,000 was used pay the investment banking and legal fees
associated with the Company's April 8, 1997 acquisition of SI and the retirement
of various SI liabilities. Additional uses of cash were for the purchase of
capital equipment, primarily for research and development and manufacturing.
This decrease in cash was partially offset by a $10,000,000 equity investment by
a subsidiary of Electricite de France in April, 1997. On April 22, 1998 the
Company completed a secondary public offering of 3,504,121 shares of common
stock and received net proceeds (before deducting offering expenses) of
$46,114,000.
 
     The Company has potential funding commitments of approximately $14,589,000
to be received after March 31, 1998 from strategic partners and government
agencies (all of which is due within the next three years). However, a total of
$5,914,000 of these commitments (representing commitments under government
contracts) is subject to cancellation.
 
     The Company's policy is to invest available funds in short-term,
intermediate-term, and long-term investment grade marketable securities,
including but not limited to government obligations, repurchase agreements,
certificates of deposit and money market funds.
 
     The Company believes that several years of further development will be
necessary before HTS wires and related products are available in significant
quantities for commercial power applications. The Company believes, based on its
current business plan, that its current cash and marketable securities should be
sufficient to fund the Company's operations for at least the next three years.
However, the Company may need additional funds sooner than anticipated if the
Company's performance deviates significantly from its current business plan or
there are significant changes in competitive or other market factors. There can
be no assurance that such funds, whether from equity or debt financing,
development contracts or other sources, will be available, or available under
terms acceptable to the Company.
 
     The Company has analyzed the computer systems and related applications of
the Company and its subsidiaries to assess the expected impact of the Year 2000
date recognition issue on these systems and applications. Certain systems will
need to be updated in order to be prepared for the Year 2000 issue, and the
Company anticipates this process will be completed by the end of fiscal 1999.
The Company does not anticipate that the costs associated with this updating or
the Year 2000 issue will have a material adverse effect on the financial
condition or results of operations of the Company.
 
     Transaction gains and losses from foreign currency transactions have not
been material to date. To date, inflation has not had a material impact on the
Company's financial results.
 
                                       A-4
<PAGE>   23
 
                            FUTURE OPERATING RESULTS
 
     The Company does not provide forecasts of its future financial performance.
However, various statements included herein, as well as other statements made
from time to time by Company representatives, which are not statements of
historical facts (including but not limited to statements concerning the future
commercial success of the Company) constitute forward looking statements and are
made under the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. There are a number of important factors which could cause
the Company's actual results of operations and financial condition in the future
to vary from that indicated in such forward looking statements. Factors that may
cause such differences include, without limitation, the risks, uncertainties and
other information set forth below.
 
     Development Stage of the Company; Technological Challenges.  To date, the
Company has been principally engaged in research and development activities.
Some of the Company's products are in the early stages of commercialization and
testing, while others are still under development. The Company believes that
several years of further development will be necessary before its HTS wires and
wire products will be available for significant commercial end-use applications,
and that significant additional development work is necessary to improve the
commercial feasibility and acceptance of its LT-SMES products. There are a
number of technological challenges that the Company must successfully address to
complete any of its commercialization and development efforts. There can be no
assurance that the Company will be able to meet such technological challenges
and commercialize any such products or that these products, if timely developed
and commercialized, will be technically or commercially successful.
 
     Uncertainty Regarding Development of Market.  To date, there has been no
widespread commercial use of HTS products. Although LTS products are currently
used in a number of commercial applications, commercial acceptance of LTS
products has been significantly limited by the cooling requirements of LTS
materials and other factors. There can be no assurance that the technological
hurdles currently limiting commercial use of HTS and LTS products will ever be
overcome, or that the market demands currently anticipated by the Company for
its HTS and LTS products will develop.
 
     History of Losses and Uncertainty of Financial Results.  The Company has
incurred net losses in each year since its inception. The Company expects to
continue to incur operating losses for at least the next few years and there can
be no assurance that the Company will ever achieve a profitable level of
operations.
 
     Uncertainties Regarding Proprietary Rights.  The Company expects that some
or all of the HTS materials used in the manufacture of its products, and certain
aspects of the technologies used by the Company in processing HTS materials, are
or will become covered by patents issued to other parties (who may include
competitors of the Company). Accordingly, the Company will need to acquire
licenses to, or successfully contest the validity of, such patents in order to
avoid patent infringement claims being brought against it. Based on commercial
practices in other industries, the Company is optimistic that such licenses will
be available. However, there can be no assurance that such licenses will be
available, or that, if available, they will be available on commercially
reasonable terms. Any litigation by the Company to contest the validity or scope
of such patents is likely to involve significant expense and may not be
successful.
 
     Competition and Technological Change.  The superconductivity industry is
characterized by rapidly changing and advancing technology. For HTS
applications, the Company's principal competitors presently include several
major Japanese companies, such as Sumitomo Electric Industries, Ltd., Hitachi,
ltd. and Furukawa Electric Co. Ltd.; several European companies, such as Siemens
A.G. in Germany and B.I.C.C. and Oxford Instruments in England; and several
companies in the U.S. such as Intermagnetics General Corporation and 3M. In the
market for industrial power quality systems and services, the Company competes
with vendors of a number of non-superconductivity products as well as developers
of SMES systems. The future success of the Company will depend in large part
upon its ability to keep pace with advancing HTS and LTS technology and
developing industry standards. There can be no assurance that the Company's
development efforts will not be rendered obsolete by research efforts and
technological advances made by others. Many of the Company's competitors have
substantially greater financial resources, research and development,
manufacturing and marketing capabilities than the Company. In addition, as the
HTS and
 
                                       A-5
<PAGE>   24
 
power quality markets develop, other large industrial companies may enter these
fields and compete with the Company.
 
     Future Capital Needs.  The Company believes, based upon its current
business plan, that its current cash and marketable securities should be
sufficient to fund the Company's operations as planned for at least the next
three years. However, the Company may need additional funds sooner than
anticipated if the Company's performance deviates significantly from its current
business plan or if there are significant changes in competitive or other market
factors. There can be no assurance that such funds, whether from equity or debt
financing, development contracts or other sources, will be available, or
available on terms acceptable to the Company.
 
     Lack of Manufacturing and Marketing Experience.  For the Company to be
financially successful, it must manufacture the products developed by it in
commercial quantities at acceptable costs and on a timely basis. The production
of commercial quantities at acceptable costs presents a number of technological
and engineering challenges for the Company, and significant start-up costs and
unforeseen expenses may be incurred in connection with efforts to manufacture
commercial quantities of the Company's products. In addition, the Company will
be required to develop a marketing and sales force that will effectively
demonstrate the advantages of its products over more traditional products, as
well as competitive superconductive products. The Company's marketing and
selling experience to date is limited. There can be no assurance that the
Company will be able to make the transition to commercial production
successfully or that the Company will be successful in its marketing efforts,
that it will be able to establish adequate sales and distribution capabilities,
that it will be able to enter into marketing agreements or relationships with
third parties on financially acceptable terms, or that any third parties with
whom it enters into such arrangements will be successful in marketing the
Company's products.
 
     Dependence on Strategic Relationships.  The Company's business strategy
includes entering into strategic relationships with corporate partners. Although
the Company has strategic relationships with Pirelli, EDF and ABB, there can be
no assurance that the Company will be able to maintain these relationships or
that these relationships will be technologically or commercially successful. In
addition, there can be no assurance that the Company will be able to negotiate
additional strategic relationships or that any such relationships, if
established, will be technologically or commercially successful.
 
     Dependence on Key Personnel.  The Company's success will depend in large
part upon its ability to attract and retain highly qualified research and
development, management, manufacturing, marketing and sales personnel. Due to
the specialized nature of the Company's business, it may be difficult to locate
and hire qualified personnel. The Company is particularly dependent upon the
services of Dr. Gregory J. Yurek, a founder and its Chairman of the Board,
President and Chief Executive Officer, and Dr. Alexis P. Malozemoff, its Chief
Technical Officer. The loss of the services of either of these individuals, or
the failure of the Company to attract and retain other key personnel, could have
a material adverse effect on the Company's business, financial condition and
results of operations.
 
     Dependence on Acquisitions Strategy.  The Company's strategy includes
acquiring companies to enhance its market position, add value to its product
lines and strengthen its technology base. The Company made two acquisitions in
1997. There can be no assurance that the Company will make any additional
acquisitions in the future. Any acquisitions present a number of new challenges
for the Company's management, including the entry into new lines of business,
the integration of new products, technologies and personnel into the Company's
existing business organization, the management and operation of geographically
dispersed operations, and the adaptation of the Company's information systems
and management structure to a larger organization. There can be no assurance
that the Company will be successful in addressing these challenges, or that
acquisitions will produce the benefits anticipated by the Company.
 
                                       A-6
<PAGE>   25
 
                                                                      APPENDIX B
 
                       REPORT OF INDEPENDENT ACCOUNTANTS
 
To the Board of Directors and Stockholders of
American Superconductor Corporation:
 
     We have audited the consolidated balance sheets of American Superconductor
Corporation as of March 31, 1998 and 1997, and the related consolidated
statements of operations, stockholders' equity and cash flows for each of the
three years in the period ended March 31, 1998. These financial statements are
the responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based upon our audits. We did not audit
the financial statements of Superconductivity, Inc., a wholly-owned subsidiary,
as of December 31, 1996 and for the years ended December 31, 1996 and 1995,
which statements reflect total assets constituting 11% of consolidated total
assets as of March 31, 1997 and net revenues constituting 32% and 34% of
consolidated net revenues for the years ended March 31, 1997 and 1996,
respectively. Those statements were audited by other auditors whose reports have
been furnished to us, and our opinion, insofar as it relates to data included in
the consolidated financial statements for such entities, is based solely on the
reports of other auditors.
 
     We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform our audits to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits and the reports of other auditors provide a
reasonable basis for our opinion.
 
     In our opinion, based upon our audits and the reports of other auditors,
the financial statements referred to above present fairly, in all material
respects, the consolidated financial position of American Superconductor
Corporation as of March 31, 1998 and 1997, and the consolidated results of its
operations and its cash flows for each of the three years in the period ended
March 31, 1998 in conformity with generally accepted accounting principles.
 
/s/ Coopers & Lybrand L.L.P.
 
Boston, Massachusetts
May 8, 1998
 
                                       B-1
<PAGE>   26
 
               REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
 
Board of Directors
Superconductivity, Inc.
Middleton, Wisconsin
 
     We have audited the accompanying balance sheet of Superconductivity, Inc.,
as of December 31, 1996, and the related statements of operations, shareholders'
equity (deficit), and cash flows for the year then ended (not presented
separately herein). These financial statements are the responsibility of the
company's management. Our responsibility is to express an opinion on these
financial statements based on our audit. The financial statements of
Superconductivity, Inc., as of December 31, 1995, and for the year then ended,
were audited by other auditors whose report dated February 29, 1996, expressed
an unqualified opinion on those statements.
 
     We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
 
     In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Superconductivity, Inc., as
of December 31, 1996, and the results of its operations and its cash flows for
the year then ended in conformity with generally accepted accounting principles.
We have not audited the financial statements of Superconductivity, Inc., for any
period subsequent to December 31, 1996.
 
/s/ Smith & Gesteland LLP
 
Madison, Wisconsin
February 7, 1997
 
                                       B-2
<PAGE>   27
 
                         REPORT OF INDEPENDENT AUDITORS
 
The Board of Directors and Shareholders
Superconductivity, Inc.
 
     We have audited the balance sheets of Superconductivity, Inc. (a
development stage company, the Company) as of December 31, 1995 and 1994, and
the related statements of operations, shareholders' equity (deficit) and cash
flows for the years then ended and the period from March 22, 1988 (inception) to
December 31, 1995 (not presented separately herein). These financial statements
are the responsibility of the Company's management. Our responsibility is to
express an opinion on these financial statements based on our audits.
 
     We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amount and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
 
     In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of the Company at December 31,
1995 and 1994, and the results of its operations and its cash flows for the
years then ended and the period from March 22, 1988 (inception) to December 31,
1995, in conformity with generally accepted accounting principles.

/s/ Ernst & Young LLP 
Ernst & Young LLP
 
Madison, Wisconsin
February 29, 1996
 
                                       B-3
<PAGE>   28
 
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                          CONSOLIDATED BALANCE SHEETS
 
<TABLE>
<CAPTION>
                                                                       MARCH 31,
                                                              ---------------------------
                                                                  1998           1997
                                                              ------------    -----------
<S>                                                           <C>             <C>
                                         ASSETS
Current assets:
  Cash and cash equivalents.................................  $  1,842,142    $   584,804
  Accounts receivable.......................................     2,991,635      3,070,573
  Notes receivable..........................................            --        383,607
  Inventory.................................................     3,229,973      2,940,656
  Prepaid expenses and other current assets.................       545,428        345,344
                                                              ------------    -----------
          Total current assets..............................     8,609,178      7,324,984
Property and equipment:
  Equipment.................................................    12,502,756     10,137,721
  Furniture and fixtures....................................       946,630        733,794
  Leasehold improvements....................................     1,980,090      1,732,215
                                                              ------------    -----------
                                                                15,429,476     12,603,730
Less: accumulated depreciation..............................   (11,006,576)    (8,835,754)
                                                              ------------    -----------
Property and equipment, net.................................     4,422,900      3,767,976
Long-term marketable securities.............................     6,167,030     15,446,106
Net investment in sales-type lease..........................       345,940             --
Other assets................................................         6,167         42,028
                                                              ------------    -----------
          Total assets......................................  $ 19,551,215    $26,581,094
                                                              ============    ===========
                          LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
  Note payable-line of credit...............................            --    $   530,000
  Accounts payable and accrued expenses.....................  $  3,333,462      4,283,612
  Deferred revenue..........................................       187,285      1,519,678
  Current portion of long-term debt.........................        29,609        673,428
                                                              ------------    -----------
          Total current liabilities.........................     3,550,356      7,006,718
Long-term debt (less current portion).......................     3,141,793      3,073,663
Commitments (Note 10)
Stockholders' equity:
  Common stock, $.01 par value Authorized
     shares -- 20,000,000; issued and outstanding
     shares -- 11,756,793 in 1998 and 10,505,118 in 1997....       117,568        105,051
     Additional paid-in capital.............................    87,961,911     76,388,679
  Deferred compensation.....................................            --        (25,480)
  Deferred contract costs -- warrants.......................    (1,328,446)      (557,265)
  Unrealized gain (loss) on investments.....................        32,706       (143,661)
  Cumulative translation adjustment.........................       (32,798)        (9,892)
  Accumulated deficit.......................................   (73,891,875)   (59,256,719)
                                                              ------------    -----------
          Total stockholders' equity........................    12,859,066     16,500,713
                                                              ------------    -----------
          Total liabilities and stockholders' equity........  $ 19,551,215    $26,581,094
                                                              ============    ===========
</TABLE>
 
   The accompanying notes are an integral part of the consolidated financial
                                  statements.

                                       B-4
<PAGE>   29
 
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                     CONSOLIDATED STATEMENTS OF OPERATIONS
 
<TABLE>
<CAPTION>
                                                               YEAR ENDED MARCH 31,
                                                    -------------------------------------------
                                                        1998            1997           1996
                                                    ------------    ------------    -----------
<S>                                                 <C>             <C>             <C>
Revenues:
  Contract revenue................................  $  9,273,901    $  6,867,444    $ 7,526,306
  Product sales and prototype development
     contracts....................................     5,013,008       2,936,567      2,366,351
  Rental/other revenue............................       841,903         746,546        871,769
                                                    ------------    ------------    -----------
          Total revenues..........................    15,128,812      10,550,557     10,764,426
Costs and expenses:
  Costs of revenue................................    14,332,712      10,577,376     11,553,016
  Research and development........................     8,641,102       8,477,365      5,704,494
  Selling, general and administrative.............     4,910,102       4,290,500      4,538,167
                                                    ------------    ------------    -----------
          Total costs and expenses................    27,883,916      23,345,241     21,795,677
Merger related fees...............................      (154,744)       (710,105)
Interest income...................................       781,599       1,177,386      1,585,168
Interest expense..................................      (238,625)       (356,366)      (214,671)
Fees -- terminated transaction....................            --        (669,627)            --
Other income (expense), net.......................       (11,314)        (23,777)       (37,529)
                                                    ------------    ------------    -----------
Net loss..........................................  $(12,378,188)   $(13,377,173)   $(9,698,283)
                                                    ============    ============    ===========
Net loss per common share
Basic.............................................  $      (1.06)   $      (1.27)   $     (0.94)
                                                    ============    ============    ===========
  Diluted.........................................  $      (1.06)   $      (1.27)   $     (0.94)
                                                    ============    ============    ===========
Weighted average number of common shares
  outstanding
Basic.............................................    11,658,034      10,497,643     10,351,993
                                                    ============    ============    ===========
  Diluted.........................................    11,658,034      10,497,643     10,351,993
                                                    ============    ============    ===========
</TABLE>
 
   The accompanying notes are an integral part of the consolidated financial
                                  statements.

                                       B-5
<PAGE>   30
 
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                     CONSOLIDATED STATEMENTS OF CASH FLOWS
 
<TABLE>
<CAPTION>
                                                        1998            1997           1996
                                                    ------------    ------------    -----------
<S>                                                 <C>             <C>             <C>
Cash flows from operating activities:
  Net loss........................................  $(12,378,188)   $(13,377,173)   $(9,698,283)
     Adjustments to reconcile net loss to net cash
       used by operations:
       Merger with AET............................       (90,569)
       Forgiveness of notes receivable............       349,368         206,744        104,778
       Depreciation and amortization..............     2,113,617       1,983,531      2,106,569
       Write down of inventory and equipment......            --         444,538      1,175,142
       Loss (gain) on disposals of property and...        24,569          (9,697)            --
       equipment Deferred compensation expense....        25,480          25,480         29,960
       Deferred contract costs-warrant............       260,679          79,613             --
       Interest accrued on convertible
          debentures..............................            --         230,746        100,383
       Changes in operating asset and liability
          accounts:
          Accounts receivable.....................      (462,031)     (1,343,043)       994,748
          Inventory...............................       159,289        (973,571)    (1,073,049)
          Prepaid expenses and other current
            assets................................      (205,631)        (73,592)       (27,796)
          Note payable-line of credit.............      (875,000)             --             --
          Accounts payable and accrued expenses...    (1,877,010)      2,082,137       (639,139)
          Deferred revenue........................    (1,974,510)        625,978        678,700
                                                    ------------    ------------    -----------
  Net cash used by operating activities...........   (14,929,937)    (10,098,309)    (6,247,987)
Cash flows from investing activities:
       Notes receivable...........................       (18,951)        (82,815)       (40,973)
       Repayment of notes receivable..............        53,190         100,000             --
       Purchase of property and equipment.........    (2,889,245)     (1,451,142)    (1,342,922)
       Purchase of long-term marketable
          securities..............................    (3,000,000)             --             --
       Sale of long-term marketable securities....    12,455,443       6,730,101      9,924,608
       Decrease (increase) in other assets........        35,861         (37,130)        28,676
       Net investment in sales-type lease.........      (345,940)             --             --
                                                    ------------    ------------    -----------
  Net cash provided by investing activities.......     6,290,358       5,259,014      8,569,389
Cash flows from financing activities:
       Payments on notes payable..................      (643,819)       (131,049)      (422,352)
       Proceeds from notes payable (net)..........            --           5,000             --
       Payments on long-term debt.................         4,693              --             --
       Proceeds from 10% convertible debentures...            --       1,200,000             --
       Net proceeds from issuance of common
          stock...................................    10,543,887          89,097        379,969
                                                    ------------    ------------    -----------
  Net cash provided by financing activities.......     9,904,761       1,163,048        (42,383)
Net increase (decrease) in cash and cash
  equivalents.....................................     1,265,182      (3,676,247)     2,279,019
Cash and cash equivalents at beginning of year....       584,804       4,261,051      1,982,032
Effect of SI's excluded results...................        (7,844)             --             --
                                                    ------------    ------------    -----------
Cash and cash equivalents at end of year..........  $  1,842,142    $    584,804    $ 4,261,051
                                                    ============    ============    ===========
Supplemental schedule of cash flow information:
  Cash paid for interest..........................  $    135,906    $    125,620    $   114,288
  Noncash issuance of common stock................  $    165,954              --    $   150,000
</TABLE>
 
   The accompanying notes are an integral part of the consolidated financial
                                  statements.

                                       B-6
<PAGE>   31
 
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
                                      COMMON STOCK                                                    UNREALIZED
                                  ---------------------   ADDITIONAL                    DEFERRED      GAIN/LOSS     CUMULATIVE
                                    NUMBER       PAR        PAID-IN       DEFERRED      CONTRACT          ON        TRANSLATION
                                  OF SHARES     VALUE       CAPITAL     COMPENSATION      COSTS      INVESTMENTS    ADJUSTMENT
                                  ----------   --------   -----------   ------------   -----------   ------------   -----------
<S>                               <C>          <C>        <C>           <C>            <C>           <C>            <C>
BALANCE AT MARCH 31, 1995.......  10,337,506    103,375   $75,134,412    $  (80,920)                  $(573,081)     $ 13,193
Exercise of warrants............      65,840        658       499,342
Exercise of stock options.......      19,660        197        29,772
Purchase of fractional shares...         (10)
Amortization of deferred
  compensation..................                                             29,960
Unrealized gain on
  investments...................                                                                      $  11,111
Translation adjustment..........                                                                                       (8,591)
Net loss........................
                                  ----------   --------   -----------    ----------    -----------    ---------      --------
BALANCE AT MARCH 31, 1996.......  10,422,996    104,230    75,663,526       (50,960)                    (61,970)        4,602
Exercise of stock options.......      82,122        821        88,275
Amortization of deferred
  compensation..................                                             25,480
Deferred contract
  costs-warrant.................                              636,878                     (636,878)
Warrant expense.................                                                            79,613
Unrealized loss on
  investments...................                                                                        (81,691)
Translation adjustment..........                                                                                      (14,494)
Net loss........................
                                  ----------   --------   -----------    ----------    -----------    ---------      --------
BALANCE AT MARCH 31, 1997.......  10,505,118    105,051    76,388,679       (25,480)      (557,265)    (143,661)       (9,892)
Exercise of stock options.......     166,794      1,668       511,385
Investment by EDF...............   1,000,000     10,000     9,929,994
Merger with AET.................      68,306        683         9,317
Stock compensation expense......       9,075         91        90,751
Amortization of deferred
  compensation..................                                             25,480
Deferred contract
  costs-warrant.................                              953,638                     (953,638)
Amortization of deferred
  contract costs................                                3,035                      182,457
Exercise of warrants............       7,500         75        75,112
Unrealized gain on
  investments...................                                                                        176,367
Cumulative translation
  adjustment....................                                                                                      (22,906)
Effect of SI's excluded
  results.......................
Net loss........................
                                  ----------   --------   -----------    ----------    -----------    ---------      --------
BALANCE AT MARCH 31, 1998.......  11,756,793   $117,568   $87,961,911    $       --    $(1,328,446)   $  32,706      $(32,798)
                                  ==========   ========   ===========    ==========    ===========    =========      ========
 
<CAPTION>
 
                                                     TOTAL
                                  ACCUMULATED    STOCKHOLDERS'
                                    DEFICIT         EQUITY
                                  ------------   -------------
<S>                               <C>            <C>
BALANCE AT MARCH 31, 1995.......  $(36,181,263)   $38,415,716
Exercise of warrants............                      500,000
Exercise of stock options.......                       29,969
Purchase of fractional shares...
Amortization of deferred
  compensation..................                       29,960
Unrealized gain on
  investments...................                  $    11,111
Translation adjustment..........                       (8,591)
Net loss........................    (9,698,283)    (9,698,283)
                                  ------------    -----------
BALANCE AT MARCH 31, 1996.......   (45,879,546)    29,779,882
Exercise of stock options.......                       89,096
Amortization of deferred
  compensation..................                       25,480
Deferred contract
  costs-warrant.................                           --
Warrant expense.................                       79,613
Unrealized loss on
  investments...................                      (81,691)
Translation adjustment..........                      (14,494)
Net loss........................   (13,377,173)   (13,377,173)
                                  ------------    -----------
BALANCE AT MARCH 31, 1997.......   (59,256,719)   $16,500,713
Exercise of stock options.......                      513,053
Investment by EDF...............                    9,939,994
Merger with AET.................      (100,569)       (90,569)
Stock compensation expense......                       90,842
Amortization of deferred
  compensation..................                       25,480
Deferred contract
  costs-warrant.................                           --
Amortization of deferred
  contract costs................                      185,492
Exercise of warrants............                       75,187
Unrealized gain on
  investments...................                      176,367
Cumulative translation
  adjustment....................                      (22,906)
Effect of SI's excluded
  results.......................    (2,156,399)    (2,156,399)
Net loss........................   (12,378,188)   (12,378,188)
                                  ------------    -----------
BALANCE AT MARCH 31, 1998.......  $(73,891,875)   $12,859,066
                                  ============    ===========
</TABLE>
 
   The accompanying notes are an integral part of the consolidated financial
                                  statements.

                                       B-7

<PAGE>   32
 
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                        NOTES TO CONSOLIDATED STATEMENTS
 
1.  NATURE OF THE BUSINESS
 
     American Superconductor Corporation (the "Company" or "ASC"), which was
formed on April 9, 1987, develops and commercializes high temperature
superconducting ("HTS") wire, wire products and systems, including current
leads, multistrand conductors, electromagnetic coils, and electromagnets and
subsystems comprising electromagnetics integrated with appropriate cooling
systems. The focus of the Company's development and commercialization efforts is
on electrical equipment for use by electric utilities and industrial users of
electrical power. For large-scale applications, the Company's development
efforts are focused on power transmission cables, motors, transformers,
generators and fault current limiters. In the area of power quality, the Company
is focused on marketing and selling commercial low temperature superconducting
magnetic energy storage ("SMES") devices, on development and commercialization
of new SMES products, and on development of power electronic subsystems and
engineering services for the power quality marketplace. The Company operates in
one business segment.
 
     The Company has devoted a significant part of its efforts to research and
development. The Company has recorded contract revenue related to research and
development contracts of $9,273,901, $6,867,444 and $7,526,306 for the fiscal
years ended March 31, 1998, 1997 and 1996, respectively. As discussed in Note
11, a significant portion of this contract revenue relates to development
contracts with three stockholders Pirelli Cavi E Sistemi S.p.A. ("Pirelli"),
Electricite de France (EDF), and Inco Alloys International, Inc. ("Inco").
Included in costs of revenue are research and development expenses of
approximately $7,494,000, $5,322,000 and $5,256,000 for the fiscal years ended
March 31, 1998, 1997, and 1996, respectively. Selling, general and
administrative expenses also included as costs of revenue for the fiscal years
ended March 31, 1998, 1997 and 1996, were approximately $3,394,000, $2,186,000
and $2,075,000, respectively.
 
     As explained more fully in Note 3 to these financial statements, on
April 8, 1997, the Company acquired Superconductivity Inc. ("SI") through the
merger of a wholly owned subsidiary of the Company into SI. SI is a manufacturer
of low temperature superconductor products for the industrial power quality
market.
 
2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
     A summary of the Company's significant accounting policies follows:
 
  Basis of Presentation
 
     The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiaries. As described more fully in Note 3, on
April 8, 1997, ASC acquired SI through the merger of a wholly owned subsidiary
of the Company into SI. These consolidated financial statements have been
prepared following the pooling of interests method of accounting and reflect the
combined financial position, operating results and cash flows of ASC and SI as
if they had been combined for all periods presented. Prior to the merger, SI's
fiscal year end was December 31. Effective with the merger, SI's fiscal year end
was changed to March 31 to conform with ASC's fiscal year end. The audited
results of SI's operations for the twelve month periods ended December 31, 1996
and 1995 are included in the Company's results of operations for the fiscal
years ended March 31, 1997 and 1996, respectively. SI's audited balance sheet at
December 31, 1996 is included in the Company's balance sheet at March 31, 1997.
As a result, SI's results of operations for the quarter ended March 31, 1997 are
not included in the consolidated statements of operations. In the quarter ended
March 31, 1997, SI recorded revenues of $262,295 and incurred a net loss of
$2,156,399 which included merger expenses of $1,457,054. Additionally, SI's cash
flow activity for the three months ended March 31, 1997 is listed as "Effect of
SI's excluded results" on the Consolidated Statement of Cash Flows to account
for the difference in the beginning cash and cash equivalents between December
31, 1996 and March 31, 1997.
 
     On July 31, 1997 the Company completed a transaction in which the Company
acquired all the outstanding stock of Applied Engineering Technologies, Ltd.
("AET"). The transaction has been accounted for under the pooling of interests
method of accounting. Due to the immaterial effect on the accompanying
 
                                       B-8
<PAGE>   33
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                NOTES TO CONSOLIDATED STATEMENTS -- (CONTINUED)
 
consolidated financial statements, the prior periods have not been adjusted to
reflect the effect on the combined financial position, operating results and
cash flows of the Company.
 
  Principles of Consolidation
 
     The consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries. All intercompany balances have been
eliminated.
 
  Cash Equivalents
 
     The Company considers all highly liquid debt instruments with original
maturities of three months or less to be cash equivalents. Cash equivalents
consist of government obligations, short-term certificates of deposit and
repurchase agreements.
 
  Accounts Receivable
 
     Due to scheduled billing requirements specified under certain contracts, a
portion of the Company's accounts receivable balance at March 31, 1998 and 1997
was unbilled. The unbilled portion included in the accounts receivable balance
was approximately $1,611,000 or 54% of total accounts receivable and $1,090,000
or 35% of total accounts receivable at March 31, 1998 and 1997, respectively.
The Company expects the amounts to be billed in the first quarter of next year.
 
  Long-term Marketable Securities
 
     Long-term marketable securities, with original maturities of more than 12
months when purchased, consist primarily of U.S. Treasury Notes and a U.S.
government agency security. These marketable securities are stated at amortized
cost plus accrued interest which approximates fair value. Interest income is
accrued as earned.
 
  Inventories
 
     Inventories are stated at the lower of cost (determined on a first-in
first-out basis) or market.
 
  Property and Equipment
 
     Property and equipment are recorded at cost and depreciated using the
straight-line method over their estimated useful lives, which range from 3 to 7
years. Leasehold improvements are amortized over the shorter of the useful life
of the improvement or the remaining term of the lease. Expenditures for
maintenance and repairs are expensed as incurred. Upon retirement or other
disposition of assets, the costs and related accumulated depreciation are
eliminated from the accounts and the resulting gain or loss is reflected in
income.
 
  Revenue Recognition
 
     The Company has entered into contracts to perform research and development
(see Note 11). Revenues from these contracts are recognized utilizing the
percentage of completion method, measured by the relationship of costs incurred
to total contract costs. Costs include direct engineering and development costs
and applicable overhead. The Company generally recognizes its prototype revenue
upon shipment, or, for certain programs, on the percentage of completion method
of accounting. Customer deposits are recorded as deferred revenue until the
related sales are recognized. The Company rents equipment to customers on a
monthly basis and recognizes rental income as it is earned.
 
  Research and Development Costs
 
     Research and development costs are expensed as incurred.
 
                                       B-9
<PAGE>   34
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                NOTES TO CONSOLIDATED STATEMENTS -- (CONTINUED)
 
  Income Taxes
 
     Deferred income taxes are recognized for the tax consequences in future
years of differences between the tax bases of assets and liabilities and their
financial reporting amounts at fiscal each year end based on enacted tax laws
and statutory tax rates applicable to the periods in which the differences are
expected to affect taxable income. Valuation allowances are established when
necessary to reduce net deferred tax assets to the amount expected to be
realized. No current or deferred income taxes have been provided because of the
net operating losses incurred by the Company since its inception.
 
  Computation of Net Loss per Common Share
 
     The Company adopted Statement of Financial Accounting Standards ("SFAS")
No. 128, "Earnings Per Share" effective December 28, 1997. SFAS No. 128 requires
presentation of basic earnings per share ("EPS") and, for companies with complex
capital structures, diluted EPS. Basic EPS excludes dilution and is computed by
dividing net income available to common stockholders by the weighted-average
number of common shares outstanding for the period. Diluted EPS includes
dilution and net income per share is computed using the weighted average number
of common and dilutive common equivalent shares outstanding during the period.
Common equivalent shares include the effect of the exercise of stock options.
For the years ended March 31, 1998, 1997 and 1996, common equivalent shares of
275,749, 338,089 and 454,195,respectively were not included for the calculation
of diluted EPS as they were considered antidilutive. The Company has restated
net loss per share for all periods presented in the accompanying consolidated
financial statements to reflect net loss per share on both a basic and a diluted
basis.
 
  Foreign Currency Translation
 
     The functional currency of the Company's foreign subsidiary is the local
currency. The assets and liabilities of this operation are translated into U.S.
dollars at the exchange rate in effect at the balance sheet date and income and
expense items are translated at average rates for the period. Cumulative
translation adjustments are excluded from net loss and shown as a separate
component of stockholders' equity. Foreign currency transaction gains and losses
are included in the net loss and have not been material to date.
 
  Risks and Uncertainties
 
     The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates and would
impact future results of operations and cash flows.
 
     The Company invests its cash and cash equivalents with high-credit, quality
financial institutions and invests primarily in investment grade-marketable
securities, including, but not limited to, government obligations, repurchase
agreements and money market funds.
 
     The Company's accounts receivable are comprised mostly of amounts owed by
government agencies and some commercial companies. The Company does not require
collateral or other security to support customer receivables. The Company
believes any credit losses will not be material.
 
3.  THE MERGER
 
     In April 1997, the Company completed a transaction (the "Merger") with SI.
This transaction, in which the Company acquired all of the outstanding stock of
SI by means of a merger of a subsidiary of the Company into SI, was accounted
for as a pooling of interests. The merger was effected through the exchange of
942,961 shares of the Company's common stock for all of the issued and
outstanding shares of SI, based on a merger exchange ratio of 0.3292 shares of
the Company's common stock for each share of SI common stock.
 
                                      B-10
<PAGE>   35
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                NOTES TO CONSOLIDATED STATEMENTS -- (CONTINUED)
 
     All fees and expenses related to the merger were expensed as required under
the pooling of interests accounting method. Charges of $75,767 in fiscal 1998
and $710,105 in fiscal 1997 have been recorded in the consolidated statement of
operations reflecting merger expenses incurred in the period. SI incurred merger
expenses of $1,457,054 in the quarter ended March 31, 1997. As noted in Note 2,
SI's results of operations for the quarter ended March 31, 1997 are not included
in the consolidated statement of operations. Merger expenses consist principally
of financial advisory, legal and accounting fees.
 
     Combined and separate results of ASC and SI for the periods preceding the
merger were as follows (in thousands):
 
<TABLE>
<CAPTION>
                                                ASC         SI       COMBINED
                                              --------    -------    --------
<S>                                           <C>         <C>        <C>
Year ended March 31, 1997
  Revenues..................................  $  7,175    $ 3,376    $ 10,551
  Net loss..................................  $(10,422)   $(2,955)   $(13,377)
Year ended March 31, 1996
  Revenues..................................  $  7,131    $ 3,633    $ 10,764
  Net loss..................................  $ (7,320)   $(2,378)   $ (9,698)
</TABLE>
 
4.  LONG-TERM MARKETABLE SECURITIES
 
     Long-term marketable securities at March 31, 1998 consisted of the
following:
 
<TABLE>
<CAPTION>
                                                                    GROSS UNREALIZED
                                    AGGREGATE COST    FAIR VALUE          GAIN
                                    --------------    ----------    ----------------
<S>                                 <C>               <C>           <C>
U.S. government and U.S government
  agency securities...............    $6,134,324      $6,167,030        $32,706
</TABLE>
 
     The Company's long-term marketable securities are classified as
available-for-sale securities and, accordingly, are recorded at amortized cost
plus accrued interest which approximates fair value. The difference between cost
and fair value is included in stockholders' equity. All of these securities
mature in one to three years.
 
5.  INVENTORIES
 
     Inventories at March 31, 1998 and 1997 consisted of the following:
 
<TABLE>
<CAPTION>
                                                         1998          1997
                                                      ----------    ----------
<S>                                                   <C>           <C>
Raw materials.......................................  $  743,016    $  546,776
Work-in-progress....................................   2,388,705     2,164,179
Finished goods......................................      98,252       229,701
                                                      ----------    ----------
                                                      $3,229,973    $2,940,656
                                                      ==========    ==========
</TABLE>
 
6.  ACCOUNTS PAYABLE AND ACCRUED EXPENSES
 
     Accounts payable and accrued expenses at March 31, 1998 and 1997 consisted
of the following:
 
<TABLE>
<CAPTION>
                                                         1998          1997
                                                      ----------    ----------
<S>                                                   <C>           <C>
Accounts payable..................................    $2,619,865    $2,919,739
Accrued professional fees.........................        27,543       585,522
Accrued expenses..................................       366,554       563,051
Accrued vacation..................................       319,500       215,300
                                                      ----------    ----------
                                                      $3,333,462    $4,283,612
</TABLE>
 
                                      B-11
<PAGE>   36
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                NOTES TO CONSOLIDATED STATEMENTS -- (CONTINUED)
 
7.  LONG-TERM DEBT
 
     Long-term debt at March 31, 1998 and 1997 consisted of the following:
 
<TABLE>
<CAPTION>
                                                                 1998          1997
                                                              ----------    ----------
<S>                                                           <C>           <C>
Subordinated convertible debentures, principal of
  $2,537,492 plus accrued interest at 10%, aggregating
  $536,171 at March 31, 1997, due January 1998............            --    $3,073,663
Subordinated notes, interest payable semiannually at 7%,
  due April 1999..........................................    $3,141,793            --
Note payable to ABB Power T & D Company Inc., interest
  payable monthly at 7.5%, with principal due April
  1998....................................................        29,609       673,428
                                                              ----------    ----------
                                                               3,171,402     3,747,091
Less amount due within one year...........................        29,609       673,428
                                                              ----------    ----------
                                                              $3,141,793    $3,073,663
                                                              ==========    ==========
</TABLE>
 
     In conjunction with the Merger, the 10% subordinated convertible debentures
were exchanged for the 7% subordinated notes of the Company, due April 8, 1999,
with interest payable semiannually. At the option of the Company, principal and
interest may also be paid in shares of the Company's common stock of equivalent
value.
 
     Subsequent to fiscal 1998 year-end, on April 22, 1998, the Company
completed a public offering of 3,504,121 shares of its common stock and received
net proceeds of $46,114,000 (before deducting offering expenses), approximately
$3,142,000 of which was then used to retire the 7% subordinated notes.
 
8.  INCOME TAXES
 
     The principal components of the Company's deferred tax liabilities and
assets were the following:
 
<TABLE>
<CAPTION>
                                                                   MARCH 31,
                                                          ----------------------------
                                                              1998            1997
                                                          ------------    ------------
<S>                                                       <C>             <C>
Deferred tax assets:
  Net operating loss carryforward.......................  $ 28,298,000    $ 22,932,000
  Research and development and other credits............     2,349,000       2,035,000
  Depreciation and other................................       911,000       1,918,000
  Valuation allowance...................................   (31,558,000)    (26,885,000)
                                                          ------------    ------------
Net.....................................................            --              --
                                                          ------------    ------------
</TABLE>
 
     At March 31, 1998 the Company had available for federal income tax purposes
net operating loss carryforwards of approximately $54,460,000, which commence
expiring in years 2005 through 2013. SI also had net operating loss
carryforwards amounting to approximately $16,284,000, the tax effect of which is
included in the above schedule. These loss carryforwards begin expiring in 2003
and their utilization by the Company will be subject to annual limitations.
Research and development and other credit carryforwards amounting to
approximately $2,349,000 are available to offset federal and state income taxes
and expire in years 2005 through 2013. Under current tax law, the utilization of
net operating loss carryforwards may be subject to annual limitations in the
event of future significant changes in ownership.
 
9.  STOCKHOLDERS' EQUITY
 
     In April 1997, the Company entered into a strategic alliance agreement with
an affiliate of EDF under which EDF purchased one million shares of the
Company's common stock at $10 per share.
 
                                      B-12
<PAGE>   37
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                NOTES TO CONSOLIDATED STATEMENTS -- (CONTINUED)
 
  Stock-Based Compensation Plans
 
     The Company has adopted the disclosure only option under Statement of
Financial Accounting Standards (SFAS) 123 "Accounting for Stock-Based
Compensation" as of March 31, 1997. Pro forma information regarding net income
and earnings per share is required by SFAS 123, and has been determined as if
the Company had accounted for its stock options under the fair value method of
that Statement. Consistent with the method of SFAS 123, the Company's net loss
and net loss per share would have increased to the pro forma amounts indicated
below:
 
<TABLE>
<CAPTION>
                                               FOR THE FISCAL YEARS ENDED MARCH 31,
                                               -------------------------------------
                                                  1998          1997         1996
                                               ----------    ----------    ---------
<S>                             <C>            <C>           <C>           <C>
Net loss (in thousands).......  As reported     $(12,378)     $(13,377)     $(9,698)
                                Pro forma       $(13,725)     $(14,095)     $(9,871)
Loss per share................  As reported     $  (1.06)     $  (1.27)     $ (0.94)
                                Pro forma       $  (1.18)     $  (1.34)     $ (0.96)
</TABLE>
 
     The pro forma amounts include the effects of all activity under the
Company's stock-based compensation plans since April 1, 1995. The fair value of
each option grant is estimated on the date of grant using the Black-Scholes
option pricing model with the following assumptions used for grants; a weighted
average risk free interest rate of 5.6%, 6.4% and 5.5% in fiscal 1998, fiscal
1997 and fiscal 1996 respectively; expected stock price volatility of 50%, for
fiscal 1998 and 45% for fiscal 1997 and fiscal 1996; no dividends; and a
weighted average life of the options of 5 years. The weighted average fair value
of options granted during fiscal 1998, fiscal 1997 and fiscal 1996 was $5.74 per
share, $5.02 per share and $6.42 per share, respectively. The above amounts may
not be indicative of future expense because amounts are recognized over the
vesting period and the Company expects it will have additional grants and
related activity under these plans in the future.
 
     The Company has six stock option plans including three Directors' Plans.
The stock option plans (the "Plans") include the 1987 Stock Plan (the "1987
Plan"), the 1993 Stock Option Plan (the "1993 Plan"), the 1996 Stock Incentive
Plan (the "1996 Plan"), the 1991 Director Stock Option Plan (the "1991 Director
Plan") the 1994 Director Stock Option Plan (the "1994 Director Plan"), and the
1997 Director Stock Option Plan (the "1997 Director Plan"). The Plans are
administered by the Compensation Committee of the Board of Directors and permit
the Company to sell or award common stock or to grant stock options for the
purchase of common stock.
 
     The Plans provide for the issuance of incentive stock options and
non-qualified stock options to purchase the Company's common stock. In the case
of incentive stock options, the exercise price shall be equal to at least the
fair market value of the common stock, as determined by the Board of Directors,
on the date of grant. The 1991, 1994 and 1997 Director Plans are stock option
plans for members of the Board of Directors who are not also employees of the
Company ("outside directors"). The 1997 Director Plan provides for the automatic
grant of stock options for the purchase of common stock by outside directors at
an exercise price equal to fair market value at the grant date. No further
grants may be made under the 1987 Plan, the 1991 Director Plan or the 1994
Director Plan.
 
     Options granted under the Plans generally become exercisable in equal
annual increments over a four or five year period and expire 10 years from the
date of grant or from two to three months after termination of employment.
 
                                      B-13
<PAGE>   38
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                NOTES TO CONSOLIDATED STATEMENTS -- (CONTINUED)
 
     The following table summarizes information about stock options outstanding
at March 31, 1998.
 
<TABLE>
<CAPTION>
                                     OUTSTANDING
                              --------------------------                EXERCISABLE
                                              WEIGHTED      -----------------------------------
                                               AVERAGE      WEIGHTED                   WEIGHTED
                                NUMBER        REMAINING     AVERAGE       NUMBER       AVERAGE
RANGE OF                      OUTSTANDING    CONTRACTUAL    EXERCISE    EXERCISABLE    EXERCISE
EXERCISE PRICE                AT 3/31/98        LIFE         PRICE      AT 3/31/98      PRICE
- --------------                -----------    -----------    --------    -----------    --------
<S>                           <C>            <C>            <C>         <C>            <C>
$ 0.27 -  4.65..............      79,015         2.3         $0.75          79,015      $0.75
  4.65 -  9.30..............     414,636         5.4          8.00         302,521       7.76
  9.30 - 13.94..............   1,346,490         8.4         11.03         326,190      11.35
 13.94 - 18.58..............     398,099         6.2         16.85         270,707      17.00
 18.58 - 23.23..............     386,250         6.1         21.25         237,450      21.22
                               ---------                                 ---------
$ 0.27 - 23.23..............   2,624,490                                 1,215,883
                               =========                                 =========
</TABLE>
 
     The following table summarizes the information concerning currently
outstanding and exercisable options:
 
<TABLE>
<CAPTION>
                                                             WEIGHTED AVERAGE      NUMBER
                                                 SHARES       EXERCISE PRICE     EXERCISABLE
                                                ---------    ----------------    -----------
<S>                                             <C>          <C>                 <C>
Outstanding at March 31, 1995.................  1,544,485         $14.25            375,495
                                                ---------         ------          ---------
Granted.......................................    482,600          13.71
Exercised.....................................    (19,660)          1.44
Canceled......................................    (14,670)         19.11
                                                ---------         ------          ---------
Outstanding at March 31, 1996.................  1,992,755         $14.21            652,885
                                                ---------         ------          ---------
Granted.......................................    766,650          10.43
Exercised.....................................    (74,880)          1.11
Canceled......................................   (138,860)         17.49
                                                ---------         ------          ---------
Outstanding at March 31, 1997.................  2,545,665         $13.28            896,895
                                                ---------         ------          ---------
Granted.......................................    576,450          10.56
Exercised.....................................   (166,794)          1.81
Canceled......................................   (330,831)         17.93
                                                ---------         ------          ---------
Outstanding at March 31, 1998.................  2,624,490         $12.63          1,215,883
                                                =========         ======          =========
Available for grant at March 31, 1998.........                                      873,891
                                                                                  =========
</TABLE>
 
  Stock Purchase Warrants
 
     The Company recorded an increase to additional paid-in capital and a
corresponding charge to deferred contract costs of approximately $336,000 in
January 1998 related to the issuance of stock purchase warrants for 250,500
shares of common stock at $10.20 per share which become exercisable over a
four-year period following the date of grant. These warrants were granted in
consideration of ongoing financial services being provided to the Company.
Expense related to these warrants was approximately $17,000 for the fiscal year
ended March 31, 1998.
 
  Deferred compensation
 
     The Company recorded an increase to additional paid-in capital and a
corresponding charge to deferred compensation of approximately $127,000 in
fiscal year 1993 related to the issuance of 10,000 shares of common stock.
Compensation expense related to this and other prior stock transactions of
approximately $25,000, $25,000, and $30,000 was recorded for the fiscal years
ended March 31, 1998, 1997 and 1996, respectively.
 
                                      B-14
<PAGE>   39
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                NOTES TO CONSOLIDATED STATEMENTS -- (CONTINUED)
 
10.  COMMITMENTS
 
     The Company rents its headquarters in Westborough, Massachusetts under an
operating lease, which expires in May 2003. The Company also rents operating
facilities near Madison, Wisconsin under two leases which expire on December 31,
2003. The Company has an option to extend these leases for additional five-year
periods. The Company also rents facilities in Woburn, Massachusetts under a
lease which expires in January 1999. Under all leases the Company pays for real
estate taxes, certain insurance coverage and operating expenses.
 
     In October 1992, the Company entered into a five-year collaborative
technology development agreement with Superlink Joint Venture ("Superlink"). In
October 1997, the Company extended the technology development agreement with
Superlink for an additional six-year period through September 2003, with
payments totaling $220,000 due the first year and payments of $300,000 due each
year for the next five years. The Company has the right to terminate this
agreement under certain conditions.
 
     Effective March 31, 1998, the Company signed an agreement with Lucent
Technologies, Inc. ("Lucent") granting the Company a royalty-bearing,
non-exclusive, worldwide license for superconductor wire under Lucent's
portfolio of high temperature superconductor patents and patent applications.
The license runs from March 31, 1998 until the expiration of the last-to-expire
patent in the portfolio.
 
     Rent expense under the leases mentioned above and research and development
expenses related to the technology agreement with Superlink Joint Venture and
the license agreement with Lucent included in the consolidated statements of
operations were as follows:
 
<TABLE>
<CAPTION>
                                               1998        1997        1996
                                             --------    --------    --------
<S>                                          <C>         <C>         <C>
Rent expense...............................  $531,546    $520,850    $495,283
                                             --------    --------    --------
Research and development expenses..........  $510,593    $135,000    $150,000
                                             --------    --------    --------
</TABLE>
 
     Minimum future lease and license fee commitments at March 31, 1998 were as
follows:
 
<TABLE>
<CAPTION>
                                                             TOTAL
                                                           ----------
<S>                                                        <C>
For the years ended March 31
1999...................................................    $1,385,453
2000...................................................     1,201,146
2001...................................................     1,201,146
2002...................................................     1,201,146
2003...................................................     1,133,404
2004...................................................       155,030
</TABLE>
 
11.  RESEARCH AND DEVELOPMENT AGREEMENTS
 
     In fiscal 1998, the Company entered into four-year research and development
contracts with ABB Power Transmission and Distribution Company (ABB) and
Electricite de France (EDF), a subsidiary of whom is a stockholder of the
Company, to develop HTS wire for power transformers. The agreements, both of
which expire on March 31, 2001 (subject to earlier termination by either party),
obligate ABB and EDF to each pay an aggregate of $5 million to the Company.
Through March 31, 1998, ABB had paid the Company $2.3 million (of which $1.0
million was recorded as revenue in fiscal 1997) and EDF had paid the Company
$1.8 million. In March 1996, the Company extended its development contract with
Pirelli, a stockholder of the Company, to jointly develop high temperature
superconducting cable wires. The Company's development
 
                                      B-15
<PAGE>   40
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                NOTES TO CONSOLIDATED STATEMENTS -- (CONTINUED)
 
contract with Inco Alloys International was terminated in December 1996. The
Company recorded revenues under these contracts as follows:
 
<TABLE>
<CAPTION>
                                                    1998          1997          1996
                                                 ----------    ----------    ----------
<S>                                              <C>           <C>           <C>
Inco...........................................          --    $  825,000    $1,100,000
Pirelli........................................  $2,500,000     2,500,000     2,831,000
ABB............................................   1,275,000     1,000,000            --
EDF............................................   1,800,000            --            --
                                                 ----------    ----------    ----------
                                                 $5,575,000    $4,325,000    $3,931,000
                                                 ==========    ==========    ==========
</TABLE>
 
     Future funding commitments under these contracts are $8,675,000 over the
next three years, $2,725,000 from ABB, $3,200,000 from EDF, and $2,750,000 from
Pirelli.
 
     In March 1996, the Company entered into a new strategic alliance with the
Electric Power Research Institute (EPRI) to develop and commercialize a possible
next-generation HTS wire. In March 1996, under the first phase of the agreement,
a warrant for 100,000 shares of common stock of the Company was granted to EPRI,
which becomes exercisable over a five-year period following the date of grant.
In March 1998, under the second phase of the agreement, the Company agreed to
grant to EPRI another warrant to purchase 110,000 shares of common stock of the
Company, which will become exercisable over the next five years. The Company
will receive exclusive license rights to certain intellectual property from
EPRI. This agreement is subject to early termination if certain conditions are
not met. The Company recorded an increase to additional paid-in capital and a
corresponding charge to deferred contract costs of $618,000 and $637,000 in
fiscal 1998 and 1997, respectively, relating to these warrants. Warrant expense
related to these agreements was $166,000 and $80,000 for the fiscal years ended
March 31, 1998 and 1997, respectively.
 
12.  COST SHARING ARRANGEMENTS
 
     The Company has entered into several cost-sharing arrangements with various
agencies of the United States government. These funds are used to directly
offset the Company's research and development and selling, general and
administrative expenses and to purchase capital equipment. The Company has
recorded costs and funding under these agreements of $3,139,000 and $1,771,000,
respectively for fiscal 1998, $3,197,000 and $1,706,000, respectively for fiscal
1997 and $2,590,000 and $985,000, respectively for fiscal 1996. At March 31,
1998, total funding received to date under these agreements was $8,130,000.
Future funding expected to be received under existing agreements is
approximately $4,078,000 over the next three years subject to continued future
funding allocations.
 
13.  RELATED PARTY TRANSACTIONS
 
     In fiscal 1995 the Company made a series of loans to an officer of the
Company in the aggregate amount of $671,000 including accrued interest. The
Compensation Committee of the Board of Directors forgave $206,700 and $104,800
in fiscal years 1997 and 1996, respectively, of principal and accrued interest
of the loans. In addition, the officer repaid $100,000 of principal in November
1996. The Company has recorded compensation expense of $349,400 in fiscal 1998
as a result of the forgiveness of the remaining principal and interest on the
loan by the Compensation Committee on May 14, 1998.
 
14.  EMPLOYEE BENEFIT PLANS
 
     The Company has implemented two deferred compensation plans under Section
401(k) of the Internal Revenue Code. Any contributions by the Company are
discretionary (none were made in fiscal 1998, 1997 or 1996). The Company does
not have post-retirement or post-employment benefit plans.
 
                                      B-16
<PAGE>   41
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
                NOTES TO CONSOLIDATED STATEMENTS -- (CONTINUED)
 
15.  WRITE DOWN OF INVENTORY AND EQUIPMENT
 
     Pursuant to Statement of Financial Accounting Standards ("SFAS") 121,
"Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to
be Disposed of", the Company recorded a provision of $407,000 included in the
consolidated statements of operations for the year ended March 31, 1996. This
provision was required to write down certain items of leased equipment to their
estimated fair value.
 
     In addition, provisions were recorded for certain work-in-process inventory
of $445,000 and $768,000 for the years ended March 31, 1997 and 1996,
respectively. These provisions were recorded due to the inventory not meeting
required performance specifications.
 
     Collectively, these provisions were included in costs of revenue for the
years end March 31, 1997 and 1996.
 
16.  SUBSEQUENT EVENTS
 
     On April 22, 1998 the Company completed a public offering of 3,504,121
shares of its common stock and received net proceeds (before deducting offering
expenses) of $46,114,000, of which approximately $3,142,000 was used to retire
the Company's subordinated notes.
 
17.  NEW ACCOUNTING PRONOUNCEMENTS
 
     In June 1997 the FASB issued Statement No. 130, "Reporting Comprehensive
Income", which establishes standards for reporting and display of comprehensive
income and its components (revenues, expenses, gains and losses) in a full set
of general purpose financial statements. This Statement requires that all items
that are required to be recognized under accounting standards as components of
comprehensive income be reported in a financial statement that is displayed with
the same prominence as other financial statements. This Statement is effective
for fiscal years beginning after December 15, 1997. Management does not believe
the implementation of this statement will have any significant effect on the
Company's financial statements.
 
     In June 1997 the FASB issued Statement No. 131, "Disclosures about Segments
of an Enterprise and Related Information", which establishes standards for the
way public enterprises report information about operating segments in annual
financial statements and requires that those enterprises report selected
information about operating segments in interim financial reports issued to
shareholders. It also establishes standards for related disclosures about
products and services, geographic areas, and major business customers. This
statement requires that a public business enterprise report financial and
descriptive information about its reportable operating segments, which are
components of an enterprise about which separate financial information is
evaluated regularly by the chief operating decision maker in deciding how to
allocate resources and in assessing performance. This Statement is effective for
financial statements for periods beginning after December 15, 1997. Management
is evaluating this Statement to determine what information is required to be
disclosed.
 
                                      B-17
<PAGE>   42
 
                      AMERICAN SUPERCONDUCTOR CORPORATION
 
              OFFICERS AND VICE PRESIDENTS, DIRECTORS AND FOUNDERS
 
BOARD OF DIRECTORS
 
Gregory J. Yurek, Ph.D.
President, Chief Executive Officer and
Chairman of the Board
 
Albert J. Baciocco, Jr.
Vice Admiral, U.S. Navy (Retired)
President, The Baciocco Group, Inc.
 
Colonel Frank Borman
Chairman of the Board, DBT Online Inc.
President, Patlex Corporation
 
Peter O. Crisp
Vice Chairman
Rockefeller Financial Services, Inc.
 
Richard Drouin, O.C., Q.C.
Partner, McCarthy Tetrault
Vice Chairman, Morgan Stanley Canada Limited
Former Chairman and Chief Executive Officer
Hydro-Quebec
 
Gerard J. Menjon
Executive Vice President
Head of Research & Development Division
Electricite de France
 
Andrew G.C. Sage II
President, Sage Capital Corporation
 
John B. Vander Sande, Ph.D.
Cecil and Ida Green Distinguished Professor
Department of Material Science and Engineering
Associate Dean of Engineering
Massachusetts Institute of Technology

CORPORATE OFFICERS AND VICE PRESIDENTS
 
Gregory J. Yurek, Ph.D.
President, Chief Executive Officer and
Chairman of the Board
 
Stanley D. Piekos
Vice President, Corporate Development,
Chief Financial Officer, Treasurer and Secretary
 
Paul F. Koeppe
Executive Vice President
Strategic Planning for Power Quality Solutions
 
Roland E. Lefebvre
Executive Vice President, Chief Operating Officer
 
Alexis P. Malozemoff, Ph.D.
Senior Vice President
Chief Technical Officer
 
Ross S. Gibson
Vice President, Human Resources
 
John B. Howe
Vice President, Electric Industry Affairs
 
Gero G. Papst, Ph.D.
Managing Director
American Superconductor Europe GmbH
 
Robert E. Schwall, Ph.D.
Vice President, Engineering
 
John D. Scudiere
Vice President, Manufacturing

FOUNDERS
 
Dr. Yet-Ming Chiang, Ph.D.
Kyocera, Professor of Ceramics
Department of Materials Science and Engineering
Massachusetts Institute of Technology
 
David A. Rudman, Ph.D.
Project Leader
Electro Magnetic Technology Division
National Institute of Standards and Technology
 
John B. Vander Sande, Ph.D.
(see above)
 
Gregory J. Yurek, Ph.D.
(see above)
<PAGE>   43

                                   SIGNATURES

         Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                                    AMERICAN SUPERCONDUCTOR CORPORATION



                                    By: /s/ Gregory J. Yurek
                                        --------------------------------------
                                    Gregory J. Yurek
                                    Chairman of the Board, President and
                                    Chief Executive Officer

                                    Date: June 25, 1998

         Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

<TABLE>
<CAPTION>
Name                              Title                                       Date
- ----                              -----                                       ----

<S>                               <C>                                         <C> 
/s/ Gregory J. Yurek              Director, Chairman of the         )         June 25, 1998
- ---------------------------       Board, President and Chief        )
Gregory J. Yurek                  Executive Officer (Principal      )
                                  Executive Officer)                )

/s/ Stanley Piekos                Vice President, Corporate         )         June 25, 1998
- ---------------------------       Development, Chief Financial      )                      
Stanley Piekos                    Officer, Treasurer (Principal     )                      
                                  Financial Officer and Principal   )                      
                                  Accounting Officer) and           )                      
                                  Secretary                         )                      

/s/ Albert J. Baciocco, Jr.       Director                          )         June 25, 1998
- ---------------------------                                         )
Albert J. Baciocco, Jr.                                             )

/s/ Frank Borman                  Director                          )         June 25, 1998
- ---------------------------                                         )
Frank Borman                                                        )

/s/ Peter O. Crisp                Director                          )         June 25, 1998
- ---------------------------                                         )
Peter O. Crisp                                                      )
</TABLE>


<PAGE>   44


<TABLE>
<S>                               <C>                                         <C> 
                                  Director                          )         June __, 1998
- ---------------------------                                         )
Richard Drouin                                                      )

/s/ Gerard J. Menjon              Director                          )         June 25, 1998
- ---------------------------                                         )
Gerard J. Menjon                                                    )

/s/ Andrew G.C. Sage, II          Director                          )         June 25, 1998
- ---------------------------                                         )
Andrew G.C. Sage, II                                                )

/s/ John B. Vander Sande          Director                          )         June 25, 1998
- ---------------------------                                         )
John B. Vander Sande                                                )
</TABLE>






<PAGE>   45



                                  EXHIBIT INDEX

<TABLE>
<CAPTION>
Exhibit No.                   Description                                                Page No.
- -----------                   -----------                                                --------

     <S>            <C>                                                                    <C>
         3.1**      -Restated Certificate of Incorporation of the
                             Registrant
         3.2*       -By-laws of the Registrant, as amended to date
         4.1*       -Specimen Certificate for shares of Common Stock,
                             $.01 par value, of the Registrant
      $$10.1*       -Employment Agreement dated as of December 4, 1991
                             between the Registrant and Gregory J. Yurek
      $$10.2*       -Employment Agreement dated as of December 4, 1991
                             between the Registrant and Alexis P. Malozemoff
        10.3*       -Form of Employee Nondisclosure and
                             Developments Agreement
      $$10.4*       -Employee Nondisclosure and Developments Agreement
                             dated as of December 26, 1990 between
                             the Registrant and Alexis P. Malozemoff
      $$10.5*       -Noncompetition Agreement dated as of July 10,
                             1987 between the Registrant and John Vander Sande
       $10.6*       -License Agreement between the Registrant and
                             MIT dated as of July 6, 1987
       $10.7*       -License Agreement between the Registrant and
                             MIT dated as of January 31, 1989
       $10.8*       -License Agreement dated as of August 1, 1991
       $10.9*       -License Agreement dated as of September 1, 1991
       $10.10**     -Second Amendment dated as of January 27, 1992
                             between the Registrant and MIT amending the
                             License Agreement dated as of July 6, 1987
                             between the Registrant and MIT
       $10.11***    -Technology Development and Patent Licensing
                             Agreement dated October 7, 1992 among the
                             Registrant and Electricity Corporation of
                             New Zealand Limited and Industrial Research Limited
      $$10.12***    -Employment Agreement dated as of December 31,
                             1992 between American Superconductor
                             Europe GmbH and Dr. Gero Papst
        10.13***    -Lease dated March 9, 1993 between CGLIC on
                             Behalf of its Separate Account R, as Landlord,
                             and the Registrant
        10.14+      -First Amendment to Lease between CGLIC, on Behalf
                             of its Separate Account R, as Landlord, and the
                             Registrant, as Tenant dated October 27, 1993
      $$10.15***    -1993 Stock Option Plan
</TABLE>





<PAGE>   46


<TABLE>
     <S>            <C>                                                                    <C>
        10.16++     -Agreement dated January 1, 1994 between Pirelli
                             Cavi S.p.A. and the Registrant
       $10.17###    -Agreement between Pirelli Cavi S.p.A. and American
                             Superconductor Corporation, dated October 1, 1995
        10.18++     -Technology Development and Patent Licensing
                             Agreement, First Amendment dated August 7, 1993
                             among the Registrant and Electricity Corporation of
                             New Zealand and Industrial Research Limited
        10.19+++    -Subcontract Agreement effective as of September 30,
                             1993 by and between the Registrant and Reliance
                             Electric Company
       $10.20#      -Fourth Amendment, dated May 15, 1995, to the
                             Exclusive License Agreement between the Registrant
                             and MIT dated July 6, 1987
      $$10.21##     -1996 Stock Incentive Plan
       $10.22###    -Management Agreement between Electric Power
                             Research Institute, Inc. and American Superconductor
                             Corporation, effective January 1, 1996
       $10.23###    -Technology License Agreement between Electric Power
                             Research Institute, Inc. and American Superconductor
                             Corporation, effective January 1, 1996
       $10.24###    -Warrant granted to Electric Power Research Institute, Inc.
                             by American Superconductor Corporation, dated
                             March 26, 1996.
        10.25@      -Strategic Alliance Agreement by and among the Registrant and CHARTH
                             (Compagnie Holding D'Applications Et De Realisations 
                             Thermiques Et Hydrauliques), dated as of April 1, 1997 
      $$10.26       -1997 Director Stock Option Plan
     $$$10.27       -Patent License Agreement between Lucent Technologies Inc.
                             and the Registrant, dated as of March 31, 1998
     $$$10.28       -Agreement dated April 1, 1997 by and among Electricite de
                             France and the Registrant
     $$$10.29       -Agreement effective April 1, 1997 by and between ABB
                             Transmission & Distribution Technology Ltd. and the
                             Registrant
        21.1        -Subsidiaries
        23.1        -Consent of Coopers & Lybrand L.L.P.
        23.2        -Consent of Smith & Gesteland, LLP
        23.3        -Consent of Ernst & Young LLP
        27.1        -Financial Data Schedule
</TABLE>

- ------------------

*    Incorporated by reference to Exhibits to the Registrant's Registration
     Statement on Form S-1 (File No. 33-43647).

**   Incorporated by reference to Exhibits to the Registrant's Annual Report on
     Form 10-K filed with the Commission on June 29, 1992.

***  Incorporated by reference to Exhibits to the Registrant's Annual Report on
     Form 10-K filed with the Commission on June 29, 1993.




<PAGE>   47



+    Incorporated by reference to Exhibits to the Registrant's Quarterly Report
     on Form 10-Q for the quarter ended December 31, 1993 filed with the
     Commission on January 26, 1994.

++   Incorporated by reference to Exhibits to Amendment No. 1 to the
     Registrant's Quarterly Report on Form 10-Q/A for the quarter ended December
     31, 1993 filed with the Commission on March 28, 1994.

+++  Incorporated by reference to Exhibits to the Registrant's Annual Report on
     Form 10-K filed with the Commission on June 29, 1994.

#    Incorporated by reference to Exhibits to the Registrant's Annual Report on
     Form 10-K filed with the Commission on June 29, 1995.

##   Incorporated by reference to Exhibits to the Registrant's Annual Report on
     Form 10-K filed with the Commission on June 28, 1996.

###  Incorporated by reference to Exhibits to the Registrant's Annual Report on
     Form 10-K/A filed with the Commission on March 10, 1997.

@    Incorporated by reference to Exhibits to the Registrant's Annual Report on
     Form 10-K filed with the Commission on June 30, 1997.

$    Confidential treatment previously requested and granted with respect to
     certain portions, which portions were omitted and filed separately with the
     Commission.

$$   Management contract or compensatory plan or arrangement required to be
     filed as an Exhibit to this Form 10-K.

$$$  Confidential treatment requested as to certain portions, which portions
     were omitted and filed separately with the Commission with this Annual
     Report on Form 10-K.



<PAGE>   1

                                                                   EXHIBIT 10.26


                       AMERICAN SUPERCONDUCTOR CORPORATION

                         1997 DIRECTOR STOCK OPTION PLAN

1.       PURPOSE.

         The purpose of this 1997 Director Stock Option Plan (the "Plan") of
American Superconductor Corporation (the "Company") is to encourage stock
ownership in the Company by outside directors of the Company whose continued
services are considered essential to the Company's future success and to provide
them with a further incentive to remain as directors of the Company.

2.       ADMINISTRATION.

         The Board of Directors shall supervise and administer the Plan. Grants
of stock options under the Plan and the amount and nature of the options to be
granted shall be automatic in accordance with Section 5. However, all questions
concerning interpretation of the Plan or any options granted under it shall be
resolved by the Board of Directors and such resolution shall be final and
binding. No director or person acting pursuant to the authority delegated by the
Board of Directors shall be liable for any action or determination relating to
or under the Plan made in good faith.

3.       PARTICIPATION IN THE PLAN.

         Directors of the Company who are not full-time employees of the Company
or any subsidiary of the Company ("Outside Directors") shall be eligible to
receive options under the Plan, except that Directors of the Company who are
representatives of an equity holder of the Company shall not be eligible to
receive options under the Plan.

4.       STOCK SUBJECT TO THE PLAN.

         (a) The maximum number of shares of the Company's Common Stock, par
value $.01 per share ("Common Stock"), which may be issued under the Plan shall
be 240,000 shares, subject to adjustment as provided in Section 7.

         (b) If any outstanding option under the Plan for any reason expires or
is terminated without having been exercised in full, the shares covered by the
unexercised portion of such option shall again become available for issuance
pursuant to the Plan.


<PAGE>   2



         (c) All options granted under the Plan shall be non-statutory options
not entitled to special tax treatment under Section 422 of the Internal Revenue
Code of 1986, as amended (the "Code").

         (d) Shares issued under the Plan may consist in whole or in part of
authorized but unissued shares or treasury shares.

5.       TERMS, CONDITIONS AND FORM OF OPTIONS.

         Each option granted under the Plan shall be evidenced by a written
agreement in such form as the President or the Executive Vice President,
Corporate Development, shall from time to time approve, which agreements shall
comply with and be subject to the following terms and conditions:

         (a) OPTION GRANT DATES AND SHARES SUBJECT TO OPTION. Options will be
granted under the Plan as follows:

                  (i)      INITIAL GRANTS TO CURRENT OUTSIDE DIRECTORS. Provided
that all stock options previously granted to a person serving as an Outside
Director under another director stock option plan of the Company are vested
completely or that such Outside Director has not yet been granted an option, an
option to purchase 40,000 shares of Common Stock shall be granted automatically
to each person serving as an Outside Director of the Company upon the approval
of the Plan by the stockholders of the Company. For persons serving as Outside
Directors whose stock options previously granted under another director stock
option plan of the Company have not vested completely as of the date of the
approval of the Plan by the stockholders of the Company, an option to purchase
40,000 shares of Common Stock shall be granted automatically on the first
business day following the date that such stock options are vested completely,
provided that such person is serving as an Outside Director as of such date.

                  (ii)     INITIAL GRANTS TO FUTURE OUTSIDE DIRECTORS. An option
to purchase 40,000 shares of Common Stock shall be granted automatically to each
Outside Director first elected to the Board of Directors after the date of the
approval of the Plan by the stockholders of the Company, upon the date of his or
her initial election to the Board of Directors.

         (b) OPTION EXERCISE PRICE. The option exercise price per share for each
option granted under the Plan shall be equal to the fair market value per share
of Common Stock on the date of grant, which shall be determined as follows: (i)
if the Common Stock is listed on the Nasdaq National Market or another
nationally recognized exchange or trading system as of the date on which a
determination of fair market value is to be made, the fair market value per
share shall be deemed to be the last reported sale price per share of Common
Stock thereon on such date (or, if no such price is reported on such date, such
price on the nearest preceding date on which such a price is reported); and (ii)
if the Common Stock is not listed on the Nasdaq


<PAGE>   3



National Market or another nationally recognized exchange or trading system as
of the date on which a determination of fair market value is to be made, the
fair market value per share shall be as determined by the Board of Directors.

         (c) TRANSFERABILITY OF OPTIONS. Except as the Board of Directors may
otherwise determine, options shall not be sold, assigned, transferred, pledged
or otherwise encumbered by the person to whom they are granted, either
voluntarily or by operation of law, except by will or the laws of descent and
distribution, and, during the life of the optionee, shall be exercisable only by
the optionee. References to a optionee, to the extent relevant in the context,
shall include references to authorized transferees, if any.

         (d) VESTING PERIOD.

                  (i)      GENERAL. Each option granted under the Plan shall
become exercisable in equal annual installments over the four year period
following the date of grant.

                  (ii)     ACCELERATION UPON AN ACQUISITION EVENT.
Notwithstanding the foregoing, each outstanding option granted under the Plan
shall immediately become exercisable in full in the event an Acquisition Event
(as defined in Section 8) of the Company occurs.

         (e) TERMINATION. Each option shall terminate, and may no longer be
exercised, on the earlier of the (i) the date ten years after the date of grant
or (ii) the date 60 days after the optionee ceases to serve as a director of the
Company for any reason, whether by death, resignation, removal or otherwise.

         (f) EXERCISE PROCEDURE. Options may be exercised only by written notice
to the Company at its principal office accompanied by (i) payment in cash or by
certified or bank check of the full consideration for the shares as to which
they are exercised or (ii) an irrevocable undertaking, in form and substance
satisfactory to the Company, by a broker to deliver promptly to the Company
sufficient funds to pay the exercise price or (iii) delivery of irrevocable
instructions, in form and substance satisfactory to the Company, to a broker to
deliver promptly to the Company cash or a check sufficient to pay the exercise
price.

         (g) EXERCISE BY REPRESENTATIVE FOLLOWING DEATH OF DIRECTOR. An
optionee, by written notice to the Company, may designate one or more persons
(and from time to time change such designation), including his or her legal
representative, who, by reason of the optionee's death, shall acquire the right
to exercise all or a portion of the option. If the person or persons so
designated wish to exercise any portion of the option, they must do so within
the term of the option as provided herein. Any exercise by a representative
shall be subject to the provisions of the Plan.


<PAGE>   4



6.       LIMITATION OF RIGHTS.

         (a) NO RIGHT TO CONTINUE AS A DIRECTOR. Neither the Plan, nor the
granting of an option nor any other action taken pursuant to the Plan, shall
constitute or be evidence of any agreement or understanding, express or implied,
that the optionee shall be entitled to continue as a director for any period of
time.

         (b) NO STOCKHOLDER RIGHTS FOR OPTIONS. An optionee shall have no rights
as a stockholder with respect to the shares covered by his or her option until
the date of the issuance to him or her of a stock certificate therefor, and no
adjustment will be made for dividends or other rights (except as provided in
Section 7) for which the record date is prior to the date such certificate is
issued. Notwithstanding the foregoing, in the event the Company effects a split
of the Common Stock by means of a stock dividend, and the distribution date
(i.e., the date on which the closing market price of the Common Stock on a stock
exchange or trading system is adjusted to reflect the split) is subsequent to
the record date for such stock dividend, an optionee who exercises an option
between the close of business on such record date and the close of business on
such distribution date shall be entitled to receive the stock dividend with
respect to the shares of Common Stock acquired upon such option exercise,
notwithstanding the fact that such shares were not outstanding as of the close
of business on such record date.

         (c) COMPLIANCE WITH SECURITIES LAWS. Each option shall be subject to
the requirement that if, at any time, counsel to the Company shall determine
that the listing, registration or qualification of the shares subject to such
option upon any securities exchange or under any state or federal law, or the
consent or approval of any governmental or regulatory body, or the disclosure of
non-public information or the satisfaction of any other condition is necessary
as a condition to, or in connection with, the issuance or purchase of shares
thereunder, such option may not be exercised, in whole or in part, unless such
listing, registration, qualification, consent or approval, or satisfaction of
such condition shall have been effected or obtained on conditions acceptable to
the Board of Directors.

7.       ADJUSTMENT TO COMMON STOCK. In the event of any stock split, stock
dividend, recapitalization, reorganization, merger, consolidation, combination,
exchange of shares, liquidation, spin-off or other similar change in
capitalization or event, or any distribution to holders of Common Stock other
than a normal cash dividend, (i) the number and class of securities available
under this Plan and (ii) the number and class of security and exercise price per
share subject to each outstanding option shall be appropriately adjusted by the
Company to the extent the Board shall determine, in good faith, that such an
adjustment is necessary and appropriate. No fractional shares will be issued
under the Plan on account of any such adjustments. If this Section 7 applies and
Section 8 also applies to any event, Section 8 shall be applicable to such event
and this Section 7 shall not be applicable.


<PAGE>   5



         Notwithstanding the foregoing, in the event the Company effects a split
of the Common Stock by means of a stock dividend, and the distribution date
(i.e., the date on which the closing market price of the Common Stock on a stock
exchange or trading system is adjusted to reflect the split) is subsequent to
the record date for such stock dividend, an optionee who exercises an option
between the close of business on such record date and the close of business on
such distribution date shall be entitled to receive the stock dividend with
respect to the shares of Common Stock acquired upon such option exercise,
notwithstanding the fact that such shares were not outstanding as of the close
of business on such record date.

8.       ACQUISITION EVENTS.

         CONSEQUENCES OF ACQUISITION EVENTS. Upon the occurrence of an
Acquisition Event (as defined below), or the execution by the Company of any
agreement with respect to an Acquisition Event, the Board shall take any one or
more of the following actions with respect to then outstanding options: (i)
provide that outstanding options shall be assumed, or equivalent options shall
be substituted, by the acquiring or succeeding corporation (or an affiliate
thereof), provided that any such options substituted for such options shall
satisfy, in the determination of the Board, the requirements of Section 424(a)
of the Internal Revenue Code of 1986, as amended; (ii) upon written notice to
the optionees, provide that all then unexercised options will become exercisable
in full as of a specified time (the "Acceleration Time") prior to the
Acquisition Event and will terminate immediately prior to the consummation of
such Acquisition Event, except to the extent exercised by the optionees between
the Acceleration Time and the consummation of such Acquisition Event; and (iii)
in the event of an Acquisition Event under the terms of which holders of Common
Stock will receive upon consummation thereof a cash payment for each share of
Common Stock surrendered pursuant to such Acquisition Event (the "Acquisition
Price"), provide that all outstanding options shall terminate upon consummation
of such Acquisition Event and each optionee shall receive, in exchange therefor,
a cash payment equal to the amount (if any) by which (A) the Acquisition Price
multiplied by the number of shares of Common Stock subject to such outstanding
options (whether or not then exercisable), exceeds (B) the aggregate exercise
price of such options.

         An "Acquisition Event" shall mean: (x) any merger or consolidation
which results in the voting securities of the Company outstanding immediately
prior thereto representing immediately thereafter (either by remaining
outstanding or by being converted into voting securities of the surviving or
acquiring entity) less than 50% of the combined voting power of the voting
securities of the Company or such surviving or acquiring entity outstanding
immediately after such merger or consolidation; (y) any sale of all or
substantially all of the assets of the Company; or (z) the complete liquidation
of the Company.


<PAGE>   6


9.       MODIFICATION, EXTENSION AND RENEWAL OF OPTIONS.

         The Board of Directors shall have the power to modify or amend
outstanding options; provided, however, that no modification or amendment may
(i) have the effect of altering or impairing any rights or obligations of any
option previously granted without the consent of the optionee, or (ii) modify
the number of shares of Common Stock subject to the option (except as provided
in Section 7).

10.      TERMINATION AND AMENDMENT OF THE PLAN.

         The Board of Directors may suspend, terminate or discontinue the Plan
or amend it in any respect whatsoever; provided, however, that without approval
of the stockholders of the Company, no amendment may (i) increase the number of
shares subject to the Plan (except as provided in Section 7), or (ii) effect any
action which requires approval of the stockholders pursuant to the rules or
requirements of the Nasdaq National Market or any other exchange on which the
Common Stock of the Company is listed.

11.      NOTICE.

         Any written notice to the Company required by any of the provisions of
the Plan shall be addressed to the Treasurer of the Company and shall become
effective when it is received.

12.      GOVERNING LAW.

         The Plan and all determinations made and actions taken pursuant hereto
shall be governed by the laws of the State of Delaware.

13.      STOCKHOLDER APPROVAL.

         The Plan is conditional upon stockholder approval of the Plan within
one year from its date of adoption by the Board of Directors, and no option may
be granted under the Plan until such stockholder approval is obtained.

                                    As adopted by the Board of Directors on 
                                    July 24, 1997 and approved by the 
                                    shareholders on September 5, 1997.




<PAGE>   1
                                                    EXHIBIT 10.27


                                              CONFIDENTIAL TREATMENT
                                     AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                     REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                     EXCHANGE ACT OF 1934, AS AMENDED
                 



                            PATENT LICENSE AGREEMENT



                                     BETWEEN



                            LUCENT TECHNOLOGIES INC.



                                       AND



                       AMERICAN SUPERCONDUCTOR CORPORATION





                         EFFECTIVE AS OF MARCH 31, 1998





                    RELATING TO SUPERCONDUCTIVE WIRE PRODUCTS
                               AND RELATED SYSTEMS
<PAGE>   2
                            PATENT LICENSE AGREEMENT

                                TABLE OF CONTENTS


ARTICLE 1 - GRANTS OF LICENSES.......................................1
         1.01     Grant..............................................1
         1.02     Duration...........................................1
         1.03     Scope..............................................1
         1.04     Ability to Provide Licenses........................2
         1.05     Publicity..........................................3
         1.06     Confidentiality....................................3

ARTICLE 2 - ROYALTY AND PAYMENTS.....................................4
         2.01     Royalty Calculation................................4
         2.02     Accrual............................................5
         2.03     Exclusions and Limitations.........................5
         2.04     Records and Adjustments............................6
         2.05     Reports and Payments...............................6

ARTICLE 3 - TERMINATION..............................................7
         3.01     Breach.............................................7
         3.02     Voluntary Termination..............................9
         3.03     Survival...........................................9

ARTICLE 4 - MISCELLANEOUS PROVISIONS.................................9
         4.01     Patents Licensed...................................9
         4.02     Disclaimer........................................10
         4.03     Indemnification...................................10
         4.04     Nonassignability and Change of Control of ASC.....10
         4.05     Addresses.........................................12
         4.06     Taxes.............................................12
         4.07     Choice of Law.....................................12
         4.08     Patents and Patent Applications...................13

         4.09     Licensing.........................................13
         4.10     Integration.......................................13
         4.11     Dispute Resolution................................13
         4.12     Outside of the United States......................14
         4.13     Releases..........................................15
         4.14     Good Faith Negotiations and Option................15


                                        i
<PAGE>   3
                            PATENT LICENSE AGREEMENT


Effective as of March 31, 1998, LUCENT TECHNOLOGIES INC., a Delaware corporation
("LUCENT"), having an office at 600 Mountain Avenue, Murray Hill, New Jersey
07974, and AMERICAN SUPERCONDUCTOR CORPORATION, a Delaware corporation ("ASC"),
having an office at Two Technology Drive, Westborough, Massachusetts 01581,
agree as follows:*


                                    ARTICLE 1

                               GRANTS OF LICENSES

1.01     GRANT

LUCENT grants to ASC under LUCENT's PATENTS personal, nonexclusive and
nontransferable licenses to make, to have made, use, lease, offer for sale, sell
and import products of the following kind:

                          SUPERCONDUCTIVE WIRE PRODUCT
                      SUPERCONDUCTIVE WIRE WITHIN A SYSTEM
             SYSTEMS PRODUCTS INCLUDING SUPERCONDUCTIVE WIRE PRODUCT

1.02     DURATION

All licenses granted herein under any patent shall continue for the entire
unexpired term of such patent.

1.03     SCOPE

(a) Licenses granted herein are not to be construed either (i) as consent by
LUCENT to any act which may be performed by ASC, except to the extent impacted
by a patent licensed herein to ASC, or (ii) to include licenses to
contributorily infringe or induce infringement under U.S. law or a foreign
equivalent thereof. As a result, the licenses granted herein to the ASC are
licenses to (i) make, have made, use, lease, offer for sale, sell and import
LICENSED PRODUCTS; (ii) make, have made, use and import machines, tools,
materials and other instrumentalities, insofar as such machines, tools,
materials and other instrumentalities are involved in or incidental to the
development, manufacture, testing or repair of LICENSED PRODUCTS which are

- --------

         * ANY TERM IN CAPITAL LETTERS WHICH IS DEFINED IN THE DEFINITIONS
APPENDIX SHALL HAVE THE MEANING SPECIFIED THEREIN.


                                        2
<PAGE>   4
or have been made by or are used, leased, owned, sold or imported by the grantee
of such license; and (iii) convey to any customer of the grantee, with respect
to any LICENSED PRODUCTS which is sold or leased by such grantee to such
customer, rights to use and resell such LICENSED PRODUCTS as sold or leased by
such grantee (whether or not as part of a larger combination); provided,
however, that no rights may be conveyed to customers with respect to any
invention which is directed to (1) a combination of such LICENSED PRODUCTS (as
sold or leased) with any other product; however, nothing herein shall prohibit
ASC from selling or delivering to third parties any LICENSED PRODUCTS made by
ASC and licensed under this Agreement, (2) a method or process which is other
than the inherent use of such LICENSED PRODUCTS itself (as sold or leased), or
(3) a method or process involving the use of LICENSED PRODUCTS to manufacture
(including associated testing) any other product. ASC customers, however, shall
have the right to service and test LICENSED PRODUCTS, but such right does not
include any rights or licenses to any patents of LUCENT, including but not
limited any rights to make, have made, offer for sale, import, use or sell
products that go to combinations of LICENSED PRODUCTS. The rights granted herein
to ASC under this Agreement do not include licenses for products manufactured by
a third party and sold by a Party to this Agreement where such sales do not meet
a legitimate business purpose but are merely for the purpose of sublicensing
LUCENT's PATENTS to such third party.

(b) The grant of each license hereunder includes the right of ASC to grant
sublicenses within the scope of such license to ASC's SUBSIDIARIES for so long
as they remain its SUBSIDIARIES. Any such sublicense may be made effective
retroactively, but not prior to the effective date hereof, nor prior to the
sublicensee becoming a SUBSIDIARY of ASC. If ASC is at least a minority owner,
but not less than a thirty percent (30%) owner, of an entity in a foreign
country where majority ownership by ASC is prohibited by law and ASC has control
and management of said entity, then LUCENT shall reasonably consider all
requests by ASC that such entity be considered a SUBSIDIARY hereunder. All such
requests must be in writing from ASC to LUCENT.

1.04     ABILITY TO PROVIDE LICENSES

LUCENT's failure to meet any obligation hereunder, due to the assignment of
title to any invention or patent, or the granting of any licenses, to the United
States Government or any agency or designee thereof pursuant to a statute or
regulation of, or contract with, such Government or agency, shall not constitute
a breach of this Agreement. As of the execution date, LUCENT is unaware of any
governmental claims to the patents licensed by this Agreement.


                                        3
<PAGE>   5
1.05     PUBLICITY

Nothing in this Agreement shall be construed as conferring upon ASC or its
SUBSIDIARIES any right to include in advertising, packaging or other commercial
activities related to a LICENSED PRODUCT, any reference to LUCENT (or any of its
SUBSIDIARIES), its trade names, trademarks or service marks in a manner which
would be likely to cause confusion or to indicate that such LICENSED PRODUCT is
in any way certified by LUCENT or its SUBSIDIARIES.

1.06     CONFIDENTIALITY

(a) Both Parties shall hold the financial terms and conditions of this Agreement
in confidence. Notwithstanding the foregoing, the confidentiality restrictions
of this Agreement shall not apply to any information:

         (i)      lawfully received by a Party to this Agreement from another
                  source having the right to so furnish such information; or

         (ii)     after it has become generally available to the public without
                  breach of this Agreement by either Party to this Agreement; or

         (iii)    which the Parties agree in writing is free of such 
                  restrictions;

         (iv)     which is necessary pursuant to any court order and where the
                  non-disclosing Party has been given notice of such an order;

         (v)      which must be disclosed as required by rules of the Security
                  Exchange Commission, but only to the extent that ASC has
                  provided LUCENT with the opportunity, at least ten (10) days
                  prior to ASC's initial EDGAR filing of the Agreement, to
                  designate the terms and conditions of the Agreement for which
                  LUCENT proposes confidential treatment in the filing, and
                  where ASC has made its initial EDGAR filing in accordance with
                  LUCENT's proposal, and ASC uses reasonable efforts to obtain
                  and to keep confidential treatment of the terms and conditions
                  designated by LUCENT;

         (vi)     which ASC discloses to its development partner, Pirelli Cavi e
                  Sistemi, S.p.A., an Italian Corporation having an office at
                  Viale Sarca 222, 20126 Milano, Italy and its wholly owned
                  subsidiaries ("Pirelli") pursuant to a confidentiality
                  agreement between ASC and Pirelli that is similar in scope to
                  this Section 1.06; or


                                        4
<PAGE>   6
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED

         (vii)    ASC, BTG USA, Inc. and LUCENT shall be permitted to disclose
                  to raw material vendors that LUCENT provides ASC with a [**]
                  for using raw material vendors that are licensed for such
                  materials and processes covered under LUCENT's PATENTS.


                                    ARTICLE 2

                              ROYALTY AND PAYMENTS

2.01     ROYALTY CALCULATION

(a) ASC will pay an initial licensing fee of [**] U.S.) due on the effective
date hereto, but payable in two (2) parts. The first part of the initial payment
in the amount of [**] U.S.) is due within the later of twenty-four (24) hours or
the next business day of execution by the last party of this Agreement. As to
this first part of the initial payment, time is of the essence; and the
agreement will have no effect if such payment is not made within the twenty-four
(24) hour time noted above. The second part of the initial payment in the amount
of [**] U.S.) is due no later than August 31, 1998. As to this second part of
the initial payment, time is of the essence; and this Agreement will
automatically terminate on September 1, 1998 if such payment is untimely. The
initial payment of [**] U.S.) is irrevocable and non-refundable.

(b) Continuing royalties shall be payable to LUCENT at the rate of [**] on all
[**] which is sold, leased, or put into use by ASC, or any of its SUBSIDIARIES
[**]. Such royalty rate shall be applied, except as otherwise provided in this
Article 2, to the FAIR MARKET VALUE of such [**].

(c) Continuing royalty payments under Section 2.01(b) are due and payable [**]
for all LICENSED PRODUCTS sold, leased or put into use after [**].

                                            
                                        5
<PAGE>   7
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED


(d) If LUCENT loses the [**] and exhausts or chooses not to file appeals during
the time period from the date of this Agreement to [**], then ASC will be
credited [**] U.S.) only against future royalties due during the time period
from [**] until [**]. If LUCENT loses the [**] and exhausts or chooses not to
file appeals after [**], then ASC will be credited [**] U.S.) in the subsequent
five (5) year period thereafter only against future royalties. If ASC incurs no
future royalty obligation or less than the credited amount of [**] U.S.), then
it forfeits the credit or balance of said credit. In no circumstance will LUCENT
make a payment to ASC pursuant said credit provided by this Section 2.01(d).

(e) If ASC purchased its raw materials for the LICENSED PRODUCTS hereunder from
a LICENSEE OF LUCENT, ASC shall have to pay a [**] royalty rate of [**] under
Section 2.01(b) for the sale of LICENSED PRODUCTS made from raw materials
purchased from a LICENSE OF LUCENT.

2.02     ACCRUAL

(a) Royalty shall accrue on any LICENSED PRODUCT [**] and shall become payable
upon the first sale, lease or putting into use of such LICENSED PRODUCT.
(Rebuilding or enlarging any product shall be deemed to be a first putting into
use of such product to the extent [**] is [**] or [**] or where any [**] is [**]
and [**] is not due to expected and normal product life wear. Testing of
LICENSED PRODUCT by on or behalf of ASC shall not be deemed putting into use).
Obligations to pay accrued royalties shall survive termination of licenses and
rights pursuant to Article 3 and the expiration of any patent.

(b) When a company ceases to be a SUBSIDIARY of ASC, royalties which have
accrued with respect to any products of such company, but which have not been
paid, shall become payable with ASC's next scheduled royalty payment.

(c) Notwithstanding any other provisions hereunder, royalty shall accrue and be
payable only to the extent that enforcement of ASC's obligation to pay such
royalty would not be prohibited by applicable law.

2.03     EXCLUSIONS AND LIMITATIONS

(a) A LICENSED PRODUCT of one or more of LUCENT's PATENTS, may be treated by ASC
as not licensed and not subject to royalty with respect to sales of such
LICENSED PRODUCT if the purchaser is licensed under the same one or more


                                        6
<PAGE>   8
patents to have said LICENSED PRODUCT made and/or imported, and the purchaser
advises ASC, in writing at or prior to the time of such sale, that it is
exercising its own license under such one or more patents with respect to such
manufacture and/or importation.

(b) Subject to the exhaustion principle, payment of a royalty shall be due for
any LICENSED PRODUCT manufactured, used, sold, put into use or imported by ASC
or its SUBSIDIARIES even though such LICENSED PRODUCT may incorporate materials
or components, which materials or components are (i) covered by one or more
claims of LUCENT's PATENTS and (ii) purchased by ASC or its SUBSIDIARIES from a
third party having a license to LUCENT's PATENTS.

2.04     RECORDS AND ADJUSTMENTS

(a) ASC shall keep full, clear and accurate records with respect to all LICENSED
PRODUCTS and shall furnish any information which LUCENT may reasonably prescribe
from time to time to enable LUCENT to ascertain the proper royalty due hereunder
on account of products sold, leased and put into use by ASC or any of its
SUBSIDIARIES. ASC shall retain such records with respect to each LICENSED
PRODUCT for at least seven (7) years from the sale, lease or putting into use of
such LICENSED PRODUCT. LUCENT shall have the right through its accredited
auditors to make an examination by giving ASC thirty (30) days written notice,
during normal business hours, of all records and accounts bearing upon the
amount of royalty payable to it hereunder. Prompt adjustment shall be made to
compensate for any errors or omissions disclosed by such examination. All such
information reviewed will be treated as confidential by LUCENT and its auditors
in accordance with Section 1.06 of this Agreement.

(b) Independent of any such examination, LUCENT will credit to ASC the amount of
any overpayment of royalties made in error which is identified and fully
explained in a written notice to LUCENT delivered within twelve (12) months
after the due date of the payment which included such alleged overpayment,
provided that LUCENT is able to verify, to its own satisfaction, the existence
and extent of the overpayment.

(c) No refund, credit or other adjustment of royalty payments shall be made by
LUCENT except as provided in this Section 2.04 and Sections 2.01(d) and (e) of
this Agreement. Rights conferred by this Section 2.04 shall not be affected by
any statement appearing on any check or other document, except to the extent
that any such right is expressly waived or surrendered by a party having such
right and signing such statement.



                                        7
<PAGE>   9
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED

2.05     REPORTS AND PAYMENTS

(a) [**] and at all times thereafter, that within sixty (60) days after the end
of each semiannual period ending on June 30th or December 31st, commencing with
the semiannual period during which this Agreement first becomes effective, ASC
shall furnish to LUCENT at the address specified in Section 4.03 a statement
certified by a responsible official of ASC showing in a manner acceptable to
LUCENT:

         (i)      all LICENSED PRODUCTS which were sold, leased or put into use
                  during such semiannual period;

         (ii)     the FAIR MARKET VALUES of all [**] or [**] LICENSED PRODUCTS;

         (iii)    the amount of royalty payable thereon without regard to any
                  credit available pursuant to Sections 2.01(d), 2.01(e) and
                  2.04(b) and the net amount payable after application of such
                  credit; and

         (iv)     all exclusions from royalty pursuant to Section 2.03.

If no LICENSED PRODUCT has been so sold, leased or put into use, the statement
shall show that fact.

(b) Within such sixty (60) days ASC shall pay in United States dollars to LUCENT
at the address specified in Section 4.03 the royalties payable in accordance
with such statement. Any conversion to United States dollars shall be at the
prevailing rate for bank cable transfers as quoted for the last day of such
semiannual period by leading United States banks in New York City dealing in the
foreign exchange market.

(c) Overdue payments hereunder shall be subject to a late payment charge
calculated at an annual rate of three percentage points (3%) over the prime rate
or successive prime rates (as posted in New York City) during delinquency. If
the amount of such charge exceeds the maximum permitted by law, such charge
shall be reduced to such maximum. This provision will not apply if the lateness
of the payment was due to the negligence of the United States Postal Service,
and it can be shown that the payment was sent via the U.S. Mail with a postmark
date at least three (3) business days prior to the date that payment was due.
Also, a wire transfer that is late due to the negligence of LUCENT's bank (as
identified in Section 4.05(b)) shall not be considered late, if without the
negligence of LUCENT's bank, the payment would have been timely.

                  

                                        8
<PAGE>   10
                                    ARTICLE 3

                                   TERMINATION

3.01     BREACH

(a) Licenses and rights granted under this Agreement shall be effective during
the term commencing on the effective date hereof and continuing until such
licenses and rights are terminated pursuant to the provisions hereof.

(b) If ASC and its SUBSIDIARIES shall fail to fulfill its obligations under
Article 2, LUCENT may, upon its election and in addition to any other remedies
that it may have, at any time, terminate all of LUCENT's obligations hereunder
and all of the licenses and rights granted by LUCENT hereunder by not less than
two (2) months written notice to ASC specifying any such breach or failure,
unless within the period of such notice all grounds specified therein for
termination pursuant to this Section 3.01(b) shall have been cured and remedied.
Other material obligations breached, except as to Sections 3.01(d), 3.01(e) and
3.01(f), by either party under this Agreement such that it is in material breach
of its obligations set forth herein, are to be remedied through the alternative
dispute resolution provisions contained herein, with not less than two (2)
months written notice to the breaching Party specifying any such breach or
failure, unless within the period of such notice all grounds specified therein
for breach pursuant to this Section 3.01(b) shall have been remedied. The
occurrence of the events of Sections 3.01(d), 3.01(e) and 3.01(f) are cause for
immediate termination in accordance with these Sections where the two (2) month
cure and remedy period will be inapplicable.

(c) The obligations of LUCENT and ASC under this Agreement that, by their nature
would survive termination of this Agreement, shall survive and continue after
any such termination.

(d) If a voluntary or involuntary petition under applicable bankruptcy laws is
filed by or against ASC and its SUBSIDIARIES, unless ASC and its SUBSIDIARIES
provides to LUCENT reasonable assurances that ASC and its SUBSIDIARIES will be
able to comply with the provisions of this Agreement, LUCENT may terminate this
Agreement. ASC and its SUBSIDIARIES shall immediately notify LUCENT of the
filing of any bankruptcy petition by or against ASC and its SUBSIDIARIES.
Notwithstanding the foregoing, a CHANGE IN CONTROL of ASC and its SUBSIDIARIES
that results from bankruptcy proceedings shall be treated as provided in Section
3.01(f).


                                        9
<PAGE>   11
(e) If a proceeding is commenced under any provision of the United States
Bankruptcy Code, voluntary or involuntary, by or against either Party, and this
Agreement has not been terminated, the non-debtor Party may file a request with
the bankruptcy court to have the court set a date within sixty (60) days after
the commencement of the case, by which the debtor Party will assume or reject
this Agreement, and the debtor Party shall cooperate and take whatever steps are
necessary to assume or reject the Agreement by such date.

(f) In the event of a CHANGE IN CONTROL of ASC, or a reasonable expectation of a
CHANGE IN CONTROL of ASC, then ASC shall provide notice to LUCENT of such actual
or expected CHANGE IN CONTROL event within ten (10) days of any resolution by
ASC's Board of Directors approving an actual or anticipated CHANGE IN CONTROL.
If ASC purports to transfer this Agreement in connection with any CHANGE IN
CONTROL of ASC, LUCENT shall have the right to terminate this Agreement unless
such transfer is permitted by the CHANGE IN CONTROL provisions effective as of
the effective date of a CHANGE IN CONTROL provided that LUCENT gives ASC written
notice of its intention to terminate at least thirty (30) days prior to the
termination date specified in the termination notice.

(g) Termination of ASC's and its SUBSIDIARIES rights pursuant to Section 3.01(f)
shall not terminate any license to the extent required to enable ASC to fulfill
contracts entered into prior to the effective date of termination.

(h) As to dispute as to payments made, if ASC makes a payment or payments to
avoid termination under Section 3.01(a) of this Agreement and ASC then
subsequently submits the asserted overpayment to dispute resolution in
accordance with Section 4.11 and ASC prevails, then in addition to refund of any
overpayment(s) made and any other award made by the arbitrator, ASC shall be
entitled to interest on its overpayment(s) at the rate specified in Section
2.05(c) of this Agreement.

3.02     VOLUNTARY TERMINATION

By written notice to LUCENT, ASC may voluntarily terminate all or a specified
portion of the licenses and rights granted to it hereunder. Such notice shall
specify the effective date (not more than six (6) months prior to the giving of
said notice) of such termination and shall clearly specify any affected patent,
invention or product.

3.03     SURVIVAL

Any termination of licenses and rights of ASC under the provisions of this
Article 3 shall not affect ASC's licenses, rights and obligations with respect
to any LICENSED PRODUCT made prior to such termination.



                                       10
<PAGE>   12
                                    ARTICLE 4

                            MISCELLANEOUS PROVISIONS

4.01     PATENTS LICENSED

LUCENT represents that LUCENT's PATENTS licensed to ASC under this Agreement are
the original work of LUCENT or its SUBSIDIARIES (or LUCENT has a valid right to
license such property) and it has the power to grant the rights described in
this Agreement to the extent that LUCENT can grant such rights and inclusive of
the limitations in the definitions herein and Section 1.04.

4.02     DISCLAIMER

EXCEPT AS OTHERWISE PROVIDED HEREIN, NEITHER BTG USA INC., LUCENT NOR ANY
SUBSIDIARIES OF BTG USA INC. OR LUCENT MAKE ANY REPRESENTATIONS, EXTEND ANY
WARRANTIES OF ANY KIND, ASSUME ANY RESPONSIBILITY OR OBLIGATIONS WHATEVER, OR
CONFER ANY RIGHT BY IMPLICATION, ESTOPPEL OR OTHERWISE, OTHER THAN THE LICENSES
AND RIGHTS HEREIN EXPRESSLY GRANTED.

4.03     INDEMNIFICATION

(a) ASC agrees to indemnify and save LUCENT and its SUBSIDIARIES and BTG USA,
Inc. and its SUBSIDIARIES harmless from any claims or demand for personal injury
or property damage (including reasonable expense of litigation and settlement of
such claims) by third parties to the extent that such claims arise out of or in
connection with the furnishing or use of any of the information and patent
licenses provided hereunder.

(b) LUCENT, BTG and ASC shall at all times retain the administrative supervision
of their respective personnel during visits to each other's facilities.
LUCENT's, BTG's and ASC's personnel shall, while on any location of either
LUCENT, BTG or ASC or their SUBSIDIARIES, comply with the other Party's or its
SUBSIDIARIES' rules and regulations with regard to safety and security. ASC
shall have full control over such personnel while on any location of any of the
others or its SUBSIDIARIES and shall be entirely responsible for their complying
with the other Party's or its SUBSIDIARIES' rules and regulations. LUCENT, BTG
and ASC agree to indemnify and save the other Party and its SUBSIDIARIES
harmless from any claims or demands, including the costs, expenses and
reasonable attorney's fees incurred on account thereof, that may be made by (i)
anyone for injuries to persons or damage to property resulting from acts or
omissions of LUCENT's, BTG's and ASC's personnel providing services and products
pursuant to this Agreement on the premises of the other Party; or (ii) LUCENT's,
and ASC's personnel under Worker's Compensation or similar laws. The Parties,
and for this Section 4.03(b) it shall include BTG, hereto


                                       11
<PAGE>   13
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED


agree to defend the other Party and its SUBSIDIARIES against any such claim or
demand while on any location of the Parties or their SUBSIDIARIES. The
indemnifications of this Section 4.03(b) shall be applicable to agents, auditors
and contractors of LUCENT, BTG and ASC.

4.04     NONASSIGNABILITY AND CHANGE OF CONTROL OF ASC

(a) LUCENT has entered into this Agreement in contemplation of personal
performance by ASC and it is LUCENT's intention that a transfer of ASC's
licenses or rights not occur without LUCENT's express written consent, except as
provided in Section 4.04(b) or the CHANGE OF CONTROL provision hereto.

(b) Subject to the limitations of the provisions herein, at any time prior to
the expiration of the Agreement, ASC may assign all of its licenses and rights
under this Agreement for the balance of the term to any successor of ASC's
entire business (hereinafter, "ACQUIROR") at the time of such assignment,
provided that (i) if such ACQUIROR [**] in a[**], such [**] agrees in writing
within sixty (60) days after the assignment to comply with all of the terms and
conditions of this Agreement during the balance of the term of the Agreement, or
(ii) if such ACQUIROR [**] with [**] or that of any of its SUBSIDIARIES, such
ACQUIROR agrees in writing within sixty (60) days after the assignment to comply
with all of the terms and conditions of this Agreement as if such successor were
ASC.

(c) Any transfer or assignment of ASC's licenses and rights in accordance with
Section 4.04(b)(ii) set forth hereinabove shall be applicable for [**] of
LICENSED PRODUCTS during the [**] following such transfer or assignment
(hereinafter, the "[**] PERIOD") based on the [**] of LICENSED PRODUCTS over the
[**] preceding such transfer or assignment (hereinafter, the "PRE-ACQUISITION
PERIOD") and thereafter to [**] of LICENSED PRODUCTS beginning in the [**] year
and for each subsequent year the agreement is in effect. The [**] of LICENSED
PRODUCTS will be determined as follows:


                                       12
<PAGE>   14
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED



         (i)      For the first year of the [**] PERIOD the [**] in United
                  States dollars of LICENSED PRODUCTS shall not exceed the [**]
                  for the [**] prior to the assignment or transfer in accordance
                  with 4.04(b)(ii) (hereinafter, the "BASE YEAR" defined as the
                  ASC's last fiscal year prior to acquisition) [**] by the [**]
                  for the PRE-ACQUISITION PERIOD. Each year's sales of LICENSED
                  PRODUCT for the remaining [**] years of the [**] PERIOD shall
                  be limited to a year to year [**] over the previous year's
                  [**] of [**] equal to the [**] of the PRE-ACQUISITION PERIOD;
                  and

         (ii)     Beginning in the [**] year and for each year thereafter, the
                  [**] in a [**] of [**] year to year shall be the [**] of the
                  [**] of ASC [**] of [**] during the PRE-ACQUISITION PERIOD or
                  the [**] of the ACQUIROR's [**] of [**] during the [**]
                  PERIOD.

(d) Except as provided for in Section 4.04(b)(i) and (ii), all other transfer or
assignment by any means, including but not limited to merger, asset sale,
divestiture or stock purchase, shall be subject to the limitation of the CHANGE
OF CONTROL provisions.

4.05     ADDRESSES

(a) Any notice or other communication hereunder shall be sufficiently given to
ASC when sent by certified mail addressed to Chief Financial Officer, American
Superconductor Corporation, Two Technology Drive, Westborough, Massachusetts
01581 (or, if no address is otherwise specified, to ASC's office above
specified), or to LUCENT when sent by certified mail addressed to Contract
Administrator, Intellectual Property Organization, Lucent Technologies Inc.,
Suite 105, 14645 N.W. 77th Avenue, Miami Lakes, Florida 33014, United States of
America. Changes in such addresses may be specified by written notice.

(b) Payments by ASC shall be made to LUCENT at Sun Trust, P.O. Box 913021,
Orlando, Florida, 32891-3021, United States of America. Alternatively, payments
to LUCENT may be made by bank wire transfers to LUCENT's account: Lucent
Technologies Licensing, Account No. 910-2-568475, Swift Code: CHASUS33, ABA
Code: 021000021, at Chase Manhattan Bank, N.A., 55 Water Street, New York, New
York 10041, United States of America. Changes in such address or account may be
specified by written notice.


                                       13
<PAGE>   15
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED

4.06     TAXES

ASC shall pay any tax, duty, levy, customs fee, or similar charge ("taxes"),
including interest and penalties thereon, however designated, imposed on ASC as
a result of the operation or existence of this Agreement, including taxes which
ASC is required to withhold or deduct from payments to LUCENT, except (i) net
income taxes imposed upon LUCENT by any governmental entity within the United
States (the fifty (50) states and the District of Columbia), and (ii) net taxes
imposed upon LUCENT by jurisdictions outside the United States which are
allowable as a credit against the United States Federal income tax of LUCENT or
any of its SUBSIDIARIES. In order for the exception in (ii) to be effective, ASC
must furnish to LUCENT evidence sufficient to satisfy the United States taxing
authorities that such taxes have been paid. Such evidence must be furnished to
LUCENT within thirty (30) days of issuance by the local taxing authority.

4.07     CHOICE OF LAW

The Parties are familiar with the principles of New York commercial law, and
desire and agree that the law of New York shall apply in any dispute arising
with respect to this Agreement.

4.08     PATENTS AND PATENT APPLICATIONS

LUCENT shall maintain LUCENT's PATENTS and prosecute the patent applications
licensed hereunder in accordance with its standard polices and procedures for
patents and applications owned by LUCENT. Within ninety (90) days of [**] LUCENT
will provide ASC with a written list of the status of LUCENT's PATENTS in all
countries where such patents have issued or have been filed.

4.09     LICENSING

LUCENT will use its best efforts to license LUCENT's PATENTS to other entities
to the extent it has the right to do so. Such best efforts would be the normal
methods and procedure followed by LUCENT in licensing its Intellectual Property,
including patents, to third parties. Best efforts hereunder does not require
LUCENT to actually license all or some of LUCENT's PATENTS to a third party, but
to follow its course of business practices to license such patents.


                                       14
<PAGE>   16
4.10     INTEGRATION

This Agreement sets forth the entire agreement and understanding between the
Parties as to the subject matter hereof and merges all prior discussions between
them. Neither of the Parties shall be bound by any warranties, understandings or
representations with respect to such subject matter other than as expressly
provided herein or in a writing signed with or subsequent to execution hereof by
an authorized representative of the Party to be bound thereby.

4.11     DISPUTE RESOLUTION

(a) If a dispute arises out of or relates to this Agreement, or the breach,
termination or validity thereof, the Parties agree to submit the dispute to a
sole mediator selected by the Parties or, at any time at the option of a Party,
to mediation by the American Arbitration Association ("AAA"). If not thus
resolved, it shall be referred to a sole arbitrator selected by the Parties
within thirty (30) days of the mediation, or in the absence of such selection,
to AAA arbitration which shall be governed by the United States Arbitration Act.

(b) Any award made (i) shall be a bare award limited to a holding for or against
a Party and affording such remedy as is deemed equitable, just and within the
scope of this Agreement; (ii) shall be without findings as to issues (including
but not limited to patent validity and/or infringement) or a statement of the
reasoning on which the award rests; (iii) may in appropriate circumstances
(other than patent disputes) include injunctive relief; (iv) shall be made
within four (4) months of the appointment of the arbitrator; and (v) may be
entered in any court.

(c) The requirement for mediation and arbitration shall not be deemed a waiver
of any right of termination under this Agreement and the arbitrator is not
empowered to act or make any award other than based solely on the rights and
obligations of the Parties prior to any such termination.

(d) The arbitrator shall be knowledgeable in the legal and technical aspects of
this Agreement and shall determine issues of arbitrability but may not limit,
expand or otherwise modify the terms of this Agreement.

(e) This Agreement shall be interpreted in accordance with the laws of the State
of New York exclusive of its conflict of laws provisions and the place of
mediation and arbitration shall be New York City.

(f) Each Party shall bear its own expenses but those related to the compensation
and expenses of the mediator and arbitrator shall be borne equally.


                                       15
<PAGE>   17
(g) A request by a Party to a court for interim measures shall not be deemed a
waiver of the obligation to mediate and arbitrate.

(h) The arbitrator shall not have authority to award punitive or other damages
in excess of compensatory damages and each party irrevocably waives any claim
thereto.

(i) The Parties, their representatives, other participants and the mediator and
arbitrator shall hold the existence, content and result of mediation and
arbitration in confidence.

4.12     OUTSIDE OF THE UNITED STATES

(a) There are countries in which the owner of an invention is entitled to
compensation, damages or other monetary award for another's unlicensed
manufacture, sale, lease, use or importation involving such invention prior to
the date of issuance of a patent for such invention but on or after a certain
earlier date, hereinafter referred to as the invention's "protection
commencement date" (e.g., the date of publication of allowed claims or the date
of publication or "laying open" of the filed patent application). In some
instances, other conditions precedent must also be fulfilled (e.g., knowledge or
actual notification of the filed patent application). The Parties agree that (i)
an invention which has a protection commencement date in any such country may be
used in such country pursuant to the terms of this Agreement on and after any
such date, and (ii) all such conditions precedent are deemed satisfied by this
Agreement.

(b) ASC hereby agrees to register or cause to be registered, to the extent
required by applicable law, and without expense to LUCENT or any of its
SUBSIDIARIES, any agreements wherein sublicenses are granted by it under
LUCENT's PATENTS. ASC hereby waives any and all claims or defenses, arising by
virtue of the absence of such registration, that might otherwise limit or affect
its obligations to LUCENT.

4.13     RELEASES

LUCENT, for itself and for its present SUBSIDIARIES, hereby releases ASC, its
present SUBSIDIARIES and all customers (purchasers and users) of products of the
kinds herein licensed as of the effective date hereof to ASC, from all claims,
demands and rights of action which LUCENT or any of its present SUBSIDIARIES may
have on account of any infringement or alleged infringement of LUCENT's PATENTS
issued in any country of the world by reason of the manufacture or any past or
future use, lease, sale, offer for sale or importation of any of such products
which, prior to the effective date hereof, were used or furnished by ASC or any
of its present SUBSIDIARIES.


                                       16
<PAGE>   18
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED


4.14     Good Faith Negotiations and Option

(a) LUCENT at its sole discretion can enter into good faith negotiations with
ASC if at some time subsequent LUCENT decides or considers to sell or convey the
patents licensed hereunder to a third party for the sale or conveyance of said
patents to ASC. LUCENT can discontinue any such negotiations with ASC in its
sole discretion at any time.

(b) ASC at its sole discretion can enter into good faith negotiations with
LUCENT if at some time subsequent to the execution of this Agreement ASC wishes
to obtain a license for systems containing SUPERCONDUCTIVE WIRE PRODUCTS used in
[**] systems. ASC shall be entitled to obtain such a license on financial terms
to be negotiated at the time of the request where such financial terms are
similar to then THIRD PARTY LICENSEES financial terms and conditions, but all
other terms and conditions will be the same as this Agreement. If LUCENT has no
THIRD PARTY LICENSEE at the time that ASC wishes to obtain a license, ASC can
obtain a license at the royalty rate herein at as well as the same terms and
conditions.



                                       17
<PAGE>   19
IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed
in duplicate originals by its duly authorized representatives on the respective
dates entered below.

                                   LUCENT TECHNOLOGIES INC.          
                                   
                                   
                                   By:   /s/ M.R. Greene
                                        ----------------------------------------
                                        M.R. Greene
                                        Acting President - Intellectual Property
                                        Division
                                   
                                   Date:  May 8, 1998
                                   
                                   AMERICAN SUPERCONDUCTOR
                                   CORPORATION
                                   
                                   
                                   By:  /s/ Gregory J. Yurek
                                        ----------------------------------------
                                        Gregory J. Yurek
                                        President and Chief Executive Officer
                                   
                                   Date:  May 8, 1998
                                   
         

              THIS AGREEMENT DOES NOT BIND OR OBLIGATE EITHER PARTY
                IN ANY MANNER UNLESS DULY EXECUTED BY AUTHORIZED
                         REPRESENTATIVES OF BOTH PARTIES


                                       18
<PAGE>   20
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED


                              DEFINITIONS APPENDIX


ACQUIROR shall mean one person or entity, or two or more persons and/or entities
constituting a "group" for purposes of the Securities Exchange Act of 1934, as
amended. For determining the COMPETITOR trigger below, the entire entity
including all subsidiaries and related companies shall be treated as a single
entity for the purpose of determining the revenue and business of the company
and the trigger point for the CHANGE OF CONTROL options. For example if the
entity owns more than fifty percent (50%) of a SUBSIDIARY its revenue and
businesses will be counted; as well as if the entity controls another entity
with less than majority interest through direct or indirect Control (as herein
defined) over a Party that entity's revenue will be counted as part of
ACQUIROR's revenue. For the purposes of this subsection, the term "Control"
shall mean the possession directly or indirectly of the power to direct or cause
the direction of the management or policies of a Party, whether through the
ability to exercise voting power, by contract or otherwise due to local law,
then that controlled entity's sales will be included in total revenue and
businesses for the entity.

CHANGE OF CONTROL occurs, except as to a transfer or an assignment permitted by
Section 4.04(b), in connection with the acquisition by an ACQUIROR of ASC's
entire business or a part to which the licenses and rights under this Agreement
relate upon any one of the following circumstances or events and the license
herein can or cannot be transferred depending on the following:

         (a)      If the ACQUIROR is a [**] at the time of the acquisition of
                  all or part of ASC, there can be no transfer or assignment of
                  this Agreement without the written consent of LUCENT;

         (b)      If the ACQUIROR is in an [**] with LUCENT at the time of the
                  acquisition of all or part of ASC, there can be no transfer or
                  assignment of this Agreement without the written consent of
                  LUCENT; or

         (c)      If neither (a) nor (b) apply to the ACQUIROR at the time of
                  the acquisition of all or part of ASC, there can be no
                  transfer or assignment of this Agreement without the written
                  consent of LUCENT unless, within [**] days of the effective
                  date of the CHANGE OF CONTROL, the [**] of [**] U.S.) to
                  LUCENT and notifies LUCENT in writing of the


                                       19
<PAGE>   21
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED

                  ACQUIROR's agreement that, effective as of the effective date
                  of the CHANGE OF CONTROL, the royalty rate provided by Section
                  2.01(b) shall be [**] and the royalty rate provided by Section
                  2.01(e) shall be [**].

A CHANGE OF CONTROL does not occur if an assignment or transfer is permitted by
Section 4.04, or if neither (a) nor (b) above apply to the ACQUIROR and the
ACQUIROR [**] as provided in (c) above, or if the [**] of ASC and ASC does not
attempt to [**] under this Agreement in connection with the acquisition. In the
event of a CHANGE OF CONTROL of ASC, LUCENT's alternatives to written consent
include, but are not limited to termination of this Agreement in accordance with
Section 3.01(f).

COMPETITOR means an ACQUIROR providing service and/or products in
microelectronics (including but not limited to integrated circuits and
optoelectronics), business communications systems (including but not limited to
messaging, voice/data and call center systems), optical networking (including
but not limited to optical line Systems), switching and access systems
(including but not limited to switching systems and access systems), wireless
networks (including but not limited to infrastructure for wireless that adhere
to global standards), network products (including but not limited to fiber
products and power systems for communications products), and all natural
improvements and extensions therefrom, ACQUIROR's that have sales of the above
products that are incidental and unrelated to their main businesses, less than
one percent of revenue, shall not be deemed a COMPETITOR.

FAIR MARKET VALUE means, with respect to any SUPERCONDUCTIVE WIRE PRODUCT sold,
leased or put into use, the amount of (i) the selling price actually obtained
for such a product or system in the form in which it is sold, whether or not
assembled (and without excluding therefrom any components or subassemblies
thereof which are included in such selling price) for a bona fide sale to a
third party, but in no case will the value be less than ASC's break-even point
for SUPERCONDUCTIVE WIRE PRODUCT alone; or (ii) the value of SUPERCONDUCTIVE
WIRE PRODUCT as a [**] of the [**] or the [**] shall be based on the [**] that
ASC receives from an unaffiliated buyer in a bona fide arm's length transaction
for an [**] of [**] but in no case less than ASC's break-even point.

In determining "selling price" the following shall be excluded:

         (a)      usual trade discounts actually allowed to unaffiliated persons
                  or entities;

         (b)      packing costs;

                 
                                       20
<PAGE>   22
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED

         (c)      costs of insurance and transportation; and
         (d)      import, export, excise, sales and value added taxes, and 
customs duties.

For the purposes of the determination of Fair Market Value for triggering
royalty payment under Article 2 herein; from [**] through [**] no more than [**]
of revenue for the LICENSED PRODUCTS that consist of SUPERCONDUCTIVE WIRE
PRODUCTS or contain SUPERCONDUCTIVE WIRE PRODUCTS can be excluded from royalty
payments if they are found to be PROTOTYPES. After [**] no more than [**] of
revenue for the LICENSED PRODUCTS can be excluded from royalty payments if they
are found to be PROTOTYPES.

LUCENT'S PATENTS means:

Japanese Patent No. 1921521

Japanese Patent No. 2079035

Japanese Application No.[**] and any patent issuing thereon

European Patent No. 0305515

The United States Letters Patents and Patent Applications listed below and any
Foreign Counterparts and U.S. Counterparts thereof, together with any divisions,
continuations, continuations-in-part, renewals, reissues, and reexaminations.
For purposes of this Appendix A, "Foreign and U.S. Counterparts" shall mean
those foreign patents and patent applications which claim priority based on: (i)
the below specified U.S. patents and patent applications, (ii) an application
from which the below specified U.S. patents issued or from which such an
application in turn claims priority, (iii) an application from which a below
specified patent application claims priority, or (iv) from which a below
specified U.S. patent or patent application claim priority.

U.S. Patent Application No.[**]([**] in [**]) and any patents which may issue 
thereon.

U.S. Patent Application No.[**] ([**] in [**]) and any patents which may issue 
thereon.


U.S. 4,145,699                  U.S. 4,880,771               U.S. 5,100,870
U.S. 4,242,419                  U.S. 4,914,081               U.S. 5,106,826
U.S. 4,249,094                  U.S. 4,933,317               U.S. 5,132,280


                                       21
<PAGE>   23
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED


U.S. 4,264,916                  U.S. 4,943,557                   U.S. 5,157,017

U.S. 4,318,741                  U.S. 4,952,554                   U.S. 5,187,149
U.S. 4,325,144                  U.S. 4,966,885                   U.S. 5,196,400
U.S. 4,342,924                  U.S. 4,992,623                   U.S. 5,210,071
U.S. 4,358,783                  U.S. 4,996,189                   U.S. 5,244,868
U.S. 4,370,568                  U.S. 5,006,504                   U.S. 5,272,132

U.S. 4,373,138                  U.S. 5,011,823                   U.S. 5,340,796
U.S. 4,391,657                  U.S. 5,039,653                   U.S. 5,364,836
U.S. 4,488,164                  U.S. 5,053,383                   U.S. 5,389,603
U.S. 4,610,032                  U.S. 5,057,877                   U.S. 5,391,323
U.S. 4,754,384                  U.S. 5,081,075                   U.S. 5,413,755
U.S. 4,797,386                                                   U.S. 5,416,063
U.S. 4,837,609                                                   U.S. 5,470,530

LICENSED PRODUCTS mean, as to grantee, any product (including specified
combinations) listed for such grantee in Section 1.01.

LICENSEE OF LUCENT means raw material suppliers licensed under LUCENT's PATENTS.

PROTOTYPES means those products that would normally be counted as LICENSED
PRODUCTS, but they are sold at prices less than [**] of ASC's costs for the
purpose of product development.

SUBSIDIARY of a company means a corporation or other legal entity (i) the
majority of whose shares or other securities entitled to vote for election of
directors (or other managing authority) is now or hereafter controlled by such
company either directly or indirectly; or (ii) which does not have outstanding
shares or securities but the majority of whose ownership interest representing
the right to manage such corporation or other legal entity is now or hereafter
owned and controlled by such company either directly or indirectly; but any such
corporation or other legal entity shall be deemed to be a SUBSIDIARY of such
company only as long as such control or ownership and control exists.


                                       22
<PAGE>   24
                                             CONFIDENTIAL TREATMENT 
                                    AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                    REQUESTED THAT THE MARKED PORTIONS OF THIS
                                    DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                    PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
                                    EXCHANGE ACT OF 1934, AS AMENDED

SUPERCONDUCTIVE WIRE PRODUCT means wire, tape or other long length conductor
exhibiting superconductivity formed from superconductive material, including
Yttrium Barium Copper Oxide (YBCO) and Bismuth Strontium Calcium Copper Oxide
(BSCCO), but specifically excluding thin film electronic products suitable for
electronics and data processing applications and whose manufacture, importation,
sale, lease or use of which by ASC or any of its SUBSIDIARIES would but for the
licenses or rights under this Agreement, constitute (i) infringement of LUCENT's
PATENTS by ASC, or such SUBSIDIARY.

SUPERCONDUCTIVE WIRE WITHIN A SYSTEM means the quantity of SUPERCONDUCTIVE WIRE
PRODUCT in a system such as a transformer, motor, generator, SMES, or fault
current limiter. Such quantity of SUPERCONDUCTlVE WIRE PRODUCT will be subject
to royalty based on the [**] of the [**] and not the [**].

SYSTEMS PRODUCT INCLUDING SUPERCONDUCTIVE WIRE PRODUCT
means systems, subassemblies and components including coils and current leads
incorporating SUPERCONDUCTIVE WIRE PRODUCT but excluding systems and
subassemblies designed for [**] Communications and data processing applications.
Such a SYSTEMS PRODUCT INCLUDING SUPERCONDUCTIVE WIRE PRODUCT will be subject to
a royalty based on the FAIR MARKET VALUE of the [**] and not the value of [**].

THIRD PARTY LICENSEE(S) means an entity licensed by LUCENT in whole or in part
under LUCENT's PATENTS for[**] and [**] systems.

[**] means [**] between application assigned to [**] with LUCENT's application
involved in the [**] being [**] having [**].




<PAGE>   1
                                                                  EXHIBIT 10.28

                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

                             



                              STRATEGIC DEVELOPMENT

                                    AGREEMENT

                                     BETWEEN

                              ELECTRICITE DE FRANCE

                                       AND

                       AMERICAN SUPERCONDUCTOR CORPORATION






<PAGE>   2


     This Agreement, dated as of April 1, 1997, is entered into by and among

                          ELECTRICITE DE FRANCE ("EDF")
                    a French Corporation with head offices at
                     2, rue Louis Murat, 75008 PARIS/FRANCE
                       herein represented by Francois Boulot, Vice President of
             R&D Division located at 1, avenue du General de Gaulle,
                           92141 CLAMART Cedex/FRANCE

                                       and

     AMERICAN SUPERCONDUCTOR CORPORATION, a Delaware corporation ("ASC"), with
offices at Two Technology Drive, Westborough, MA 01581.

     WHEREAS, ASC is engaged in the research, development, commercialization,
production and marketing of superconductor products for the electric power
industry;

     WHEREAS, EDF is an electric utility that seeks to provide the best possible
service to its customers at the lowest possible cost and to enhance its
competitive position;

     WHEREAS, EDF believes that high temperature superconductivity is and will
be one of the most significant technological developments affecting the
electricity industry;

     WHEREAS, EDF believes that ASC is and will be a leader in the development
and commercialization of high temperature superconductor products;

     WHEREAS, ASC has a development program for alternating current ("AC") and
high resistivity sheathing ("HRS") high temperature superconductor ("HTS")
conductors and is in discussions with ABB Power T&D Company, Inc. ("ABB")
whereby ABB will be offsetting some of ASC's development costs for AC and HRS
HTS conductor development period. This total program amounts to 15 MUS$. The
present Agreement deals with EDF contribution to this program and amounts to 5
MUS$. The words ((conductors)) and ((wires)) are used interchangeably.

     WHEREAS, EDF wants to maximise the benefit from this program with the
shortest delay, by actively participating in the developments, through technical
and financial support for AC and HRS HTS superconductors

     It is understood that EDF and ABB shall have a separate agreement wherein
EDF will be working with ABB to develop and install HTS transformers
manufactured by ABB using the AC and HRS HTS conductors developed by ASC under
this Agreement and the ASC/ABB agreement; and

     NOW, THEREFORE, in consideration of the mutual promises and covenants
contained in this Agreement, the parties hereto agree as follows:



                                       -2-


<PAGE>   3


                       ARTICLE 1: PERFORMANCE OF THE WORK

     1.1 WORK. ASC shall use its best efforts, within commercially reasonable
limits, to perform the work (the "Work") as set forth in the Statement of Work
in Attachment A, in the schedule (the ((Schedule))) attached hereto. The
((schedule)) defines the Work (detailed in Attachment A), the period of
performance, the Budget (detailed in Attachment B as defined in Subarticle 2.3).

     1.2 PERIOD OF PERFORMANCE. This Agreement when signed will be effective
April 1st, 1997. Its total duration is 48 months from that date. ASC shall use
its best efforts, within commercially reasonable limits, to complete the Work,
within the time period(s) set forth in the Schedule (the "Period of
Performance") and within the Budget.

     1.3 FORCE MAJEURE. Force Majeure conditions of the Chambre de Commerce
Internationale in Geneva, as defined in Attachment C, apply for this Agreement.

     1.4 ORGANISATION. Two committees follow the performance of the Work.

A Steering Committee is formed in order to approve project reports, decide on
changes, corrections and interpretations in the project targets (technically,
financially, timing), approve publications and/or information to third parties.
Representatives on the Steering Committee are:

                  -ASC              A.P. Malozemoff
                  -EDF              P.G. Therond

A Technical Committee is formed in order to follow the progress of the Work, as
defined in Attachment A, and propose changes, corrections in the project target
if necessary, propose publications or information to third parties.
Representatives on the Technical Committee are:

                  -ASC              G. Riley Jr
                  -EDF              C. Levillain

The representatives are appointed by ASC and EDF respectively and may be changed
during the course of the Agreement.

                                ARTICLE 2: COSTS

     2.1 COST REIMBURSEMENT. EDF shall reimburse ASC for all costs incurred in
the performance of the Work, subject to the limitations contained below in this
Article 2, and Article 3 of this Agreement. In case of termination as defined in
Article 11, payments already given by EDF shall be kept by ASC. Payment for the
last quarter



                                       -3-


<PAGE>   4


corresponding to the termination shall be calculated using the ratio between the
duration already over compared to the total duration of the quarter.

     2.2 BEST EFFORTS. ASC agrees to use its best efforts, within commercially
reasonable limits, to perform the Work within the "Budget" as set forth in
Article 2, Subarticle 2.3.

     2.3 BUDGET. EDF's payments of funds for each contract year are set forth in
the Schedule of Development Cost (Attachment B). The Budget, which amounts to a
total of 5MUS$ represents the maximum amount of EDF funds that ASC is authorized
to expend or commit for the Work. This budget includes any US taxes that may be
applicable. Attachment B shows the yearly budget that ASC is authorized to
expend and commit for the work as of the last day of the applicable contract
year. ASC may carry forward any unexpended committed funds into succeeding
contract years.

     2.4 ACCOUNTING PROCEDURES. ASC's costs shall be determined on the basis of
ASC's accounting system, procedures and practices employed as of the effective
date and during the performance of this Agreement; provided that ASC shall use
generally accepted accounting principles and cost reimbursement practices.

     2.5 AUDIT RIGHTS. ASC shall maintain books, records, documents, and other
evidence, in sufficient detail to reflect properly all costs incurred in
performing this Agreement. The audit of corporate allocations will be limited to
the supporting documentation at the division(s) performing the Work. A certified
public accounting firm designated by EDF, from a list of such firms as proposed
by ASC, may audit such accounting records at all reasonable times with prior
notice by EDF. EDF shall bear the expense of such audits. It is the intent of
the parties that such audits shall ordinarily be performed not more frequently
than once every twelve (12) months during the performance of the Work. The
certified public accounting firm conducting the audit will certify the accuracy
of ASC's costs, calculations and appropriateness of the allocation methodology.

                               ARTICLE 3: PAYMENTS

     Subject to the provisions of Article 2, EDF shall pay ASC the total amount
of each invoice received by EDF, after receipt by EDF of the quarterly report of
the preceding quarter. The period of time covered, including the beginning and
ending dates, must be specified on each invoice. Invoices shall be submitted in
advance on a quarterly basis as set forth in the Schedule of Development Costs,
defined in Attachment B.

     Requests for payment with accompanying invoices shall refer to the EDF
research project number (M12 / 1K8715 / EL 751, M12 L 09) and shall be submitted
in duplicate by ASC to the attention of "Bureau de Gestion des
Approvisionnements":



                                       -4-


<PAGE>   5


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED


     EDF, Direction des Etudes et Recherches
     1, avenue du General de Gaulle
     F-92141 CLAMART CEDEX
     FRANCE

The payments shall be made within 45 days after receipt of invoice, without
agios.

                               ARTICLE 4: PAY-BACK

     4.1 TECHNICAL PROGRESS REPORTS. ASC shall submit quarterly technical
progress reports to EDF, for the attention of EDF representative in the
technical Committee. Such reports shall be in sufficient detail to disclose Work
accomplished and results achieved during the reporting period. The content of
the reports is detailed in Attachment A. In addition, such reports shall include
a summary in non-technical language which briefly describes the Work and sets
forth the important results and contents of the report. ASC informs EDF in such
reports about the Work performed for the development of AC and HRS HTS
conductors.

     4.2 REPORT DISTRIBUTION. All technical reports of any nature developed and
furnished under this Agreement are intended solely for the purpose of
communicating and transferring information relating to research and are subject
to Article 7.

     4.3 ROYALTIES. For [**] from [**] of HTS commercial conductors by ASC for
transformers, ASC will pay to EDF a royalty of [**] on [**] HTS [**] sales. For
the purpose of this royalty calculation, sales for the [**] as described under
Article 4.4 will be excluded. For the purpose of this royalty calculation, [**]
will be excluded the first [**] and included after [**] and until [**] from the
[**] of HTS [**] by ASC for transformers.

     4.4 COMMERCIAL DISCOUNTS. In recognition of EDF's contribution to the
development of HTS conductors for transformers, ASC undertakes to sell any AC
and HRS HTS conductor developed by ASC under this Agreement, which is to be used
in HTS transformers designated for and sold in the [**] to the manufacturers of
these transformers at pricing not to exceed to the one proposed to ABB under
ASC's agreement with ABB on development of AC and HRS HTS wires. The current
price discount to ABB amounts to a [**] price discount from the lowest
commercial price available from ASC for similar quantities for any AC and HRS
HTS conductors developed by ASC under this Agreement, or any HTS conductor
originating from the Work and this discount shall not be taken into
consideration in determining the lowest



                                       -5-


<PAGE>   6


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

commercial price. When a HTS transformer is commissioned for use in the [**],
EDF will notify ASC. It is agreed that ASC shall have no right to influence any
negotiation between EDF and any transformer manufacturer.

     The definition of a commercial conductor sale under this Agreement is sale
of HRS or AC wire which is applicable to a High Temperature Superconducting
Transformer which is either the [**] in the [**] of [**] HTS transformers, or
the [**] in the [**] of [**] HTS transformers, whichever is sold HRS. The
above-mentioned discount will apply during [**] from the [**] of HTS commercial
conductors for HTS transformers by one of these designated manufacturers.

                      ARTICLE 5: DATA, RECORDS AND REPORTS

     ASC agrees to maintain the records in sufficient detail to properly reflect
all Work done and results achieved in the performance thereof. Ownership of all
records and other data produced, generated or procured under this Agreement,
including under any subcontracts, shall be as provided in Subarticle 6.1.

                     ARTICLE 6: INTELLECTUAL PROPERTY RIGHTS

     6.1 OWNERSHIP. ASC shall own exclusively all right, title, and interest in
and to all discoveries, inventions, data and documentation conceived or first
reduced to practice by ASC in the course of the Work (the "Technology") and to
any patents or patent applications, copyrights or other intellectual property
rights based on the technology.

     In the event of a jointly-made invention, such joint invention shall be
jointly owned by EDF and ASC and, if ABB has contributed to the invention, by
ABB. The parties shall mutually determine whether or not application(s) for
patents shall be filed, the party which will prepare, file and manage such
application and the country or countries in which the same are to be filed. For
jointly-made invention, it is the intention of EDF and ASC that ASC will be the
primary means for developing and commercializing such conductor developed in the
framework of this Agreement.

     6.2 LICENSE. In case ASC will not continue to perform the Work defined in
the present Agreement because ASC terminates the Agreement for convenience in
accordance with Article 11.1 and in case EDF is interested to continue on its
own, ASC shall license for HTS transformer application only on a world-wide
basis such patents, copyrights or other intellectual property rights based on
the technology developed in the



                                       -6-


<PAGE>   7


context of the Work detailed in the present Agreement to a third party. ASC has
to make sure in licensing conditions that payback items described in Articles
4.3 and 4.4 are transferred to the licensee.

                           ARTICLE 7: CONFIDENTIALITY

     7.1 EDF INFORMATION.

          (a) ASC acknowledges that during the term of this Agreement it may be
exposed to certain information which is confidential or proprietary to EDF ("EDF
CONFIDENTIAL INFORMATION"). All EDF Confidential Information shall be marked by
EDF as "EDF CONFIDENTIAL". ASC shall protect and maintain such EDF CONFIDENTIAL
INFORMATION in the same manner and to the same degree it protects its own
confidential information.

          (b) ASC agrees that during the term of this Agreement and for a period
of ten (10) years unless both parties agree to extend the period beyond ten (10)
years, ASC and its affiliates will not use any EDF CONFIDENTIAL INFORMATION
except in accordance with the provisions and for the purposes of this Agreement,
and will not disclose any EDF CONFIDENTIAL INFORMATION to any third party
without the prior written consent of EDF.

     7.2 ASC INFORMATION.

          (a) The parties contemplate that in the performance of the Work ASC
furnishes information to EDF that is confidential or proprietary to ASC or has
been provided to ASC by a third party on a confidential basis ("ASC CONFIDENTIAL
INFORMATION"). This includes information concerning the Work or the Technology,
or information developed by ASC apart from this Agreement which is generally
related to the subject of this Agreement. ASC shall clearly mark it as "ASC
CONFIDENTIAL INFORMATION". EDF shall protect and maintain such ASC CONFIDENTIAL
INFORMATION in the same manner and to the same degree it protects its own
confidential information.

          (b) EDF agrees that during the term of this Agreement and for a period
of ten (10) years thereafter unless both parties agree to extend the period
beyond ten (10) years, EDF or EDF Affiliates will not use any ASC CONFIDENTIAL
INFORMATION except in accordance with the provisions, for EDF or affiliates
internal needs and for the purpose of this Agreement, and will not disclose any
such ASC CONFIDENTIAL INFORMATION to any third party without the prior written
consent of ASC.

     7.3 JOINT INVENTIONS. Reports concerning joint inventions, when marked
confidential, will be treated as such by both parties except that they may be
shared with ABB and ABB Affiliates in accordance with the agreements between ABB
and ASC or EDF and ABB.



                                       -7-


<PAGE>   8


     7.4 THIRD PARTIES. If one Party needs for the achievement of the Work
defined in the Agreement to subcontract or involve any third Party, that Party
shall also deal with confidentiality issues with this third Party, as defined in
this Article 7.

     7.5 EXCEPTIONS. The provisions of this Article 7 shall not apply to either
party's CONFIDENTIAL INFORMATION to the extent that:

          (a) such information was generally known or otherwise in the public
domain prior to disclosure hereunder, or becomes so known subsequent to such
disclosure through no fault of the receiving party; or

          (b) such information is received by the receiving party after the
Effective Date of this Agreement without restriction from a third party not
under an obligation to the disclosing party not to disclose it and otherwise not
in violation of the disclosing party's rights; or

          (c) such information is furnished to third parties by the disclosing
party without a similar restriction on the third party's rights, or

          (d) such information is already in the possession of the receiving
party, as shown by written records, without violation of this Agreement.

          (e) such information has been independently developed by the receiving
party without reference to or reference on the other party's Confidential
Information.

     7.6 COURT ORDER. In the event either party's Confidential Information is
subpoenaed or otherwise required to be produced or made available by the other
party to a third party by order of a court or governmental administrative
agency, the party required to produce such information shall promptly notify the
other party in writing and allow ten (10) days or, if less, the maximum amount
of time possible under the circumstances, for response by the disclosing party
before producing such documents. The receiving party will cooperate with the
disclosing party in obtaining a protective court order or take such other action
as may be appropriate under the circumstances.

     7.7 SURVIVORSHIP. The provisions of this Article 7 shall survive any
termination of this Agreement for 5 years.



                                       -8-


<PAGE>   9


              ARTICLE 8: REPRESENTATIONS, WARRANTIES AND COVENANTS

     8.1 BINDING OBLIGATION. This Agreement is the valid and legally binding
obligation of each party in accordance with its terms, subject to bankruptcy,
reorganization, insolvency, moratorium and similar laws and to general
principles of equity which are within the discretion of courts of applicable
jurisdiction.

     8.2 NO LITIGATION OF CLAIMS. ASC represents and warrants to EDF that to the
best of ASC's knowledge at the time of execution of this Agreement, there is no
pending litigation or knowledge of a claim made by any third party which may
substantially affect ASC's ability to fulfill its obligations pursuant to this
Agreement.

     8.3 AGREEMENTS WITH EMPLOYEES. Except as otherwise prevented by law, both
parties will maintain with their respective employees, agents, subcontractors
and consultants who perform under this Agreement and who have access to the
Technology, written agreements sufficient to enable each party to perform its
obligations hereunder.

     8.4 COMPLIANCE WITH LAWS. Each party will comply with all laws and
regulations applicable to the performance of its obligations hereunder,
including, without limitation, all safety, health and environmental laws, and
will obtain all necessary government authorizations, approvals and permits
required to perform the Work.

     8.5 NO INFRINGEMENT. ASC shall perform the Work in a manner so that to the
best of ASC's knowledge, neither the Technology being developed, the
deliverables being supplied to EDF, nor the exercise by EDF of any of the rights
granted hereunder infringes any intellectual property right of any third party;
provided, however, the foregoing covenant shall not apply to patent rights, and
to copyrights unless ASC knowingly infringes such copyrights.

                          ARTICLE 9: PUBLICITY RELEASES

     PRIOR APPROVAL. Unless required by law or stock market regulations neither
party may issue any publicity releases (including news releases and advertising)
relating to this Agreement and the Work performed hereunder without the prior
written approval of the other party. EDF and ASC will coordinate their responses
to any substantial inquiry from news media concerning this Agreement.

             ARTICLE 10: INDEMNIFICATION AND LIMITATION OF LIABILITY

     10.1 INDEMNITY. Each party (party A) shall protect, defend, indemnify and
hold harmless the other party (party B), its agents, employees and directors
from any claim, loss, cost, liability or expense (including court costs and
reasonable fees of attorneys and other professionals) arising out of or
resulting from any breach by party A of the representations, warranties and
covenants made in Article 8.



                                       -9-


<PAGE>   10


     10.2 GENERAL INDEMNITY. Notwithstanding Subarticle 10.1 herein each party
(party A) shall protect, defend, indemnify and hold harmless the other party
(party B), its agents, employees and directors from any claim, loss, cost,
liability or expense (including court costs and reasonable fees of attorneys)
arising out of any injury, including death, or any property damage suffered by
any third party associated with Party B as a result of or related to any
negligent act or negligent failure to act of party A's, its subcontractors, its
subsidiaries or any third parties which have been involved by party A for the
achievement of the Work, or of any of their respective employees, agents and
directors in connection with or related to the Work or the performance of this
Agreement except to the extent that any losses, costs, liabilities, claims or
expenses are the result of any negligent act or negligent failure to act of the
party B, its agents, employees and directors.

     10.3 CONDITIONS AND OBLIGATIONS. Party A's obligations under Subarticle
10.1 and 10.2 above are conditioned upon (i) party B giving notice, which is
timely under the particular circumstances, to party A's representative
(specifically named in Article 12 herein), of any claim made against the party B
or any claim made by the party B hereunder, provided, however, notice shall be
considered timely unless party A has suffered substantive or irreparable
prejudice as a result of a delay by party B in giving notice to party A in (a)
the defense of such claim or (b) party A giving notice to an applicable insurer
of such claim and (ii) party B giving party A the right to control and direct
any investigation, defense and settlement of such claims, provided, however,
party A shall not settle, compromise or resolve such claim (except if such
settlement, compromise or resolution consists only of a payment of money to be
made by ASC) without the prior written approval of the party B (which approval
shall not be unreasonably withheld). Party B shall provide full and timely
cooperation to party A in the defense or settlement of such claims.

     10.4 LIMITATION OF LIABILITY.

          (i) IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY
SPECIAL, INDIRECT, CONSEQUENTIAL OR INCIDENTAL DAMAGES, HOWEVER CAUSED AND ON
ANY THEORY OF LIABILITY, ARISING OUT OF THIS AGREEMENT, EVEN IF SUCH PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

          (ii) THE TOTAL CUMULATIVE LIABILITY OF ASC TO EDF, ARISING FROM
INTELLECTUAL PROPERTY INFRINGEMENT OR IN ANY WAY CONNECTED TO THE PERFORMANCE OR
NONPERFORMANCE OF THIS AGREEMENT, WHETHER IN INTELLECTUAL PROPERTY INFRINGEMENT,
CONTRACT, TORT (INCLUDING NEGLIGENCE OR STRICT LIABILITY) OR OTHERWISE FOR
DAMAGE OR LOSS OF OTHER PROPERTY OR EQUIPMENT, LOSS OF PROFITS OR REVENUE, LOSS
OF USE OF EQUIPMENT OR POWER SYSTEM, COST OF CAPITAL, COST OF PURCHASED OR
REPLACEMENT POWER OR TEMPORARY EQUIPMENT



                                      -10-


<PAGE>   11


(INCLUDING ADDITIONAL EXPENSES INCURRED IN USING EXISTING FACILITIES), CLAIMS OF
CUSTOMERS OF EDF, SHALL NOT EXCEED THE FUNDING RECEIVED BY ASC FROM EDF.

                             ARTICLE 11: TERMINATION

     11.1 TERMINATION. This Agreement may be terminated, without cause and for
its convenience, by any party at any time upon ninety (90) days written notice
to the other party.

     11.2 SURVIVAL. The provisions of Subarticle 2.5 (Audit Rights), Article 5
(Data), Article 6 (Intellectual Property Rights), Article 8 (Representations,
Warranties and Covenants), Article 10 (Indemnification and Limitation of
Liability), Article 13 (Dispute Resolution) and Article 14 (Miscellaneous) shall
survive completion or termination of this Agreement for any reason. The
provision of Article 7 (Confidentiality) shall survive completion or termination
of this Agreement during ten (10) years.

                               ARTICLE 12: NOTICES

     Any notices or communications required or permitted under this Agreement
shall be in writing and personally delivered or sent to the address of each
party as set forth below, or to such other address as either party may
substitute by written notice to the other in any manner expressly provided for
herein.

                  (a)      Notices to EDF under this Agreement:
                           Direction des Etudes et Recherches
                           Attn.: Chef du Service Materiels Electriques
                           1, avenue du General de Gaulle
                           F-92141 CLAMART Cedex
                           FRANCE


                  (b)      Notices to ASC under this Agreement:
                           American Superconductor Corporation
                           Attn.:  President
                           Two Technology Drive
                           Westborough, MA 01581

                         ARTICLE 13: DISPUTE RESOLUTION

     13.1 MEDIATION AND ARBITRATION. If a dispute arises out of or relates to
this Agreement, or any breach thereof, and if such dispute cannot be settled
through direct negotiation between the parties, and if the parties mutually
agree, the parties shall submit the dispute to mediation with a mediator at the
Chambre de Commerce



                                      -11-


<PAGE>   12


Internationale of Geneva. The mediation may be initiated by the written request
of either party and sent to the other party and shall commence within fifteen
(15) days of receipt of such notice, unless otherwise agreed by the parties.
These disputes arising in connection with the present Agreement shall be finally
settled under the Rules of Conciliation and Arbitration of the International
Chamber of Commerce. If the procedure of conciliation fails, the dispute is
settled through arbitration according international trade customs and practices,
by one or more arbitrators appointed in accordance with the said Rules. The
language of the mediation shall be English.

     13.2 Each party shall bear its own expense of such mediation proceedings,
unless otherwise agreed by the parties.

                            ARTICLE 14: MISCELLANEOUS

     14.1 ASSIGNMENT. Except to accomplish the sale or transfer of a business
unit or division, or reorganization of either party, this Agreement may not be
assigned, in whole or in part, by either party without the prior written consent
of the other party which consent shall not be unreasonably withheld. If this
Agreement is assigned for any reason by either party, terms and conditions of
this Agreement will continue.

     14.2 BENEFIT. Subject to Subarticle 14.1 above, this Agreement is binding
upon and shall inure to the benefit of the parties hereto, their
representatives, successors and permitted assigns.

     14.3 WAIVER. No failure or successive failures on the part of either party,
its successors or assigns, to enforce any covenant or agreement, and no waiver
or successive waivers on its or their part of any condition of this Agreement
shall operate as a discharge of such covenant, agreement, or condition, or
render the same invalid, or impair the right of either party, its successors and
assigns, to enforce the same in the event of any subsequent breach or breaches
by the other party hereto, its successors or assigns.

     14.4 ENTIRE AGREEMENT. This Agreement constitutes the entire Agreement
between the parties and supersedes all previous agreements and understandings
relating to the Work, including any letter agreement between the parties. This
Agreement may not be altered, amended, or modified except by a written
instrument signed by the duly authorized representatives of both parties.

     14.5 WARRANTY DISCLAIMER. WITHOUT LIMITING ASC'S OBLIGATIONS PURSUANT TO
ARTICLE(S) 8 AND 11 HEREIN, IN RECOGNITION THAT THE NATURE OF THE WORK INVOLVES
RESEARCH AND DEVELOPMENT, ASC MAKES NO WARRANTIES OF ANY KIND, EXPRESS OR
IMPLIED, EXCEPT ARTICLE 4, REGARDING THE WORK.



                                      -12-


<PAGE>   13


     14.6 SEVERABILITY. Any provision of this Agreement that is prohibited or
unenforceable in any jurisdiction shall be ineffective to the extent of such
prohibition or unenforceability without invalidating the remaining provisions
hereof. Any such prohibition or unenforceability in any jurisdiction shall not
invalidate or render unenforceable such provision in any other jurisdiction.

     14.7 FURTHER ASSURANCES. If, at any time, either party has reasonable
grounds to believe that the other party may be unable to perform its obligations
hereunder, the first party may in writing demand adequate assurance of due
performance, and until it receives such assurance to its satisfaction, it may
suspend performance of its obligations hereunder.

     14.8 EXPORT REGULATIONS. All technical data or commodities of United States
origin made available directly or indirectly hereunder for use outside the
United States shall be used subject to and in accordance with any applicable
laws and regulations of the departments and agencies of the United States
Government. The recipient of such technical data or commodities agrees not to
re-export, directly or indirectly, any technical data of United States origin
acquired from the Disclosing Party or any commodities using such data to any
destination requiring United States Government approval for such reexport until
a request for approval has been submitted to and granted by the United States
Government.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized representatives.


Electricite de France                      American Superconductor Corporation

By: /s/ Boulet Francais                    By:  /s/ G.J. Yurek
   --------------------------                  --------------------------------


Print Name: Boulet Francais                Print Name: G.J. Yurek
           ------------------                         -------------------------

Title: Director                            Title: President
      -----------------------                    ------------------------------

Date: January 2nd 1998                     Date: January 2, 1998
     ------------------------                   -------------------------------



                                      -13-


<PAGE>   14


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED


                ASC Confidential Information under this Agreement

                      SCHEDULE TO THE DEVELOPMENT AGREEMENT
                                     BETWEEN
                                   EDF AND ASC


1.0      STATEMENT OF WORK

1.1      The Statement of Work is attached hereto as Attachment A, which is
         hereby deemed incorporated and made an integral part of this Agreement.

2.0      PERIOD OF PERFORMANCE
         Alliance Agreement will be for a four year period, covering April 1,
         1997 through March 31, 2001.

3.0      BUDGET
         The budget is set forth in this Article 3 and in Attachment B to this
         Schedule.

3.1      EDF will pay ASC for the development outlined in this Agreement as per
         Attachment B.

4.0      DELIVERABLES

4.1      TECHNICAL PROGRESS REPORTS
         ASC shall submit to the EDF with respect to the Work a technical
         progress report on a quarterly basis.

4.3      PROTOTYPE CONDUCTORS MILESTONES

         The milestones may be [**] in preliminary design review for the [**]
         and [**] transformers. All values listed are minimum performance
         requirements with [**], and [**]. AC loss values are determined by [**]
         unless otherwise specified.

4.3.1    [**] GENERATION [**]:  feasibility demonstrated in [**] with the 
         following combined characteristics:
         1. [**] at [**] and in [**] to plane.
         2. [**] at [**] and in [**] to plane.



                                      -14-


<PAGE>   15


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

                ASC Confidential Information under this Agreement

3.       [**] and operating [**] total current [**] consistent with the above 
         [**]  specifications.

4.3.2    [**] GENERATION [**]: feasibility demonstrated in [**] with the 
         following combined characteristics:
         1.  [**] at [**] and in [**] to plane.
         2.  [**] at [**] and in [**] to plane.
         3.  [**] and operating [**] total current [**] consistent with the 
             above [**] specification.

4.3.3    [**] GENERATION [**]: [**] process demonstrated with characteristics of
         4.3.2.

4.3.4    [**] GENERATION [**]:  feasibility demonstrated in [**] with the 
         following combined characteristics:
         1.  [**] at [**] and in [**] to plane determined by a [**] measurement.
         2.  [**] at [**] and in [**] to plane determined by a [**] measurement.
         3.  [**] and operating [**] total current [**] consistent with the
             above [**] specifications.

4.3.5    [**] GENERATION [**]: [**] completed and first production [**] with
         4.3.2 specs supplied to ABB.

4.3.6    [**] GENERATION [**]: [**] completed and [**] with 4.3.4 specs supplied
         to ABB.

4.3.7    [**] GENERATION [**]: feasibility demonstrated in [**] with the 
         following combined characteristics:
         1.  [**] at [**] and in [**] to plane.
         2.  [**] and operating [**] total current [**] consistent with the
             above [**] specification.
         3.  [**] resistivity [**] rated current

4.3.8    [**] GENERATION [**]: [**] demonstrated with the characteristics of
         4.3.7.

4.3.9    [**] GENERATION [**]: feasibility demonstrated in [**] with the 
         following combined characteristics:
         1.  [**] at [**] and in [**] to plane.



                                      -15-


<PAGE>   16


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED



                ASC Confidential Information under this Agreement

         2.  [**] and operating [**] total current [**] consistent with
             above [**] specification.
         3.  [**] resistivity [**] rated current

4.3.10   [**] GENERATION [**]: [**] available from [**] to [**], with
         characteristics of 4.3.7.

4.3.11   [**] GENERATION [**]: [**] completed and [**] length with 4.3.9 specs
         supplied to supplied to ABB.

4.4      DEVELOPMENT DOCUMENTATION
In the quarterly reports, progress on the Work on the basis of tasks defined in
Attachment A and [**] will be presented and discussed. The following tasks will
also be dealt with.

4.4.1    Conductor Requirement Specifications

4.4.2    Conductor Design Specifications

4.4.3    Test Plan

4.4.4    Test Analysis Report

4.4.5    [**] for [**] conductor and associated costs on reasonable basis
         available at the time of the preparation of the report.



                                      -16-


<PAGE>   17


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED



                ASC Confidential Information under this Agreement

                                  ATTACHMENT A
                    TO ALLIANCE AGREEMENT BETWEEN ASC AND EDF
         ASC STATEMENT OF WORK FOR HTS TRANSFORMER WIRE DEVELOPMENT AND
                                  DEMONSTRATION


Wire [**] will be developed in the context of several designs being considered
for an HTS transformer. The two main types of wires include 1) [**] with [**]
and [**] for use in the [**] of the [**] and 2) an [**] with [**] for use [**]
of the [**]. [**] may also be used [**] the [**]. Critical program wire
performance issues include (i) [**] and [**], (ii) achieving the [**] under
[**], (iii) [**] within [**], (iv) achieving [**] in the [**], and (v) achieving
an architecture with [**] during a [**].

The general HTS wire development process proceeds in three stages: first, a
feasibility stage using [**]; second, a process development stage for [**] wire;
and third, a scaleup for [**]. After feasibility, each [**] stage has an
anticipated duration of approximately [**]. This program proposes to [**] this
development process for a [**] prototype by using [**] throughout the entire
[**], and to enable a [**] which will incorporate [**].

Through the course of the program, several generations of wire with increasingly
advanced specifications (summarized in 4.3) are identified as Generation [**],
with Generation [**] referring to [**] (not taken beyond feasibility),
Generation [**] referring to the [**], and Generation [**] referring to the
[**]. This program covers feasibility and [**] for HRS and AC wire types and for
all different generations of both [**] Generation [**] AC wire (Generation [**]
is not specified) which is excluded. [**] and [**] of [**] is contingent on [**]
and a specific [**] program for [**]. [**] of any of the wires is also [**] of
the program, [**],which is included.

The anticipated commercial price target, averaged over [**], is [**].

The Wire Development Program is divided into four major segments: [**], with the
[**]. Major milestones are listed in Section 4.3 of the Schedule. All fields,
currents, and voltages are [**] (unless otherwise specified). Generation [**]
conductor specifications will be reviewed by [**] in the light of Generation
[**] milestone status and [**] requirements.



                                      -17-


<PAGE>   18


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED



                ASC Confidential Information under this Agreement

HRS  [**] DEVELOPMENT:

HRS [**] will build on the [**], with either a [**] to [**] indicated in the
Schedule, Section 4.3. [**] may need to be considered depending on the design
established in the [**], and [**] for this task needs to be determined.

Task 1. HRS GEN [**] FEASIBILITY. A baseline [**] for a [**] will be developed,
and demonstrated in [**], with Generation [**] as in the Schedule, Section 4.3.7
[**]; and [**].
Both [**] approaches to [**] the [**] will be investigated.

Task 2. HRS [**]. Subject to positive results on [**] of [**] from Task 14, the
feasibility of [**], consistent with [**] established by ABB [**], will be
tested at ASC [**]. Samples will also be provided to ABB for test. [**] beyond
feasibility will be negotiated based on the results of this task.

Task 3. HRS GEN [**] PROCESS. A [**] and [**] and with the other HTS Gen [**]
will be developed in [**], starting in [**] to the [**] of Task 1 and completed
by [**]. Issues of [**] will be addressed.

Task 4. HRS GEN [**] PROCESS. The [**] of Task 1 will be developed for [**] and
combined with the [**] of Task 3, to demonstrate by [**] with the Generation
[**].

Task 5. HRS GEN [**] SCALE-UP. A [**] of Generation [**] will be established,
culminating with the delivery of a [**] to ABB by [**]. Additional delivery of
this [**] for the first [**] prototype will then continue after [**] of this
program.

Task 6. HRS GEN [**] FEASIBILITY. Generation [**] will be developed in [**],
meeting Section 4.3.9 specs of the Schedule [**], and [**], for a feasibility
milestone by [**].

Task 7. HRS GEN [**] PROCESS. The Generation [**] will be developed [**],
addressing [**] issues. The [**] will be delivered to ABB by [**]. Delivery of
this [**] in production quantities will require [**] and will continue after
[**] of this program for [**].

[**]DEVELOPMENT:
[**] requires [**].



                                      -18-


<PAGE>   19


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED



                ASC Confidential Information under this Agreement

Task 8. [**]GEN [**] FEASIBILITY. [**] with Generation [**] specs of Section
4.3.1 of the Schedule [**] and [**] will be developed via a [**] approach.
Feasibility will be demonstrated in [**] by [**].

Task 9. [**] GEN [**] FEASIBILITY. [**] with Generation [**] specs of Section
4.3.2 of the Schedule [**], and [**] will be developed via [**] in the [**] and
achieving [**]. Feasibility will be demonstrated in [**] by [**].

Task 10. [**] GEN [**] PROCESS. [**] development of the Generation [**] of Task
9 will begin on [**] and provide a [**] for delivery to ABB by [**]. Scale-up
for pilot production will occur after [**]. This task is [**] on [**] such as
that from the [**], and on a targeted prototype which requires [**].

Task 11. [**] GEN [**] FEASIBILITY. [**] with Generation [**] of Section 4.3.4
of the Schedule [**] will be developed via [**] in the [**] and achieving [**]
in Task 13. Feasibility will be demonstrated in [**] by [**].

Task 12. [**] GEN [**] PROCESS. [**] development of the Generation [**] of Task
8 will begin on [**] and provide [**] to ABB by [**]. Scale-up for commercial
production will occur after [**] of this program.

[**]:
Task 13: [**] DEVELOPMENT: This task will target [**] of HRS and/or [**] as
needed to meet the total current requirements of the Gen [**] specs. In
particular, [**] is expected to be required for reaching the [**] by [**] for
Gen [**] and by [**] for Gen [**].

CHARACTERIZATION AND TEST:
These studies will be done in close collaboration with ABB and EDF.

Task 14. [**] FEASIBILITY TESTING. An early task will focus on demonstrating
[**] for [**] in HRS [**]. This will start with [**] in applied field.
Experiments comparing [**] will be conducted in collaboration with ABB. A first
milestone for these experiments is targeted for [**]. [**] or the [**] will be
agreed upon with ABB. If adequately [**] are obtained in these first round
tests, such studies will be extended to HRS [**] and [**], with a milestone for
establishing [**] by [**]. Specs for, and basic approach to, HRS [**]
development will be reviewed upon the completion of this milestone.



                                      -19-


<PAGE>   20


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED



     ASC Confidential Information under this Agreement

Task 15. [**] TESTING. [**] techniques for [**]will be established for [**], and
routine [**] will be established to monitor ongoing [**].

Task 16. [**] TESTING. [**] will be constructed and measured for [**] to [**]
for all generations of [**] as soon as [**] become available. These tests will
confirm [**] in the [**]. Also tests of [**] in [**] will be conducted.

Task 17. [**] TESTING. [**] tests, [**], of HRS and [**] and [**] will be
conducted as different generations become available. Specs will be established
based on [**] design and manufacturing requirements, including [**] and [**].

Task 18. PROGRAM MANAGEMENT. The technical program will be managed via an ASC
program manager in accordance with this agreement.



                                      -20-


<PAGE>   21


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED



                                  ATTACHMENT B

                          SCHEDULE OF DEVELOPMENT COSTS


EDF payments to ASC are made as defined in Article 3. Follow expected dates for
invoices to be sent by ASC to EDF and related payments:

                               $
                               $
                               $

                               $
                               $
                               $
                               $

                               $
                               $
                               $
                               $

                               $
                               $
                               $
                               $





                                      -21-


<PAGE>   22


                           ATTACHMENT C: FORCE MAJEURE
                        CHAMBRE DE COMMERCE INTERNATIONAL

1.   Either of the contracting Parties shall not be held responsible for the non
     accomplishment of any of its contractual obligations if it can be proved
     that: - this non-accomplishment is the result of impending circumstances
     beyond the control of the Parties hereto; - the contracting Party could not
     reasonably have been expected to foresee such impending circumstances and
     the effects thereof on its ability to perform its obligations under this
     contract at the time it was entered into; and - the contracting Party could
     not reasonably have averted or overcome such impending circumstances or at
     least the effects thereof.

2.   Impeding circumstances as used in the above paragraph shall mean any
     circumstances arising out of any of the events listed below, which include
     but are not limited to:
     (a) war, declared or undeclared, civil war, riots and revolution, acts of
     piracy, sabotage;
     (b)natural disasters such as violent storms, cyclones, earthquakes, tidal
     waves, floods, destructions by lightning;
     (c) explosions, fires, destructions of machines, factories and facilities
     of whatever nature;
     (d) boycotts, strikes and lock-outs of whatever form, work-to-rule,
     occupations of factories and premises, stoppages taking place in the
     companies of the contracting Party requesting the exemption of its
     liability thereof;
     (e) actions taken by authorities, whether legal or illegal, with the
     exception of the actions the risk of which is assumed by the Party in
     question in accordance with other clauses of this contract, and which fall
     outside the scope of the provisions of paragraph 3 here under.

3.   For the purposes of the above paragraph, and unless otherwise stipulated
     herein, impeding circumstances shall not include failure to obtain
     authorizations, licenses, entry visas or residence authorizations, or
     authorizations required for the performance of the contract and which have
     to be issued by any public authority whatsoever of the country of the Party
     requesting exemption of its liability.

4.   The Party requesting the exemption of its liability shall give prompt
     notice to the other Party of the circumstances involved and their effects
     on its ability to fulfill its contractual obligations as soon as it is
     aware of such circumstances and their effects on its ability to perform its
     obligations. Notice shall also be given to the other Party of the coming to
     an end of the reason for this liability exemption.

5.   The reason for liability exemption shall take effect from the time the
     impeding circumstances arise or, if notice thereof is not given promptly,
     from the time such



                                      -22-


<PAGE>   23


     notice is given. The failure to give such notice shall render the
     defaulting Party liable to the payment of damages which would otherwise
     have been able to be avoided.

6.   A reason for liability exemption under the present clause shall exempt the
     defaulting Party from the payment of damages, penalties and other
     contractual sanctions, with the exception of the payment of interests on
     sums owing, for as long as and insofar as this reason continues.

7.   Such a liability exemption reason also suspends the agreement performance
     deadline for a reasonable period, thereby excluding any rights the other
     Party may have to terminate or cancel the agreement. To determine what is
     to be considered a reasonable period, account shall be taken of the ability
     of the defaulting Party to resume agreement performance and the degree to
     which the other Party would benefit from such performance in spite of the
     delays. Pending the defaulting Party resuming performance of its
     obligations, the other Party shall suspend the performance of its own
     obligations.

8.   If such reasons extend beyond the period agreed by the Parties (the
     applicable period shall be specified herein by the Parties) or, failing
     such arrangements, beyond a reasonable period, either Party shall be
     entitled to rescind the agreement giving due notification thereof.

9.   Either Party may keep what it has obtained through the performance of the
     agreement prior to its termination. Each Party is accountable to the other
     with regard to any gain without cause arising out of this performance. The
     final balance shall be paid without delay.")



                                      -23-



<PAGE>   1

                                                                 EXHIBIT 10.29

                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED









                                    AGREEMENT
                                     BETWEEN
                       AMERICAN SUPERCONDUCTOR CORPORATION
                                       AND
                 ABB TRANSMISSION & DISTRIBUTION TECHNOLOGY LTD.









<PAGE>   2


                                    AGREEMENT

     This Agreement is entered into and shall be effective as of April 1, 1997
("Effective Date") by and between ABB Transmission & Distribution Technology
Ltd., a corporation of Switzerland, with its principal office at
Affolternstrasse 52, CH-8050 Zurich, Switzerland (hereinafter referred to as
"ABB") and represented in the U.S.A. by ABB Power T&D Company Inc., its agent
and American Superconductor Corporation, a Delaware Corporation with offices at
Two Technology Drive, Westborough, MA 01581, (hereinafter, together with its
Affiliates, "ASC").

                                   DEFINITIONS

     In this Agreement the terms listed below have the following meanings:

     D.1 ASC BACKGROUND TECHNOLOGY. All AC and HRS HTS wire discoveries,
inventions, data, computer programs and documentation conceived or first reduced
to practice by ASC prior to the effective date of this Agreement or outside the
course of the Work and incorporated into the Deliverables or AC and HRS HTS
wire.

     D.2 ASC INTELLECTUAL PROPERTY RIGHTS. All intellectual property rights in
the Technology, including without limitation all current and future worldwide
patents and other patent rights, utility models, copyrights, mask work rights,
trade secrets, and all applications and registrations with respect thereto.

     D.3 ASC BACKGROUND INTELLECTUAL PROPERTY RIGHTS. All intellectual property
rights in ASC Background Technology, including with out limitation all current
and future worldwide patents and other patent rights, utility models,
copyrights, mask work rights, trade secrets and all applications and
registrations with respect thereto.

     D.4 DATA. Books, records, reports, articles, research notes, charts,
graphs, comments, computations, analyses, blueprints, specifications, drawings,
recordings, photographs, samples of materials, and other graphic or written data
generated in connection with the Work.

     D.5 THIRD PARTY INFORMATION. Copyrighted works or proprietary or
confidential information of a third party.

     D.6 ASC PRIOR INVENTION. Any invention or know-how made or developed by ASC
and/or licensed to ASC prior to the date of this Agreement or outside the course
of the Work.

     D.7 ASC CONFIDENTIAL INFORMATION. Information concerning ASC business and
technology and related information which is confidential or proprietary to ASC.


         

<PAGE>   3


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED


     D.8 ABB CONFIDENTIAL INFORMATION. Information concerning ABB's or ABB
Affiliates' business and technology and related information which is
confidential or proprietary to ABB or ABB Affiliates.

     D.9  i) ABB PATENTS. ABB's patents, and the associated knowledge necessary
to apply the patents, developed prior to and during the course of the Work,
relating to the design and manufacture of AC and HRS HTS wires for application
in Transformers.

          ii) ABB AFFILIATES' PATENTS. ABB Affiliates' patents, and the
associated knowledge necessary to apply the patents, developed prior to and
during the course of the Work, relating to the design and manufacture of AC and
HRS HTS wires for application in Transformers.

     D.10 TRANSFORMER. An electromagnetic device comprising a magnetic circuit
and both input and output windings and with primary winding voltages of [**]
class or greater, a [**] and power ratings of [**] and both with and without a
[**] included in the [**]. This shall include alternating current ("AC") [**]
for [**] and [**] system transformers and [**] with primary voltages of [**] and
above and power ratings of [**] and above and all for transmission and
distribution of electric power. This shall not include other power devices such
as [**].

     D.11 AFFILIATES. With respect to either ABB or ASC shall mean any entity in
which ABB or ASC or their parent company(ies) (one or more parent companies in
an upward series) shall at the time in question directly or indirectly own fifty
percent (50%) or more of the shares or other interest carrying fifty percent
(50%) or more of the voting power to elect directors or other managers of the
said entity.

     D.12 AC WIRE. HTS Wire which can maintain low alternating current ("AC")
losses in a [**].

     D.13 HRS WIRE. HTS Wire with high longitudinal resistivity sheathing in the
[**].

     D.14 WORK. The technical work done under this Agreement and as further set
forth in Article 1, Subarticle 1.1.

     D.15 TECHNOLOGY. All discoveries, inventions, data, computer programs and
documentation conceived or first reduced to practice by ASC in the course of the
Work.


                                       -2-


<PAGE>   4


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

     D.16 CURRENT LIMITER. A stand-alone device or component for limiting fault
currents in electric power transmission and distribution systems using high
temperature superconductor wires. This can be[**] but is not part of the
transformer winding. Transmission Current Limiters are designed for preventing
fault overload in power transmission systems operating at voltages [**], and
distribution Current Limiters are designed for preventing fault overload in
systems which operate at voltages [**].

     D.17 HTS. High temperature superconductors for use at [**].

     D.18 ASC FISCAL YEAR. The ASC Fiscal year goes from April 1 of the previous
year to March 31 of the following year. E.g. April 1, 1997-March 31, 1998 is the
1998 Fiscal year.

     D.19 LINE TRANSMISSION AND DISTRIBUTION FIELD. The field of line
transmission and distribution of (i) electrical power from at least one point to
another and (ii) electrical control signals, where "Line Transmission and
Distribution" means transmission and distribution by cable, wire or the like
physical link in the form of an elongated conductor which is used to transport
electrons, provided however that this field does not include [**] when used for
the generation of magnetic fields. Certain cables for the transmission of [**]
are included in the Line Transmission and Distribution Field.

     NOW, THEREFORE, in consideration of the premises and of the mutual
covenants and agreements hereinafter set forth, the parties intending to be
legally bound, agree as follows:

                                   BACKGROUND

     B.1 ABB is organized to manufacture, sell and conduct and, as it deems
appropriate to engage others to conduct research and development with respect to
the transmission, distribution, and utilization of electric energy.

     B.2 ASC has in the past and is presently equipped and qualified to perform
research, manufacturing and development in the area of high temperature
superconductors ("HTS"). ASC also has expertise in HTS wire current leads, coil
design, coil manufacturing and cryointegration and can be a potential supplier
of these technologies and products. ASC also desires to be in the business of
development, manufacturing and the offering for sale of Current Limiters.


                                       -3-


<PAGE>   5


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED


     B.3 ABB and ASC, from time-to-time have been working together since April
1, 1996, and it is understood by both parties that the cost for HTS wire
development will be more than [**], and that there are significant technical and
business risks related to this development. Therefore, to offset some of ASC's
development cost for AC and HRS wire, ABB desires to contribute to the cost of
additional research and development by ASC as described herein, and to have the
results thereof made available to ABB under this agreement.

     B.4 ABB's primary purpose in entering into this Agreement is for ASC to
develop and make available to ABB certain information and deliverables, and to
establish various pricing discount rights with respect thereto, for the benefit
of ABB.

     B.5 Outside of this Agreement, ABB will be responsible for design,
development, manufacturing and marketing of Transformers and any other devices
(except for [**]) in which ABB may wish to develop using the AC and HRS HTS wire
developed under this Agreement, including the necessary research and development
of the [**] as appropriate.

     B.6 Under this Agreement ASC will be responsible for the development,
manufacturing and delivery to ABB of the AC and HRS HTS wire that will meet
certain performance targets as provided for under the Schedule to this
Agreement. ASC will also collaborate closely with ABB in the test of wire and
subset model coils and other relevant physical measurements to ensure that the
wire meet ABB specifications.

     B.7 ASC and Electricite de France ("EDF") are establishing a separate
agreement ("ASC/EDF Separate Agreement") whereby EDF will provide certain
development funding directly to ASC for the development of the AC and HRS HTS
wires. Under the ASC/EDF Separate Agreement ASC may share certain information
with EDF resulting from the Work undertaken as a part of this Agreement. All
such shared information will be governed by the provisions of Article 9,
Subarticle 9.2.

     B.8 It is understood that ASC has the right to sell AC and HRS HTS wires
developed under this Agreement to third parties, and ABB has the right to
purchase any HTS wires from third parties.

     B.9 ASC and Pirelli Cavi S.p.A. ("Pirelli") entered into a separate
agreement dated October 1, 1995 granting Pirelli: certain exclusive licenses in
the Line Transmission and Distribution Field; a right of first negotiation
concerning research directed to the development, manufacture, installation or
operation of products which are designed to


                                       -4-


<PAGE>   6


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED


be used for transmission of voice, data, or video signals; a one-time only right
to enter into an agreement based on an ASC proposal for research and development
and commercial exploitation of Transmission Current Limiters; and a right of
first refusal for any third party agreement for the research and development and
commercial exploitation of Transmission Current Limiters.

                              OBJECTS OF AGREEMENT

     O.1 The overall objective of this Agreement is to develop AC and HRS HTS
wires for application in Transformers at [**]. ABB anticipates that the
development of these wires in the timeframe defined in this Agreement and with
the performance characteristics indicated herein, will permit prototype
Transformers in the range of [**] to be available for field installation and
evaluation in the years [**] with Transformers in the range of [**] available
commercially in the [**] timeframe.

     O.2 The parties recognize their mutual interdependence under this
Agreement, and that it is in the best interest of both Parties to work together
to achieve its overall objective. It is expected that the successful completion
of this Agreement will result in further joint efforts to enhance and extend the
technology developed under this Agreement. ASC and ABB acknowledge that they are
independent parties and that no partnership, joint venture or other joint
arrangement has been expressly or impliedly agreed to under this agreement and
that nothing in this agreement shall make either party the agent or legal
representative of the other for any purpose whatsoever, nor does it grant either
party any authority to assume or to create any obligations on behalf of or in
the name of the other, except as expressly set forth herein.

                                    ARTICLE 1

     PERFORMANCE OF THE WORK

     1.1 WORK. ASC shall use its best efforts, within commercially reasonable
limits, to perform the work (the "Work") and deliver the deliverables (the
"Deliverables") set forth in the Statement of Work in the schedule attached
hereto and made a part hereof (the "Schedule") within the "Budget" as defined in
Subarticle 2.3 below. The Work shall be performed by ASC under the general
direction of the project review board (The "PRB") as defined in the Schedule -
Attachment C.

     1.2 PERIOD OF PERFORMANCE. ASC shall use its best efforts, within
commercially reasonable limits, to complete the Work, including submission of
technical reports within


                                       -5-


<PAGE>   7



the time period(s) set forth in the Schedule (the "Period of Performance") and
within the Budget.

     1.3 PROJECT MANAGERS. A project manager will be designated by ABB (the "ABB
Project Manager") and by ASC (the "ASC Project Manage") as defined in the
Schedule. ABB and ASC, at any time, may designate a new project manager by
written notice to the other party. The ASC Project Manager will maintain contact
with the ABB Project Manager during the Period of Performance. ASC will provide
briefings on the progress of the Work, in addition to the reports required by
this Agreement, as reasonably requested by the ABB Project Manager. Reports,
communications, and questions of a technical nature shall be transmitted to the
ABB Project Manager at the address set forth in Article 16. Matters of a
contractual nature, including but not limited to Agreement terms, annual
funding, the Period of Performance and issues affecting the Budget (as defined
in Subarticle 2.3 below), shall be sent to the ABB Project Manager in accordance
with Article 16 of this Agreement with an information copy to the ABB Business
Development Manager.

     1.4 FORCE MAJEURE. ASC shall not be liable for failure to perform or delay
in performance resulting solely from one or more of the following conditions:
from acts of God, acts of civil or military authority, acts (including delays or
failures to act) of any governmental authority, insurrection or riot, fire,
strike, work stoppage or other labor difficulties, failure or delay beyond ASC's
reasonable control in obtaining necessary materials from usual sources, or any
cause beyond ASC's reasonable control.

     1.5 COST OF EXCUSABLE DELAYS. The entire cost of any measures taken at the
request of ABB to overcome such excusable delay or delays will be for ABB's
account above the Budget defined in the Schedule.

                                    ARTICLE 2

     COSTS

     2.1 COST REIMBURSEMENT. ABB shall reimburse ASC for all costs incurred in
the performance of the Work, subject to the limitations contained below in this
Article 2, and Article 3 of this Agreement.

     2.2 BEST EFFORTS. ASC agrees to use its best efforts, within commercially
reasonable limits, to perform the Work within the "Budget" as set forth in
Article 2, Subarticle 2.3.

     2.3 BUDGET. The total project budget (The Budget) is set forth in the
Schedule. ABB's commitment of funds for each contract year is set forth in the
Schedule. ABB shall not be obligated for costs in excess of that set forth in
The Budget. A Joint Steering Committee as set forth below in this Subarticle
2.3, shall have the authority to revise the


                                       -6-


<PAGE>   8


Budget based on recommendations of the Project Review Board (PRB). The
composition and duties of the PRB are set forth in Attachment C to this
Agreement. A Joint Steering Committee will be established to coordinate joint
business opportunities and to give directions to the PRB, and to review progress
and approve recommendation by the PRB with respect to milestones and budgets.
This Committee will meet annually or more frequently as needed. The Joint
Steering Committee shall be composed of two representatives for each party.

     2.4 ACCOUNTING PROCEDURES. ASC's costs shall be determined on the basis of
ASC's accounting system, procedures and practices employed as of the effective
date and during the performance of this Agreement; provided that ASC shall use
generally accepted accounting principles and cost reimbursement practices.

     2.5 ALLOWABLE COSTS. The costs for which ASC shall be reimbursed under this
Agreement include all costs, direct, indirect and overhead incurred in the
performance of the Work. Costs must be incurred within the Period of
Performance, except for an amount equivalent to that paid by ABB to ASC prior to
the Period of Performance specified in the Schedule. Factors to be considered in
determining whether an individual item of cost is allowable includes (i)
reasonableness of the item, (ii) allocability of the item to the Work, (iii)
ASC's use of generally accepted accounting principles, and (iv) the other terms
and conditions of this Agreement. ABB and ASC will finalize the direct, indirect
and overhead rates as promptly as practicable in accordance with procedures
followed by ASC and acceptable to the ABB Corporate Audit Manager. ABB agrees
that the indirect and overhead rates will be consistent with the established
practices and procedures utilized by ASC for its cost reimbursement contracts
with other corporate partners.

     2.6 AUDIT RIGHTS. ASC shall maintain books, records, documents, and other
evidence based on the procedures set forth above, sufficient to reflect properly
all costs incurred in performing this Agreement. The audit of corporate
allocations will be limited to the supporting documentation at the division(s)
performing the Work. A certified public accounting firm designated by ABB, from
a list of such firms as proposed by ASC, may audit such accounting records at
all reasonable times with prior notice by ABB. ABB shall bear the expense of
such audits. It is the intent of the parties that such audits shall ordinarily
be performed not more frequently than once every twelve (12) months during the
performance of the Work. The certified public accounting firm conducting the
audit will certify the accuracy of ASC's costs, calculations and appropriateness
of the allocation methodology. Such accounting firm will be required to execute
an appropriate confidentiality agreement.

                                    ARTICLE 3

     PAYMENTS


                                       -7-


<PAGE>   9


     3.1 INVOICING. Invoices shall be submitted in advance on a quarterly basis
in triplicate as set forth in the Schedule. The period of time covered,
including the beginning and ending dates, must be specified on each invoice. The
invoice will reflect the payments to be made by ABB as reflected in the
Schedule. Actual cost and planned expenditures will be reviewed at the PRB
meetings.

     3.2 PAYMENTS. Subject to the provisions of Article 2, ABB shall pay ASC the
total amount of each invoice received and approved by ABB. Requests for payment
with accompanying invoices shall refer to the ABB research project number and
shall be submitted by ASC to the attention of the ABB Accounts Payable. ABB's
payments shall be directed to AS C's address shown on the invoice unless the
parties agree otherwise. If ABB has not paid an invoice within ninety (90) days
of receipt by ABB, or ABB has not notified ASC of the problem(s) associated with
such invoice, a finance charge of one percent (1.0%) per month, or part thereof,
shall accrue and be paid by ABB.

                                    ARTICLE 4

     REPORTS

     4.1 TECHNICAL PROGRESS REPORTS. ASC shall submit technical progress reports
to the ABB Project Manager at such regular intervals as are set forth in the
Schedule. Such reports shall be in sufficient detail to disclose Work
accomplished and results achieved during the reporting period. In addition, such
reports shall include a summary in non-technical language which briefly
describes the Work and sets forth the important results and contents of the
report. Insofar as it has a right to do so, and disclosing information deemed to
be confidential information, in accordance with Article 9.2, ASC shall endeavor
to keep ABB generally informed in such reports as to the development of work
performed by ASC for its own account or in connection with research contracts in
effect with others, when such work is pertinent to the Work hereunder.

     4.2 REPORT DISTRIBUTION. All technical reports of any nature developed and
furnished under this Agreement are intended solely for the purpose of
communicating and transferring information relating to research and are subject
to Article 9 of this Agreement. Technical progress and preliminary reports
furnished by ASC to ABB hereunder and any report resulting from this Agreement
may be distributed to ABB's Affiliates subject to Article 9 of this agreement.

     4.3 ADMINISTRATIVE/FINANCIAL REPORTS. ASC shall provide administrative and
financial reports as set forth in the Schedule.

                                    ARTICLE 5

     DATA



                                       -8-


<PAGE>   10


     ASC agrees to maintain the Data in sufficient detail to properly reflect
all Work done and results achieved in the performance thereof. Ownership of all
Data produced, generated or procured under this Agreement, including under any
subcontracts, shall be as provided in Subarticle 7.1.

                                    ARTICLE 6

     COMPUTER PROGRAMS

     6.1 OWNERSHIP. Title and ownership of computer programs copyrights and
patents therein, shall be as provided in Subarticle 7.1.

     6.2 SECURITY. If ASC uses computer software of any kind (designed for
workstations or personal computers) in the performance of the Work, including
but not limited to development thereof, ASC shall systematically check all such
computer software against computer virus contamination. ASC shall check all such
computer software before transmittal of any computer software outside of the
development environment and in a manner acknowledged by ABB to be accepted
industry practice.

                                    ARTICLE 7

     INTELLECTUAL PROPERTY RIGHTS

     7.1 OWNERSHIP.

     (i) Subject to the provisions of Subarticles 7.1(ii), (iii), 7.3 and 7.4
below, relating to ABB Patents, third party rights or ASC's abandonment of the
development technology, ASC shall own exclusively all right, title, and interest
in and to Technology, and ASC Intellectual Property Rights therein.

     (ii) ABB agrees to grant and hereby grants to ASC a nonexclusive, worldwide
license, to incorporate ABB Patents in AC and HRS HTS wires (a) royalty free to
ASC for AC and HRS HTS wires sold to ABB or ABB Affiliates, and (b) royalty
bearing for sales or use by other than ABB or ABB Affiliates on terms to be
mutually agreed upon in the future.

     (iii) ABB endeavors to obtain for ASC a nonexclusive, world-wide license to
incorporate ABB Affiliates' Patents in AC and HRS HTS wires, (a) royalty free to
ASC for AC and HRS HTS wires sold solely to ABB or ABB Affiliates, and (b)
royalty bearing for sales or use by other than ABB or ABB Affiliates on terms to
be agreed upon with the ABB Affiliates.


                                       -9-


<PAGE>   11


     (iv) In the event of a joint invention, such joint invention shall be
jointly owned by ABB and ASC. In the event of a joint invention among ABB, ASC
and a third party, such joint invention shall be jointly owned by ABB, ASC and
such third party.

     The parties shall mutually determine under the auspices of the PRB and, if
a third party inventor is included, in coordination with the third party,
whether or not application(s) for patents shall be filed, the party which will
prepare, file and manage such application and the country or countries in which
the same are to be filed. Unless otherwise agreed, all expenses incurred for
filing and prosecution of such joint invention applications shall be divided
equally between the parties.

     Each joint owner shall possess an equal and undivided interest in any joint
invention, with the unrestricted right to make, have made, use, sell, license
and sublicense the invention without accounting to the other joint owners. Items
which may be joint inventions will be reviewed at each PRB meeting.

     (v) ASC hereby grants to ABB and ABB Affiliates an irrevocable, exclusive,
perpetual, worldwide, royalty-free license in the field of Transformers, under
all ASC Intellectual Property Rights relating to Transformers except those
relating to AC and HRS HTS Wire to make, have made, use and sell Transformers
incorporating this portion of the Technology. ASC agrees to grant and hereby
grants to ABB and ABB Affiliates a non-exclusive, worldwide license in the field
of Transformers under all ASC Background Intellectual Property Rights relating
to Transformers except those relating to AC and HRS HTS Wire to make, have made,
use and sell Transformers incorporating these portions of the ASC Background
Intellectual Property Rights (a) royalty-free for Transformers made from AC and
HRS HTS Wire purchased from ASC, and (b) royalty-bearing for Transformers made
from third party wire on terms to be mutually agreed upon in the future.

     7.2 NO CLAIM. The Parties agree that they will not assert or establish or
assist any third party with respect to any claim for intellectual property
rights inconsistent with those granted to ABB or ASC herein.

     7.3 INCORPORATION OF ASC PRIOR INVENTION. If ASC incorporates into
Deliverables or AC or HRS HTS Wire any ASC Prior Invention, such ASC Prior
Inventions shall become part of the ASC Background Intellectual Property Rights
licensed by ASC to ABB in Section 7.4 ii) below, to the extent that ASC has the
right to do so and shall otherwise become subject to the provisions of 7.4 iii).

     7.4 LICENSING. ASC agrees to grant and does hereby grant to ABB to the
extent that ASC may grant such licenses and undertake such obligations without
breach of law, i) an irrevocable, exclusive, perpetual, worldwide, royalty free
license, with rights to sublicense, under ASC Intellectual Property Rights to
make, have made, use and sell products incorporating Technology in the field of
Transformers and, to make, have


                                      -10-


<PAGE>   12


made, use and sell AC and HRS HTS Wire incorporating Technology (except for
products in the Line Transmission and Distribution Field) and, ii) an
irrevocable non-exclusive, perpetual, worldwide, royalty free license, with
rights to sublicense, under ASC Background Intellectual Property Rights, to
make, have made, use and sell products in the field of Transformers, and, to
make, have made, use and sell AC and HRS HTS Wire incorporating Technology
(except for products in the Line Transmission and Distribution Field) and iii)
if ASC knowingly after a reasonable investigation incorporates into the
Technology Third Party Information, ASC agrees to use reasonable efforts at an
appropriate time and at a reasonable cost for the value obtained, to obtain a
non-exclusive license for ABB to use such Third Party Information; provided,
however, that the foregoing grants and obligations shall only apply in the event
that ASC abandons AC and/or HRS HTS wire technology or the Technology as
evidenced by, i) an inability to fill orders based on mutually agreed
specifications and delivery dates at the time of a firm purchase order from ABB
for a period of eighteen months, during the duration of this Agreement or for
commercial orders for 10 years thereafter, provided, ABB has supported the
development effort at ASC through commercialization as set forth in this
Agreement, and as long as ASC has provided them, ABB has purchased ninety
percent (90%) of its requirements of AC and HRS HTS wires for Current Limiters
and Transformers from ASC for commercialization; or, ii) ASC's notification to
ABB in writing that they will no longer supply AC and HRS HTS wires; or iii)
termination of this Agreement under the provisions of Article 15, Subarticles
15.3 or 15.4. or, (iv) ASC rejects this Agreement pursuant to section 365 of the
United States Bankruptcy Code. In the event the licence in this paragraph is
exercised, the Technology will be supplied to ABB to the extent necessary
through training and in documentary form in sufficient detail to be
self-explanatory, consistent with provisions of subarticle 18.7 and so as to
enable one skilled in the art, to make, use and sell AC and HRS HTS Wire
incorporating the Technology and ASC Prior Invention, and this may include
multiple week visits by ABB or its authorized representative to the ASC
facilities where the Work is done to observe the Work in sufficient detail to
make use of the Technology.

     7.5 LICENSING TO EDF AFTER ASC ABANDONMENT OF TECHNOLOGY. In the event that
ASC abandons AC and/or HRS HTS wire technology or the Technology under the
conditions set forth in Section 7.4 above, and ABB exercises its rights under
Section 7.4 above, ABB, contingent upon EDF continuing the funding of ABB or
whomever ABB selects to continue with the completion of the Work, or has fully
funded the Work as set forth under the ASC/EDF Separate Agreement, agrees to
grant and does hereby grant to EDF the same rights provided to EDF as set forth
in the ASC/EDF Separate Agreement, Article 4: Pay-back, section 4.3 Royalties
and section 4.4 Commercial Discounts; Such Article and Sections are set forth in
Attachment D.

     7.6 ABB agrees that no AC or HRS HTS wires developed under this Agreement,
no HTS wires sold to it or its Affiliates by ASC, and no AC or HRS HTS wires
manufactured by it or for it or its Affiliates under any license granted by ASC
or using any Technology developed hereunder will be used for products in the
[**].



                                      -11-


<PAGE>   13


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED



                                    ARTICLE 8

     INTENTIONS AND EXPECTATIONS OF THE PARTIES

     8.1 BUSINESS PLAN FOR HTS BASED POWER TRANSFORMERS

     a) Outside of this Agreement ABB has successfully demonstrated a 630 kVA,
HTS transformer based on DC HTS wires supplied by ASC, in the first quarter of
1997.

     b) ABB and/or it's Affiliate(s) plan to have in place an agreement with a
third party (or parties) to provide funding support to ABB for the HTS
transformer prototype development and construction.

     c) ABB and/or its Affiliate(s) plan to deliver [**] HTS transformer
prototypes for markets in Europe and the United States in [**].

     8.2 BUSINESS PLAN FOR HTS WIRE PRODUCTION.

     By [**], ABB and ASC will develop a business plan that will project the
potential for HTS wires, the timing of beta test sites, the timelines for
commercialization etc. Two years before the expected commencement of either
commercial sales or sale of prototypes, the parties will develop a procedure to
be followed for forecasting and meeting the future needs of ABB and facility
requirements of ASC on an ongoing basis. Once ABB and ASC have agreed to the
forecast and delivery requirements, ABB will be given "preferred availability"
rights and ASC will first meet the ABB requirements for the AC and HRS HTS wire
before other customers for AC and HRS HTS wire. This preferred availability
right will be for the same period as the price discount in section 8.3 a). As
part of this business plan the parties will mutually agree on the definition of
commercial sale.

     8.3 COMMERCIAL DISCOUNTS

     a) ASC will provide to ABB and ABB Affiliates, an irrevocable right to at
least a [**] price discount from the lowest commercial price available from ASC
for similar quantities for all commercial products purchased from ASC which
embody the Technology. However, since ASC has agreed to discount certain
transactions concerning the [**] in consideration of EDF's development funding
for the HRS and AC HTS conductor Work, ASC shall have the right to assign a [**]
to the EDF development


                                      -12-


<PAGE>   14


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

funding as a portion of [**] of these transactions only. Thus, ABB agrees that
no [**] under this section 8.4 shall be applied to the [**] price. The ABB price
discount will apply until such time as ABB [**] to ASC under this Agreement or
[**] from the [**] of HTS commercial conductors [**], whichever is the earliest.

     b) In further recognition of ABB's contribution to the development of AC
and HRS HTS wires, ASC agrees that at no time will any royalties payable or paid
by ASC to EDF on AC or HRS HTS wires under the ASC/EDF Agreement be considered
in determining the price of such wires offered for sale or sold to ABB or ABB
Affiliates.

     8.4 DISCOUNTS ON DEMONSTRATION AND PROTOTYPE WIRE

     a) ASC understands that it is ABB's goal that, in the period of the
Agreement the total cost to ABB of the HTS conductor purchased for any
demonstration Transformer system shall not exceed [**] of the total cost of the
demonstration Transformer system to ABB. The conductors produced during this
period will be demonstration and prototype conductors, not commercial
conductors. During this period ASC agrees that if the applicable discount
offered to ABB under Article 8.4 b) or 8.4 c) results in a total HTS conductor
cost for any demonstration Transformer system which exceeds ABB's [**] goal, ASC
will increase its discount by up to an additional [**] to meet ABB's [**] goal.
In the event that the total cost to ABB of the HTS conductor is still greater
than [**] of the total cost of the demonstration Transformer system to ABB, both
ASC and ABB will share the remaining cost difference equally between them. ASC's
fully loaded HTS conductor cost and the total cost of ABB's demonstration
Transformer system will be based on GAAP accounting.

     b) In the period of the Agreement ASC will offer to ABB wires based on the
Technology for the first prototype transformer, "EDF Transformer", and any
associated experimental coils at a [**] discount to the ASC fully loaded cost
per unit for use in the field of Transformers. The fully loaded cost will be
based on GAAP accounting.

     c) In the period of the Agreement ASC will offer to ABB wires based on the
Technology for the second prototype transformer, "SCE transformer", and any
associated experimental coils a [**] discount to the ASC fully loaded cost per
unit or, if in effect at that time, the established market price for such wires
for the use in the fields of Transformers.

                                    ARTICLE 9



                                      -13-


<PAGE>   15


         CONFIDENTIALITY AND RESTRICTIONS ON DISCLOSURE AND USE

     9.1 ABB INFORMATION.

     a) ASC acknowledges that during the term of this Agreement it may be
exposed to certain information concerning ABB's business and technology and
related information which is confidential or proprietary to ABB. All ABB
CONFIDENTIAL INFORMATION shall be marked by ABB as "ABB CONFIDENTIAL". ASC shall
protect and maintain such ABB CONFIDENTIAL INFORMATION in the same manner and to
the same degree it protects its own confidential information, but in no event
with less than reasonable care.

     b) ASC agrees that during the term of this Agreement and for a period of
ten (10) years, thereafter unless both parties agree to extend the period beyond
ten (10) years, it will not use any ABB CONFIDENTIAL INFORMATION except in
accordance with the provisions and for the purposes of this Agreement, and will
not disclose any ABB CONFIDENTIAL INFORMATION to any third party without the
prior written consent of ABB.

     9.2 ASC INFORMATION. The parties contemplate that in the performance of the
Work ASC may furnish information to ABB that is confidential or proprietary to
ASC. ASC shall clearly mark it as "ASC CONFIDENTIAL INFORMATION". ABB shall
protect and maintain such ASC CONFIDENTIAL INFORMATION in the same manner and to
the same degree it protects its own confidential information, but in no event
with less than reasonable care. ABB agrees that during the term of this
Agreement and for a period of ten (10) years, thereafter unless both parties
agree to extend the period beyond ten (10) years, ABB or ABB Affiliates with a
need to know only will not use any ASC CONFIDENTIAL INFORMATION except in
accordance with the provisions and for the purpose of this Agreement, and will
not disclose any such ASC CONFIDENTIAL INFORMATION to any third party (except to
ABB Affiliates who require access to such information and who agree to be bound
by Article 9) without the prior written consent of ASC. The Technology, when
marked confidential will be treated as such by the parties, except that
information strictly related to AC and HRS wire may be disclosed by ASC to EDF
in accordance with their Separate Agreement; provided, however, that ABB
CONFIDENTIAL INFORMATION shall not be disclosed to EDF without the prior written
consent of ABB.

     9.3 EXCEPTIONS. The provisions of this Article 9 shall not apply to either
party's CONFIDENTIAL INFORMATION to the extent that:

     a) such information was generally known or otherwise in the public domain
prior to disclosure hereunder, or becomes so known subsequent to such disclosure
through no fault of the receiving party; or



                                      -14-


<PAGE>   16


     b) such information is received by the receiving party after the Effective
Date of this Agreement without restriction from a third party not under an
obligation to the disclosing party not to disclose it and otherwise not in
violation of the disclosing party's rights; or

     c) such information is furnished to third parties by the disclosing party
without a similar restriction on the third party's rights, or

     d) such information is already in the possession of the receiving party, as
shown by written records, without violation of this Agreement.

     e) such information has been independently developed by the receiving party
without reference to or reference on the other party's Confidential Information.

     9.4 COURT ORDER. In the event either party's Confidential Information is
subpoenaed or otherwise required to be produced or made available by the other
party to a third party by order of a court or governmental administrative
agency, the party required to produce such information shall promptly notify the
other party in writing and allow ten (10) days or, if less, the maximum amount
of time possible under the circumstances, for response by the disclosing party
before producing such documents. The receiving party will cooperate with the
disclosing party in obtaining a protective court order or take such other action
as may be appropriate under the circumstances.

     9.5 SURVIVORSHIP. The provisions of this Article 9 shall survive any
termination of this Agreement.

                                   ARTICLE 10

     REPRESENTATIONS, WARRANTIES AND COVENANTS

     10.1 ASSIGNMENTS AND LICENSES. Each party represents and warrants for
itself to the other party on a continuing basis that each party has the right
and power to make any assignments and the right and power to grant any licenses
as may be provided for in this Agreement.

     10.2 BINDING OBLIGATION. This Agreement is the valid and legally binding
obligation of each party in accordance with its terms, subject to bankruptcy,
reorganization, insolvency, moratorium and similar laws and to general
principles of equity which are within the discretion of courts of applicable
jurisdiction.

     10.3 NO LITIGATION OF CLAIMS. ASC represents and warrants to ABB that to
the best of ASC's knowledge at the time of execution of this Agreement, there is
no pending litigation or knowledge of a claim which may substantially affect
ASC's ability to fulfill its obligations pursuant to this Agreement.


                                      -15-


<PAGE>   17



     10.4 AGREEMENTS WITH EMPLOYEES. Except as otherwise prevented by law, both
parties will maintain with their respective employees, agents, subcontractors
and consultants who perform under this Agreement and who have access to the
Technology, written agreements sufficient to enable each party to perform its
obligations hereunder.

     10.5 COMPLIANCE WITH LAWS. Each party will comply with all laws and
regulations applicable to the performance of its obligations hereunder,
including, without limitation, all safety, health and environmental laws, and
will obtain all necessary government authorizations, approvals and permits
required to perform the Work.

     10.6 ASC represents and warrants to ABB that the ASC/EDF Separate Agreement
shall not diminish or abrogate the rights of ABB under this Agreement.

     10.7 ASC PROMISES AND COVENANTS.

     NO INFRINGEMENT. ASC shall perform the Work in a manner so that to the best
of ASC's knowledge, neither the Technology being developed, the Deliverables
being supplied to ABB, nor the exercise by ABB of any of the rights granted
hereunder, infringes any intellectual property right of any third party;
provided, however, the foregoing covenant shall not apply to patent rights, and
to copyrights unless ASC knowingly infringes such copyrights.

                                   ARTICLE 11

         VISITS AND INSPECTIONS

         11.1 VISITS. ABB and any of its authorized representatives, shall have
the right, with reasonable notice, during ordinary business hours to visit the
offices of ASC and its subsidiaries, if any, and to visit and inspect the site
or sites at which the Work is being performed, to the extent that such visits do
not unreasonably interfere with the Work. These visits and inspections may
include multiple week visits by ABB to participate in specific tasks that will
be mutually defined, and to observe the Work in sufficient detail to make
informed decisions on the direction and use of the Work as it relates to design
of Transformers and Current Limiters. Any such long term visiting ABB employees
or representatives shalt have signed or will sign a confidential agreement
acceptable to ASC for protecting ASC Confidential Information.

     11.2 FACILITIES. ASC shall provide all reasonable facilities and assistance
for the safety and convenience of such representatives during their visits,
including making personnel engaged in the performance of the Work available for
consultation at all reasonable times.

                                   ARTICLE 12


                                      -16-


<PAGE>   18


     PUBLICITY RELEASES

     PRIOR APPROVAL. Unless required by law or stock market regulations neither
party may issue any publicity releases (including news releases and advertising)
relating to this Agreement and the Work performed hereunder without the prior
written approval of the other party. Such approval shall not be unreasonably
withheld. ABB and ASC will coordinate their responses to any substantial inquiry
from news media concerning this Agreement.

                                   ARTICLE 13

     INDEMNIFICATION AND LIMITATION OF LIABILITY

     13.1 INDEMNITY. Both parties shall protect, defend, indemnify and hold
harmless the other party its agents, employees and directors from any claim,
loss, cost, liability or expense (including court costs and reasonable fees of
attorneys and other professionals) arising out of or resulting from any breach
of the representations, warranties and covenants made in Article 10; not
withstanding Subarticle 10.6, ASC will indemnify ABB against any claims that the
Deliverables under this agreement infringe any third party patents and
copyrights.

     13.2 GENERAL INDEMNITY. Notwithstanding Subarticle 13.1 herein. each party
shall protect, defend, indemnify and hold harmless the other party, its agents,
employees and directors from any claim, loss, cost, liability or expense
(including court costs and reasonable fees of attorneys) arising out of any
injury, including death, or any property damage suffered by any third party as a
result of or related to any negligent act or negligent failure to act of such
parties subcontractors or its subsidiaries, or of any of their respective
employees or agents in connection with or related to the Work or the performance
of this Agreement except to the extent that any losses, costs, liabilities,
claims or expenses are the result of any negligent act or negligent failure to
act of the other party, its agents, employees and directors, such directors only
when acting in their official capacity.

     13.3 CONDITIONS AND OBLIGATIONS. Each party's obligations under Subarticles
13.1 and 13.2 above are conditioned upon (i) the other party giving notice,
which is timely under the particular circumstances, to such party's
representative (as such representative is specifically named in Article 16
herein), of any claim made against the other party or any claim made by the
other party hereunder, provided, however, notice shall be considered timely
unless such party has suffered substantive or irreparable prejudice as a result
of a delay by the other party in giving notice to such party in (y) the defense
of such claim or (z) such party giving notice to an applicable insurer of such
claim and (ii) the other party giving such party the right to control and direct
any investigation, defense and settlement of such claims, provided, however,
such party shall not settle,


                                      -17-


<PAGE>   19


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

compromise or resolve such claim (except if such settlement, compromise or
resolution consists only of a payment of money to be made by ASC) without the
prior written approval of the other party (which approval shall not be
unreasonably withheld). The other party shall provide full and timely
cooperation to such party in the defense or settlement of such claims.

     13.4 LIMITATION OF LIABILITY. (i) IN NO EVENT WILL EITHER PARTY BE LIABLE
TO THE OTHER FOR ANY SPECIAL, INDIRECT, CONSEQUENTIAL OR INCIDENTAL DAMAGES,
HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, ARISING OUT OF THIS AGREEMENT,
EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. (ii) THE
TOTAL CUMULATIVE LIABILITY OF ASC TO ABB, ARISING FROM INTELLECTUAL PROPERTY
INFRINGEMENT OR IN ANY WAY CONNECTED TO THE PERFORMANCE OR NONPERFORMANCE OF
THIS AGREEMENT, WHETHER IN INTELLECTUAL PROPERTY INFRINGEMENT, CONTRACT, TORT
(INCLUDING NEGLIGENCE OR STRICT LIABILITY) OR OTHERWISE FOR DAMAGE OR LOSS OF
OTHER PROPERTY OR EQUIPMENT, LOSS OF PROFITS OR REVENUE, LOSS OF USE OF
EQUIPMENT OR POWER SYSTEM, COST OF CAPITAL, COST OF PURCHASED OR REPLACEMENT
POWER OR TEMPORARY EQUIPMENT (INCLUDING ADDITIONAL EXPENSES INCURRED IN USING
EXISTING FACILITIES), CLAIMS OF CUSTOMERS OF ABB, SHALL NOT EXCEED THE FUNDING
RECEIVED BY ASC FROM ABB.

                                   ARTICLE 14

     INSURANCE

     14.1 REQUIREMENTS. ASC shall not commence the Work until it obtains, and
shall maintain for the term of the Agreement insurance in the types and amounts
required under this Article 14, or provides equivalent protection through an
insurance program.

     14.2 COVERAGE. ASC shall obtain and maintain the following insurance:

     a) General Comprehensive Liability Insurance, including Contractual
Liability Insurance covering all of ASC's obligations under this Agreement
subject to a single aggregate policy limit of [**] per occurrence and [**]
aggregate.


                                      -18-


<PAGE>   20


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

     b) Insurance or self insurance covering all of ASC's obligations under this
Agreement regarding worker's compensation including employer's liability in an
amount of [**] and/or all other insurance required by law in the jurisdiction in
which the Work will be performed.

     c) ASC shall require that its subcontractors carry worker's compensation
including Employer's Liability and General Comprehensive Liability Insurance
including Contractual Liability Insurance, in the amount of [**].

     14.3 CHANGES. All commercial policies of insurance applied for or obtained
to meet the requirement of this Agreement shall not be materially changed or
canceled until thirty (30) days prior written notice has been given to ABB.

                                   ARTICLE 15

     TERMINATION

     15.1 TERMINATION. This Agreement may be terminated, without cause and for
its convenience, by ABB at any time upon ninety (90) days written notice to ASC,
but in the event that ABB terminates for convenience prior to commercialization,
the licenses granted to ABB under 7.4 shall also terminate. In full discharge of
any payment obligations to ASC in respect of this Agreement and such
termination, ABB shall pay for costs and noncancellable commitments incurred
prior to the date of termination and fair closeout costs to be negotiated by the
two parties, in accordance with Article 2. ASC shall take all reasonable steps
to minimize termination costs.

     15.2 If ABB fails to commit adequate funds to support the Work, and such
failure results in a substantial reduction in the scope of the Work or a
substantial extension of the period of performance, ASC may, by providing prompt
notification of its election thereof to ABB, treat such failure as a termination
by ABB pursuant to Subarticle 15.1 above, but this will only apply if ABB
reduces its funding by twenty-five percent (25%) or greater as compared to the
budget set forth in the schedule. Unless otherwise notified by ABB, ASC may
carry forward any unexpended committed funds into succeeding contract years.

     15.3 If ASC fails to commit adequate funds, and such failure results in a
substantial reduction in the scope of the Work or a substantial extension of the
period of performance, ABB may, by providing prompt notification of its election
thereof to ASC, treat such failure as a termination by ASC, but this will only
apply if ASC reduces


                                      -19-


<PAGE>   21


its funding by twenty-five percent (25%) or greater as compared to the budget
set forth in the Schedule. If this Agreement terminates pursuant to this
Subarticle 15.3, ABB shall not be obligated to make any further payments, beyond
those due as of the date of termination, to ASC hereunder; any license granted
to ABB pursuant to this Agreement shall continue; and, any license granted to
ASC pursuant to this Agreement shall cease.

     15.4 TERMINATION FOR BANKRUPTCY OR INSOLVENCY. ABB may terminate this
Agreement by giving ten (10) days written notice to ASC if ASC files or has
filed against it any petition in bankruptcy or any proceeding relating to
insolvency, receivership, liquidation, or composition for the benefit of
creditors, if that petition or proceeding is not dismissed within thirty (30)
days after filing. Such termination shall be effective as of the tenth day
following such notice. If ABB terminates this Agreement pursuant to this
Subarticle 15.4, ABB shall not be obligated to make any further payments, beyond
those due as of the date of termination, to ASC hereunder; any license granted
to ABB pursuant to this Agreement shall continue; and, any license granted to
ASC pursuant to this Agreement shall cease.

     In the event ASC files for bankruptcy and a court of appropriate
jurisdiction enters a final order authorizing ASC to reject this Agreement, ABB
shall have the rights set forth in Section 365(n) of the Bankruptcy Code.

     15.5 SURVIVAL. The provisions of Subarticle 2.6 (Audit Rights), Article 5
(Data), Article 6 (Computer Programs), Article 7 (Intellectual Property Rights),
Article 9 (Confidentiality), Article 10 (Representations, Warranties and
Covenants), Article 13 Indemnification and Limitation of Liability, Article 17
(Dispute Resolution) and Article 18 (Miscellaneous) shall survive completion or
termination of this Agreement for any reason.

                                   ARTICLE 16

     NOTICES

     Any notices or communications required or permitted under this Agreement
shall be in writing and personally delivered or sent to the address of each
party as set forth below, or to such other address as either party may
substitute by written notice to the other in any manner expressly provided for
herein.

     a) Notices to ABB under this Agreement:

        1)       ABB Project Manager
                 ABB Power T&D Company Inc.
                 1021 Main Campus Drive
                 Raleigh, NC 27606



                                      -20-


<PAGE>   22


         2)       ABB Power T&D Company Inc.
                  Attn:   Manager Business Development
                  1021 Main Campus Drive
                  Raleigh, NC 27606

 (b)      Notices to ASC under this Agreement:
          American Superconductor Corporation
          Attn:    Chief Financial Officer
          Two Technology Drive
          Westborough, MA 01581


                                   ARTICLE 17
 
     DISPUTE RESOLUTION

     17.1 MEDIATION. If a dispute arises out of or relates to this Agreement, or
any breach thereof, and if such dispute cannot be settled through direct
negotiation between the parties, and if the parties mutually agree, the parties
shall submit the dispute to mediation with a mediator to be mutually agreed upon
by the parties. The mediation may be initiated by the written request of either
party and sent to the other party and shall commence within fifteen (15) days of
receipt of such notice, unless otherwise agreed by the parties. In the event the
parties fail to mutually agree on mediation procedures or if the mediation fails
to resolve any dispute, either party may enforce its rights in a court of
competent jurisdiction.

     17.2 Each party shall bear its own expense of such mediation proceedings,
unless otherwise agreed by the parties.

                                   ARTICLE 18

     MISCELLANEOUS

     18.1 GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the laws of the Commonwealth of Massachusetts, without reference
to conflicts of law principles.

     18.2 ASSIGNMENT. Except to accomplish the sale or transfer of a business
unit or division, or sale or reorganization of either party, this Agreement may
not be assigned, in whole or in part, by either party without the prior written
consent of the other party which consent shall not be unreasonably withheld.

     18.3 BENEFIT. Subject to Subarticle 18.2 above, this Agreement is binding
upon and shall inure to the benefit of the parties hereto, their
representatives, successors and permitted assigns.


                                      -21-


<PAGE>   23


     18.4 WAIVER. No failure or successive failures on the part of either party,
its successors or assigns, to enforce any covenant or agreement, and no waiver
or successive waivers on its or their part of any condition of this Agreement
shall operate as a discharge of such covenant, agreement, or condition, or
render the same invalid, or impair the right of either party, its successors and
assigns, to enforce the same in the event of any subsequent breach or breaches
by the other party hereto, its successors or assigns.

     18.5 ENTIRE AGREEMENT. This Agreement constitutes the entire Agreement
between the parties and supersedes all previous agreements and understandings
relating to the Work, including any letter agreement between the parties. This
Agreement may not be altered, amended, or modified except by a written
instrument signed by the duly authorized representatives of both parties.

     18.6 INDEPENDENT CONTRACTOR. ASC shall perform its obligations hereunder as
an independent contractor and shall be solely responsible for its own financial
obligations. Nothing contained herein shall be construed to imply a joint
venture or principal and agent relationship between the parties and neither
party shall have any right, power or authority to create any obligation, express
or implied, on behalf of the other in connection with the performance hereunder.

     18.7 ADDITIONAL OBLIGATIONS. At any time or from time to time on and after
the Effective Date of this Agreement, ASC shall at the reasonable request of ABB
(i) deliver to ABB such records, data or other documents consistent with the
provisions of this Agreement, and (ii) execute, and deliver or use its
reasonable efforts to cause to be delivered, all such assignments, consents,
documents or further instruments of transfer or license, and (iii) take or cause
to be taken all such other actions, as ABB may reasonably deem necessary or
desirable in order for ABB to obtain the benefit of this Agreement and the
transactions contemplated hereby.

     18.8 WARRANTY DISCLAIMER. WITHOUT LIMITING ASC'S OBLIGATIONS PURSUANT TO
ARTICLE(S) 10 AND 14 HEREIN, IN RECOGNITION THAT THE NATURE OF THE WORK INVOLVES
RESEARCH AND DEVELOPMENT, ASC MAKES NO WARRANTIES OF ANY KIND, EXPRESS OR
IMPLIED, BY STATUE OR OTHERWISE, REGARDING THE WORK; AND ASC SPECIFICALLY
DISCLAIMS ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
PURPOSE AND ANY WARRANTIES FROM COURSE OF DEALING OR USAGE OF TRADE.

     18.9 HEADINGS. The Article and Subarticle headings contained in this
Agreement and in the Schedule and Exhibits hereto are for convenience of
reference only and shall not in any way affect the meaning or interpretation of
this Agreement, the Schedules or the Exhibits.


                                      -22-


<PAGE>   24


     18.10 SEVERABILITY. Any provision of this Agreement that is prohibited or
unenforceable in any jurisdiction shall be ineffective to the extent of such
prohibition or unenforceability without invalidating the remaining provisions
hereof, and any such prohibition or unenforceability in any jurisdiction shall
not invalidate or render unenforceable such provision in any other jurisdiction.

     18.11 FURTHER ASSURANCES. If, at any time, either party has reasonable
grounds to believe that the other party may be unable to perform its obligations
hereunder, the first party may in writing demand adequate assurance of due
performance, and until it receives such assurance to its satisfaction it may
suspend performance of its obligations hereunder.

     18.12 EXPORT REGULATIONS. All technical data or commodities of United
States origin made available directly or indirectly hereunder for use outside
the United States shall be used subject to and in accordance with any applicable
laws and regulations of the departments and agencies of the United States
Government. The recipient of such technical data or commodities agrees not to
re-export, directly or indirectly, any technical data of United States origin
acquired from the Disclosing Party or any commodities using such data to any
destination requiring United States Government approval for such re-export until
a request for approval has been submitted to and granted by the United States
Government.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized representatives.


ABB Transmission & Distribution          American Superconductor Corporation
Technology Ltd.

By: /s/ F. Gabella                       By: /s/ G.J. Yurek
   -----------------------------------      ----------------------------------

Print Name: F. Gabella                   Print Name: G.J. Yurek
           ---------------------------              --------------------------

Title:  Business Mgr.                    Title:    President
      --------------------------------         -------------------------------

Date:  Jan 2nd, 1998                     Date:  Jan. 2. 1998
      --------------------------------         -------------------------------



                                      -23-



<PAGE>   25


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

                            SCHEDULE TO THE AGREEMENT
                                     BETWEEN
                                   ABB AND ASC

     1.0 STATEMENT OF WORK

     1.1 The Statement of Work is attached hereto as Attachment A, which is
hereby deemed incorporated and made an integral part of this Agreement.

     2.0 PERIOD OF PERFORMANCE

     Agreement will be for a four year period, covering April 1, 1997 through
March 31, 2001.

     3.0 BUDGET

     The budget is set forth in this Article 3 and in Attachment B to this
Schedule. The parties contemplate that the budget to perform the work will be
[**].

     3.1 ABB has paid ASC 0.3 MUSD towards the development outlined in this
Agreement in calendar year 1996 and ABB will pay ASC; 1.75 MUSD in calendar year
1997; including 0.7 MUSD paid prior to April 1, 1997; [**] in calendar year
1998; [**] in calendar year 1999; and [**] in calendar year 2000, and [**] in
calendar year 2001, for a total of 5.0 MUSD.

     3.2 ASC will spend 5.0 MUSD total towards the development outlined in this
Agreement in their Fiscal Years 1998, 1999, 2000 and 2001 with target levels of
0.625 MUSD in FY 1998, [**] in FY 1999, [**] in FY 2000, and [**] in FY 2001.
Any spending below or above target in the first fiscal years may be compensated
in subsequent fiscal years.

     3.3 The Schedule of the development costs payable to ASC by ABB are
detailed in Attachment B to this Schedule.

     3.4 The parties contemplate that EDF will contribute 5.0 MUSD to the Work
under the provisions of the Separate Agreement.

     4.0 DELIVERABLES


                                      -24-


<PAGE>   26


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED



     4.1 All deliverables identified in this Article 4 are to be made to ABB as
specified by the ABB Project Manager.

     4.2.1 Technical Progress Reports

     ASC shall submit to the ABB Project Manager a technical progress report
with respect to the Work at the PRB meetings.

     4.2.2 Administrative/Financial Reports

     The invoicing as identified in Article 3.1 of the Agreement shall serve as
the Administrative/Financial Report; provided, however, upon request of the ABB
Project Manager or the PRB, ASC shall provide to ABB or the PRB various
estimates and forecasts as to the time and costs to complete the Work.

     4.3 Prototype Conductor Milestones (1)

     The milestones may be modified in preliminary design review for the [**]
transformers. All values listed are minimum performance requirements with [**].
AC loss values are determined by [**] unless otherwise specified.

     4.3.1 [**] GENERATION [**]: feasibility demonstrated in [**] with the
following combined characteristics:

     1. [**] at [**] and in [**] to plane.

     2. [**] at [**] and in [**] to plane.

     3. [**] and operating [**] total current [**] consistent with the above
[**] specifications.

     4.3.2 [**] GENERATION [**]: feasibility demonstrated in [**] with the
following combined characteristics:

     1. [**] at [**] and in [**] to plane.

- --------
    (1)  SECTION 4.3 INCLUDES ASC CONFIDENTIAL INFORMATION UNDER THIS AGREEMENT.


                                      -25-


<PAGE>   27


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

     2. [**] at [**] and in [**] to plane.

     3. [**] and operating [**] total current [**] consistent with the above
[**] specification.

     4.3.3 [**] GENERATION [**] : [**] process demonstrated with characteristics
of 4.3.2.

     4.3.4 [**] GENERATION [**]: feasibility demonstrated in [**] with the
following combined characteristics:

     1. [**] at [**] and in [**] to plane determined by a [**] measurement.

     2. [**] at [**] and in [**] to plane determined by a [**] measurement.

     3. [**] and operating [**] total current [**] consistent with the above
[**] specifications.

     4.3.5 [**] GENERATION [**]: [**] completed and first production [**] with
4.3.2 specs supplied to ABB.

     4.3.6 [**] GENERATION [**]: [**] completed and [**] with 4.3.4 specs
supplied to ABB.

     4.3.7 [**] GENERATION [**]: feasibility demonstrated in [**] with the
following combined characteristics:

     1. AC loss 0.25 mW/Am at [**] and in [**] to plane.

     2. [**] and operating [**] total current [**] consistent with the above
[**] specification.

     3. [**] resistivity [**] rated current.

     4.3.8 [**] GENERATION [**]: [**] process demonstrated with the
characteristics of 4.3.7.

     4.3.9 [**] GENERATION [**]: feasibility demonstrated in [**] with the
following combined characteristics:


                                      -26-


<PAGE>   28


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

     1. [**] at [**] and in [**] to plane.

     2. [**] and operating [**] total current [**] consistent with above [**]
specification.

     3. [**] resistivity [**] rated current.

     4.3.10 [**] GENERATION [**]: [**] available from [**], with characteristics
of 4.3.7.

     4.3.11 [**] GENERATION [**]: [**] completed and [**] piece length with
4.3.9 specs supplied to ABB.2.

     4.4   Development Documentation

           To be developed by the PRB

     4.4.1 Conductor Requirement Specifications

     4.4.2 Conductor Design Specifications

     4.4.3 Test Plan

     4.4.4 Test Analysis Report

     5.0 INVOICING

     All invoicing shall make reference to this Agreement by Number and shall be
mailed to ABB at the following address:

     ABB Power T&D Company Inc.
     Electric Systems Technology Institute
     Attention: Accounts Payable
     1021 Main Campus Drive
     Raleigh, NC 27606

     6.0 PROJECT MANAGERS

     a)   ABB designates    Dr. Steinar Dale as ABB Project Manager
     b)   ASC designates    Dr. Alex Malozemoff as ASC Project Manger


                                      -27-


<PAGE>   29


     7.0 AGREEMENT WITH EMPLOYEES

     a) There are no items specifically listed.







                                      -28-


<PAGE>   30


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED

                                  ATTACHMENT A
                        TO AGREEMENT BETWEEN ASC AND ABB
                 ASC STATEMENT OF WORK FOR HTS TRANSFORMER WIRE
                          DEVELOPMENT AND DEMONSTRATION

Wire [**] will be developed in the context of several designs being considered
for an HTS transformer. The two main types of wires include 1) [**] wire with
[**] and [**] for use in the [**] of the [**] and 2) an [**] with [**] for use
[**] of the [**] . [**] may also be used throughout the [**] . Critical program
wire performance issues include (i) [**] and [**], (ii) achieving the [**] under
[**], (iii) [**] within [**] , (iv) achieving [**] in the [**], and (v)
achieving an architecture with [**] during a [**].

The general HTS wire development process proceeds in three stages: first, a
feasibility stage using [**]; second, a process development stage for [**]; and
third, a scaleup for [**]. After feasibility, each [**] stage has an anticipated
duration of approximately [**]. This program proposes to [**] this development
process for a [**] prototype by using [**] throughout the entire [**], and to
enable a [**] which will incorporate [**].

Through the course of the program, several generations of wire with increasingly
advanced specifications (summarized in 4.3) are identified as Generation [**],
with Generation [**] referring to a [**] (not taken beyond feasibility),
Generation [**] referring to the level required for the [**], and Generation
[**] referring to the level required for [**]. This program covers feasibility
and [**] for HRS and AC wire types and for all different generations of both
[**] of Generation [**] AC wire (Generation [**] is not specified) which is
excluded. [**] and [**] of [**] is contingent on funding and a specific separate
program for a [**]. [**] of any of the wires is also outside the bounds of the
program, except for [**], which is included. These program elements and their
anticipated time periods are summarized in the attached Gantt chart.

The anticipated commercial price target, averaged over the [**], is [**].

The Wire Development Program is divided into four major segments: [**], with the
[**]. Major milestones are listed in Section 4.3 of the Schedule. All fields,
currents, and voltages are [**] (unless otherwise specified). Generation [**]
conductor specifications will be reviewed by [**] in the light of Generation
[**] milestone status and [**] requirements.

HRS [**] DEVELOPMENT:


                                      -29-


<PAGE>   31


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED



HRS [**] will build on the [**], with either a [**] to [**] indicated in the
Schedule, Section 4.3. [**] may need to be considered depending on the design
established in the [**], and [**] for this task needs to be determined.

Task 1. HRS GEN [**] FEASIBILITY. A baseline [**] for a [**] will be developed
and demonstrated in [**] , with Generation [**] as in the Schedule, Section
4.3.7 [**]; and [**] rated current). Both [**] approaches to increase the [**]
will be investigated.

Task 2. HRS. [**] Subject to positive results on [**] of [**] from Task 14, the
feasibility of [**], consistent with [**] established by ABB by [**], will be
tested at ASC [**]. Samples will also be provided to ABB for test. [**] beyond
feasibility will be negotiated based on the results of this task.

Task 3. HRS GEN [**]. A [**] with the [**] and the other HTS Gen [**] will be
developed in [**], starting in [**] to the [**] of Task 1 and completed by [**].
Issues of [**] will be addressed.

Task 4. HRS GEN [**]. The [**] of Task 1 will be developed for [**] and combined
with the [**] of Task 3, to demonstrate by [**] with the Generation [**].

Task 5. HRS GEN [**] A [**] of Generation [**] will be established, culminating
with the delivery of a [**] to ABB by [**]. Additional delivery of this [**] for
the [**] will then continue after [**] outside the bounds of this program.

Task 6. HRS GEN [**] FEASIBILITY. Generation [**] will be developed in [**]
meeting Section 4.3.9 specs of the Schedule ( [**], and [**]), for a feasibility
milestone by [**].

Task 7. HRS GEN [**] The Generation [**] will be developed [**] , addressing
[**] issues. The first [**] length will be delivered to ABB by [**]. Delivery of
this [**] in production quantities will require [**] and will continue after
[**] outside the bounds of this program for [**].

[**] DEVELOPMENT:

 [**] requires  [**].

Task 8. AC GEN [ **] FEASIBILITY. [**] with Generation [**] specs of Section
4.3.1 of the Schedule ([**]) will be developed via a [**] approach. Feasibility
will be demonstrated in [**].


                                      -30-


<PAGE>   32


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED


Task 9. AC GEN [**] FEASIBILITY. [**] with Generation [**] specs of Section
4.3.2 of the Schedule ([**]) will be developed via [**] in the [**] and [**] by
cabling. Feasibility will be demonstrated in [**] by [**] .

Task 10. AC GEN [**]. [**] of the Generation [**] of Task 9 will begin on [**]
and provide a [**] for delivery to ABB by [**]. Scale-up for pilot production
will occur after [**]. This task is [**] on [**] such as that from the [**], and
on a targeted prototype which requires AC Gen [**].

Task 11. AC GEN [**] FEASIBILITY. [**] with Generation 2 [**] of Section 4.3.4
of the Schedule ([**]) will be developed via [**] in the [**] and achieving [**]
in Task 13.
Feasibility will be demonstrated in [**].

Task 12. AC GEN [**]. [**] of the Generation [**] of Task 8 will begin on [**]
and provide a [**] to ABB by [**]. Scale-up for commercial production will occur
after [**], [**] of this program.

CABLING:

Task 13. [**] DEVELOPMENT: This task will target [**] of HRS and/or [**] as
needed to meet the total current requirements of the Gen [**] specs. In
particular, [**] is expected to be required for reaching the [**] by [**] for
Gen [**] and by [**] for Gen [**].

CHARACTERIZATION AND TEST:

These studies will be done in close collaboration with ABB and EDF.

Task 14. [**] FEASIBILITY TESTING. An early task will focus on demonstrating
[**] in HRS [**]. This will start with [**] in applied field. Experiments
comparing [**] will be conducted in collaboration with ABB. A first milestone
for these experiments is targeted for [**]. [**] for the [**] will be agreed
upon with ABB. If adequately [**] are obtained in these first round tests, such
studies will be extended to HRS [**] and [**], with a milestone for establishing
[**] by [**]. Specs for, and basic approach to, HRS [**] development will be
reviewed upon the completion of this milestone.

Task 15. [**] TESTING. [**] techniques for [**] will be established for [**] and
[**] will be established to monitor ongoing [**].


                                      -31-


<PAGE>   33


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED


Task 16. [**] TESTING. [**] will be constructed and measured for [**] to access
[**] for all generations of HRS and [**] as soon as [**] become available. These
tests will confirm [**] in the [**]. Also tests of [**] in HRS and [**] will be
conducted.

Task 17. [**] TESTING. [**] tests, both [**] of HRS and [ **] will be conducted
as different generations become available. Specs will be established based on
[**] design and manufacturing requirements, including [**] and [**] .

Task 18. PROGRAM MANAGEMENT. The technical program will be managed via an ASC
program manager in accordance with this agreement.



                                      -32-


<PAGE>   34


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED



                ATTACHMENT B: SCHEDULE OF ABB DEVELOPMENT COSTS:
<TABLE>
<CAPTION>
                  YEAR                           ABB PAYMENT TO ASC                   ASC FISCAL YEAR

<S>               <C>                            <C>                                 <S>
A1.               1996                           0.3 MUSD
                  Qtr. 4 1996                             0.3 MUSD                    1997

A2.               1997                           1.75 MUSD
                  Qtr. 1 1997                             0.70 MUSD                   1997
                  Qtr. 2 1997                             0.35 MUSD                   1998
                  Qtr. 3 1997                             0.35 MUSD                   1998
                  Qtr. 4 1997                             0.35 MUSD                   1998

A3.               1998                            [**]
                  Qtr. 1 1998                              [**]                       1998
                  Qtr. 2 1998                              [**]                       1999
                  Qtr. 3 1998                              [**]                       1999
                  Qtr. 4 1998                              [**]                       1999

A4.               1999                            [**]
                  Qtr. 1 1999                              [**]                       1999
                  Qtr. 2 1999                              [**]                       2000
                  Qtr. 3 1999                              [**]                       2000
                  Qtr. 4 1999                              [**]                       2000

A5.               2000                            [**]
                  Qtr. 1 2000                              [**]                       2000
                  Qtr. 2 2000                              [**]                       2001
                  Qtr. 3 2000                              [**]                       2001
                  Qtr. 4 2000                                                         2001

A6.               2001                            [**]                                2001
</TABLE>


                                      -33-


<PAGE>   35


                 TOTAL ABB PAYMENTS TO ASC FOR 1996-2001; 5 MUSD










                                      -34-


<PAGE>   36


                       ATTACHMENT C: PROJECT REVIEW BOARD

     1- The PRB shall be composed of 2 representatives of each party, with the
possibility of inviting specialists whenever required by the complexity of any
item to be discussed.

     2- The PRB has the duty of:

     2.1 agreeing to any changes to the scope of the Statement of Work set forth
in Attachment A, including changes in any specific targets to be achieved or any
time limits.

     2.2 monitoring performance against the Statement of Work, and setting up
check points for the critical results to be achieved.

     2.3 recommending action as required to achieve the objectives of the
Agreement, including change of scope if convenient in the light of new
developments in the field.

     2.4 monitoring cost of the work and advising the Joint Steering Committee
of ABB and ASC of any change with respect to the original plan.

     3- At least one of the ABB representatives shall be a person with
significant involvement in R&D on superconductivity.

     One of the ASC representatives shall be the person responsible for the
implementation in ASC of the Statement of Work.

     4- The PRB shall meet quarterly, and shall have access to the necessary
technical and financial documentation, which shall be provided by the Parties
before the meeting.

     5- The decisions of the PRB shall be taken unanimously. In case of failure
to agree, the relevant matter shall be submitted to the Joint Steering Committee
of ABB and ASC for final decision.




                                      -35-



<PAGE>   37


                                                          CONFIDENTIAL TREATMENT
                                         AMERICAN SUPERCONDUCTOR CORPORATION HAS
                                      REQUESTED THAT THE MARKED PORTIONS OF THIS
                                     DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT
                                     PURSUANT TO RULE 24B-2 UNDER THE SECURITIES
                                                EXCHANGE ACT OF 1934, AS AMENDED


              ATTACHMENT D: ACS/EDF AGREEMENT, ARTICLE 4: PAY-BACK

     4.3 ROYALTIES. For [**] from [**] of HTS commercial conductors by ASC for
transformers, ASC will pay to EDF a royalty of [**] on [**] HTS [**] sales. For
the purpose of this royalty calculation, sales for the [**] as described under
Article 4.4 will be excluded. For the purpose of this royalty calculation, sales
to ABB will be excluded the [**] and included after [**] and until [**] from the
[**] of HTS [**] by ASC for transformers.

     4.4 COMMERCIAL DISCOUNTS. In recognition of EDF's contribution to the
development of HTS conductors for transformers, ASC undertakes to sell any AC
and HRS conductor developed by ASC under this Agreement, which is to be used in
HTS transformers designated for and sold in the [**] to the manufacturers of
these transformers at pricing not to exceed to the one proposed to ABB under
ASC's agreement with ABB on development of AC and HRS HTS wire. The current
price discount to ABB amounts to a [**] price discount from the lowest
commercial price available from ASC for similar quantities for any AC and HRS
HTS conductors developed by ASC under this Agreement, or any HTS conductor
originating from the Work, and this discount shall not be taken into
consideration in determining the lowest commercial price. When a HTS transformer
is commissioned for use in the [**], EDF will notify ASC. It is agreed that ASC
shall have no right to influence any negotiation between EDF and any transformer
manufacturer.

The definition of a commercial conductor sale under this Agreement is sale of
HRS or AC wire which is applicable to a High Temperature Superconducting
Transformer which is either the [**] in the [**] of [**] HTS transformers, or
the [**] in the [**] HTS transformers, whichever is sold first.

The above-mentioned discount will apply during [**] from the [**] of HTS
commercial conductors for HTS transformers by one of these designated
manufacturers.


                                      -36-

<PAGE>   1
                                                                    EXHIBIT 21.1


Subsidiaries

1.       American Superconductor Europe GmbH (*) - established in Germany
2.       ASC Holding Corp. (*) - incorporated in Delaware
3.       ASC Securities Corp. (**) - incorporated in Massachusetts
4.       Superconductivity, Inc. (*) - incorporated in Delaware





*        Wholly owned subsidiary of American Superconductor Corporation
**       Wholly owned subsidiary of ASC Holding Corp.

<PAGE>   1
                                                                    Exhibit 23.1




                       CONSENT OF INDEPENDENT ACCOUNTANTS

     We consent to the incorporation by reference in the Registration Statements
of American Superconductor Corporation on Form S-8 (File Nos. 33-44962,
33-44963, 33-64832, 33-74418, 33-86106, 33-86108, 333-39653, and 333-37163) of
our report dated May 8, 1998, on our audits of the consolidated financial
statements of American Superconductor Corporation as of March 31, 1998 and 1997,
and for each of the three years in the period ended March 31, 1998, which report
is included in the Form 10-K of American Superconductor Corporation.


/s/ Coopers & Lybrand L.L.P.

Coopers & Lybrand L.L.P.
Boston, Massachusetts
June 25, 1998





<PAGE>   1
                                                                    Exhibit 23.2


                             SMITH & GESTELAND, LLP
                     Partnership In Your Success-Since 1948


                       CONSENT OF INDEPENDENT ACCOUNTANTS


     We consent to the incorporation of our report dated February 7, 1997, on 
our audit of the consolidated financial statements of Superconductivity, Inc.,
as of December 31, 1996, and for the year then ended, which report is included
in this Registration Statement on Form 10K into the Company's previously filed 
Registration Statements on Form S-8 (file numbers 33-44962, 33-44963, 33-64832, 
33-74418, 33-86106, 33-86108, 333-37163 and 333-39653).




Madison, Wisconsin            /s/ Smith & Gesteland, LLP
June 25, 1998                 SMITH & GESTELAND, LLP



  Certified Public Accountants and Business Consultants * Post Office Box 1764
                            * Madison, WI 55701-1764



<PAGE>   1
                                                                    Exhibit 23.3




                        CONSENT OF INDEPENDENT AUDITORS


We consent to the incorporation by reference in the Registration Statements 
(Form S-8 Nos. 33-44962, 33-44963, 33-64832, 33-74418, 33-86108, 33-86106, 
333-39653, 333-37163) pertaining to various employee and director stock option
plans of American Superconductor Corporation of our report dated February 29,
1996, with respect to the financial statements of Superconductivity, Inc.
included in the Current Report on Form 10K for the fiscal year ended March 31,
1998, filed by American Superconductor Corporation with the Securities and
Exchange Commission.


                                        /s/ Ernst & Young LLP

                                        Ernst & Young LLP



Milwaukee, Wisconsin
June 24, 1998


<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-START>                             APR-01-1997
<PERIOD-END>                               MAR-31-1998
<EXCHANGE-RATE>                                      1
<CASH>                                           1,842
<SECURITIES>                                     6,167
<RECEIVABLES>                                    2,992
<ALLOWANCES>                                         0
<INVENTORY>                                      3,230
<CURRENT-ASSETS>                                 8,609
<PP&E>                                          15,429
<DEPRECIATION>                                (11,007)
<TOTAL-ASSETS>                                  19,551
<CURRENT-LIABILITIES>                            3,550
<BONDS>                                              0
                                0
                                          0
<COMMON>                                           118
<OTHER-SE>                                      12,741
<TOTAL-LIABILITY-AND-EQUITY>                    19,551
<SALES>                                          5,013
<TOTAL-REVENUES>                                15,129
<CGS>                                            4,603
<TOTAL-COSTS>                                   14,333
<OTHER-EXPENSES>                                13,551
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 239
<INCOME-PRETAX>                               (12,378)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (12,378)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (12,378)
<EPS-PRIMARY>                                   (1.06)
<EPS-DILUTED>                                   (1.06)
        

</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission